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ABSTRACT
Many epidemiological and experimental studies hi-tve
strongly implicated human papillomavirus type 16 (1IJ.>V-16) in
cervical neoplasia. The oncogenic potential of this virus C':l1l
be demonstrated by transforrr,ation of primary baby rilt kidney
(BRK) cells by cotransfection of the viral genome with the
activated EJ-~ oncogene. I performed a mutiltional ana.lysis
of the viral genome to map the regions essent ial for its
transforming activity. For the 5V40-bascd C"lrly refJjon
expression plasmids, the disruption of the E6, E2, E!; and the
3' region of the E;l open reading frames (ORFs) did not affect
the transforming activity of mutated plasmids, whercas the
insertion of translation termination linkers within tile E7 OIU'
abolished transformation, Additional sequences prusent in the
3'-flanking region of the E7 onF were also required [or
efficient transformation.
The 3' flanking region sequences were analyzed in detail
in SV40-based E7 expression plasmids by progressive deletion
analysis and site-directed mutagenesis. Disruption of the
nucleotide (nt) 880 splice donor site within this J'-flunkjnlJ
region abolished transforf'latlon. Regeneration of the wi.hl-
type sequence in a previously transformation incompetent
splice site mutunt restored trunsformation. Mutating the
wild-type splice donor site to the consensus splice site
resul ted in higher levels of transformation, whereas mutating
the +2 position of the consensus sequence significantly
reduced the frequency of transforttation. It was sho...--n with
RNase protection assays that the transformation-deficient
splice site mutants acculllulated lower levels of E7 RNA,
prhlarily because of rapid destabilization of E7 RNA.
The splice sites present within the E6 ORF were examined
for their ability to substitute for the loss of nt 880 splice
donor site function. The wild-type E6 splice sites, as well
as the heterologous splice sites ot the SV40 intron, v:ere able
to partially substitute for the nt 880 splice site function.
These results indicated that the efficient accumulation of
HPV-16 E7 RNA and transformation of eRK cells depend on the
presence of an intron in the transcription unit.
Recent studies have indicated the presence of naturally
occurring HPY-16 antisense (AS) RNA in cervical carcinomas.
I have detected AS E7 and E7/E1 RNA in Cos-l cells transiently
transfected with SV40-based HPV-16 early region expression
plasmids. By deletion mutation analysis, the AS promoter was
localized to nt 403l-43J8 of HPV-16. primer extension
analysis and RNase protection assays indicated that the AS RNA
was initiated from multiple sites in an A.T-rich region around
nt 4100. The AS promoter was active When cloned downstream of
the chloramphenicol acetyl transferase (Cat) gene, giving rise
to AS Cat RNA.
ii
AS E7 RNA was detected in both the nucleus and cytoplilsm.
The AS RNA formed a duplex with the sense (S) E7 RNA. 't'he
presence of AS RNA was correlated with reduced splicing of 1:":7
RNA from the nt 880 splice site and the synthesis of' In
protein.
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CHAPTER 1
INTRODUCTION
1.1 PAPILLOHAVIRUBEB (PVs)
Human papillomaviruses (HPV) play important
etiological role in the development of neoplastic lesions of
the epithelial tissue such as common cutaneous warts and
genital, oral and laryngeal cancers. Of different types of
flPVs, HPV type 16 (HPV-16) has been considered to be
important, because several epidemiological and experimental
studies have incriminated this virus as causing cervical
cancer, the second most common cancer of women (zur Hausen,
1991) . The in vitro transformation of rodent cells is a
commonly used system to demonstrate the oncogenic potential of
HPVs. using this assay system, I have been stUdying the
rcg ions of HPV-16 required for its oncogenic activity.
addition, I have also studied the possible posttranscriptional
mechanisms, such as splicing and the naturally occurring
antisense (AS) RNA, by Which the oncogenic activity of HPV-16
is regulated.
The family papovaviridae r.:onsists of two subfaJllil ies,
papovavirinae and papillomavirinae (Murphy and Kingsbury,
1990) . Papillomaviruses (PVs) are members of the subfamily
papillomavirloae. PVs induce prol iterative lesions of
cutaneous and mucosal epithelia in higher vertebrates,
inclUding humans. The ccttontail rabbit papillomavirus (CRPV)
"'hlch causes cutaneous papillomatosis was tha rirst mcmber or
this group to be identified (Shope .lnd llurst, 1933).
subsequently, bovine papillomavirus (BPV) , which C<luses
fibropapillolllas in bovines was identified and since then, it
has served as a model for the understandinCj of the molecular
biology of PVs (Black et al., 1%3; Lancaster and Olson,
1982) .
HPVs are highly epitheliotropic viruses that cause
proliferative disorders of their target tioouc (Shah and
Howley, 1990). B~sed on the cross hybridization of their
genomes, HPVs have been grouped into dif(erent types (Coggin
and zur Hausen, 1979). More than 60 different types !lave been
identified to date (de villiers, 1989). Of theoe,
approximately 25 different types are associated with the lower
anoqenital tract mucosa. Based on the relative tendency of
the lesions to progress to malignancy, genital IlPVs arc
classified into high risk and low risk groups (d~ Villicrs,
1989; Shah and Howley, 1990). High risk llPVs, such as IJPV-16,
-18, -31, and -JJ, are frequently found in high grade cervical
intraepithelial neoplasia, which has a higher tendency for
malignant conver!lion. In contrast, low risk IlPVs, such as
HPV-6 and -11, are commonly found in benign genital condylomas
and nasal and laryngeal papillomas, that have <l lower tendency
for malignant conversion (Broker and Botchan, 1986; Galloway
and McDougall, 1989: Shah and Howley, 1990).
1. ~. ~ Phy9 ical propertie9
PVs are small, naked, icosahedral viruses with covalently
closed circular double stranded DNA genome of approximately
8, 000 base pairs (bp). The viral genome is found in a
chromatin-like complex in association with cellular proteins
such as histones (Favre et al., 1975; Pfister et al., 1977).
rv capsid is composed of 72 capsorneres with 12 pentons and 60
hcxons (Salunke et al., 1989). Virions have a buoyant density
of l. 34 glml and measure ap~roximately 55 nm in diameter
(sterling et al., 1990; Zhou et al., 1991; Kirnbauer et al.,
1992). The 55 kDa major capsid protein encoded by the L1 open
reading frame (ORF) of the virus constitutes approximately 80%
of the total virion protein. The 70 kDa minor capsid protein
is encoded by the L2 ORF (Howley, 1990).
1.1.2 HPV life-cycle
Studies of the life-cycle of HPVs are hindered primarily
by the lack of a suitable cell culture system for HPV
cuI tivation and propagation, because the v ira I gene
expression is closely coupled to differentiation of the host
epithelial cells. The expression of late genes of the virus
and productive viral infection restricted to
differentiated epithelial cells (sterling et al., 1990;
Dollard et al., 1992; Meyers et al., 1992). Keratinocytes,
the natural target for HPV infection fail to support a
productive infection of HPVs when optimal conditions for
differentiation of keratinocytes are not provided ('l'.,jehnliln
and LaPorta, 1987; Compton et a1., 1989). It has not been
possible to achieve the terminal diff';!rcntitltion of
keratinocytes in Y.i.tJ;,:Q. Recently, several groups hilVe
reported the successful cultivation and propagat.ion of 1ll'Vs In
different systems. HPV-l1 has been successfully propagated by
implanting infected neonatal tissue under the renal cilpslllc 01
nude mice (Kreider et al., 1985; 1987; Stoler ct al., l'I'lll).
Similarly, transplantation of an HPV-16-positive celJ I inc,
which maintains the viral genome in an episomal form into nude
mice, resulted in the production of virus particles (starl in<J
et al., 1990). More recently, terminal different lilt ion or
keratinocytes in organotypic (raft) cultures ilnd the'
production of HPV-ll and -JIb virions in these cultures h,lVe
been achieved (Dollard et al., 1992; Meyers at al., 19'J7.)
1.1.3 Genome orqanizl'tion
A number of PVs tlave been cloned and sequenced (de
Villiers, 1989; Howley, 1990). A remarkable similarity j n the
genome organization has been noticed among all the~c PVn. All
ORFs of PVs are encoded on the same strand of DNA nnd il low
ORFs are overlapping. Many ORFs are well conserved with
respect to their presence, size, position and function among
different Pvs. However, certain ORFs were not found in the
genomes of all papillomaviruses. Compared with the genome of:
BPV-l, HPV-16 contained no equivalent of the E8 ORF (Howley,
1990). 'fhe HPV-16 genome consists of 6 early region (E6, E7,
E1, E2, E4 ilnd E5) and 2 late region (Ll and L2) ORFs. Fig.
1.1 depicts the genomic organization of HPV-16. All PVs have
0.6-1 kilobase pairs (kbp) of sequence which is devoid of
significant ORFs and this region is variously termed as the
long control region (LeR) , noncoding region (NCR), and
upstream regulatory region. This region provides binding
sites for several cellular ann viral transcription and
replication factors (Broker und Botchan, 1986; Pfister, 1987:
Galloway and McDougall, 1989; Howley, 1990).
1.1 .... PV proteins
1.1.4.1 E6
The EG OnF of the high risk HPVs prc:·duce unspliced E6,
tlnd two internally spliced, E6* and E6**, mRNAs (Smotkin et
al., 1989). In contrast, the low risk HPVs, which lack these
E6 splice sites, can not produce E6* and E6** mRNAs (Smotkin
et al., 1989; Roggenbuck et al., 1991). The ability of only
the high risk HPVs to produce E6* and E6** mRNAs has suggested
iln important role for the products of these mRNAs in the
process of oncogenesis. However, products of E6* and E6**
mRN!l.s have not 'teen detected to date in high risk HPV-
transformed cells, ex.cept for a HPV-18 transformed cell line
(Roggenbuck et al., 1991).
The full length E6 protein of HPV-16 is a 151 amino acid
(AA), basic, Zn·· -binding protein (Androphy et al., 1987a:
Barbosa et al., 1989: Gross.an and Laillins, 1989; VOl/sdell,
1990; Hunger et al., 1992). Pour Cys-X-X-Cys aotifs present
in the carboxy terminus of the protein arc known to coord inate
Zn" binding (Barbosa et aL, 1989). The E6 protein binds
double stranded DNA nonspecifically (Mallon et al., J9Wl;
Grossman et al., 1989: Imai et aI., 1989). Recent studieu
have indicated that the E6 proteins of both high risk '-Iml low
risk HPVs can transcriptionally transactivate severill vi r;l I
and cellular promo'.:.ers (Lamberti et al., 1990: Scdmiln ct ;1 I.,
1991; Desaintes et al., 1992; Munger et al., 1992; Smits at
aI., 1992).
The oncogsnic potential of E6 has been dcmonstr.lted by
several groups. The full length E6 of HPV-16 and -18 C;ln
transform NIH 3TJ cells to anchorage independence (Bedell et
a1., 2.989; Sedman et al., 1991). The full length EG, but not
the E6* or E6** can cooperate with E7 to immortalize primary
huaan keratinocytes and fibroblasts (Hawley-Nelson et a I.,
1989; Munger et al., 1989b; watanabe et al., 1989).
reported recently that the £6 proteins of high risk IlPVs but
not low risk HPVs can immortalize baby mouse kidney (/lMK)
cells in EJ-x:M cooperation assays (Storey and Banks, 199:1).
One of the mechanisms by which HPVs induce tumor~
involves their interaction with cellular tumor suppres~or
proteins. The £6 protoins of both high and low risk IlPVs bind
the tumor suppressor protein, pS3 (Schetfner et ill., 1990;
Werness et al., 1990; Crook et al., 1991a; Munger et al.,
1992) . Unlike other DNA. tumor virus oncoproteins, such as
SV40 large T antigen and the adenovirus 55 kDa E1B, which bind
and stabilize p5J, the ~6 proteins of high risk HPVf\ lead to
selective degradation of p5J (Scheffner et al., 1990; Crook et
al., 1991a; Levine et al., 1991; Levine, 1992). Very low
levels of p5J in HPV-16-positive cervical carcinoma cell
lines, HPV-16-immortalized human keratinocytes and high risk
IIPV E6-immortalized BMK cells suggest that p53 may be a
physiological target for E6 (Matlashewski et al., 1986;
Scheffner et al., 1991; storey and Banks, 1993). Recent
studies have indicated that the domains of E6 responsible for
binding p53 and directing its degradation are separable (Crook
at al., 1991a). The degradation of p5J by E6 is mediated by
ubiquitin and requires an additional 100 kDa cellular protein
(Scheffner et al., 1990; Huibregtse et al., 1991: 1993).
The high risk HPVs affect the function of p5J by more
than one machanism. Recently, it was shown that the HPV-16 E6
protein interferes with the transactivating activity of wild-
type pSJ (Mietz et al., 1992).
The E7 protein of HPV-16 is a 19 kDa, Znh-binding,
phosphoprotein (Smotkin and Wettstein, 1986; 1987; Seedorf et
ill., 1987: Barbosa et al., 1989; Sato et al., 1989a). The E7
protein W<lS detected in both the cytoplasm and nucleus when
analyzed by cell fractionation (Smotkin <lnd \~ettstcin, 1987;
Sato et a1., 1987a). A recent study has convincingly shown
that E7 is a nuclear matrix associated protein (Greenfield at
al., 1991).
A consistent feature of a majority of cervical C<lncers
and cancer-derived cell lines is the expression of E7 ORF of
the high risk HPvs that they contain (Pater <Ind Pilter, 1985;
Schwarz et aI., 1985; 'iee et aI., 1985; Schneider-Gadickc and
Schwarz, 1986; Smotkin and wettstein, 1986: Seedorf et al.,
1987; shirasawa et a1., 1988: Cone et a1., 1992; Cooper et
aI., 1992). In agreement with this observation, severa]
experimental studie!:. have implicated 1':7 as the major oncogene
of HPVs. The E7 ORF expressed from strong heterolocJous
promoter-enhancer sequences can immortalize primary rodent
cells and transform established rodent cells (Miltlashewski et
al., 1987a: Randa et a1., 1988a: 1988b; Phelps ct al., 1088;
storey et aI., 1988: Tanaka et aI., 1080; Edmonds and Vousden,
1989; Chesters et al., 1990; Watanabe et al., 1990; Munger et
aI., 1992). Further, in cooperation with 86, F.7 can
immortalize primary human keratinocytes (Schlegel ct ill.,
1988; Hawley-Nelson et al., 1989; Munger et al., 1989b;
Barbosa et al., 1991; Halbert et al., 1991). The continued
expression of E7 was also required for the milintcnance of the
transformed phenotype (Ct'ook et al., 1989; Storey et al.,
1991). The level of E7 expression correlated well with the
growth rate of transformed cells (von Knebel Doeberitz et al.,
1988; 1991; 1992; Crook et al., 1989; storey at a1., 1991).
Recent studies have indicated that the E7 genes of the
low risk HPVs have a weak immortalizing/transforming activity
(Storey et a1., 1990a; Halbert et al., 1992). The differences
in the oncogenic potential of the E7 genes of high risk and
low risk HPVs reside in the amino terminal 30 AAs of these
proteins (Munger et aI., 1992a; Pater et a1., 1992a; Takami et
al., 1992).
The E7 protein bears significant structural and
functional similarity to the transforming genes of adenovirus,
E11\ and SV40 large T antigen. AAs 6 to 20 and 41 to 56 of E7
arc similar to AAs 41 to 56 in the conserved region (en) land
121 to 139 in CR2, respectively, of adenovirus type 5 El/\
(Phelps at a1., 1988; Watanabe et a1.. 1990). Biological
activities that these two proteins have in common are,
immortalization of primary cells, transformation of rodent
cells in cooperation with activated oncogenes, induction of
host DNA synthesis and transcriptional regulation of viral and
cellUlar promoters (Vousden, 1990; Nevins 1991, Shenk and
Flint, 1991; Munger et a1., 1992).
Similar to E1A, E7 interacts with several cellular
proteins and some of these interactions are essential for the
diverse biological activities of E7. The E7 proteins of both
high and low risk HPVs bind the tumor suppressor gene product
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pRb and the binding affinities corresponds to the oncogenic
potential of these HPVs (Dyson et ai., 1989; Munger at al.,
1989; Barbosa et al., 1990, Gage et al., 1990; Heck et aL,
1992; Sang and Barbosa, 1992a). The correlation between the
transforming potential of HPVs and pRb binding was
demonstrated by showing that the oncogenic potentiul of a low
risk HPV, HPV-6, E7 can be increased by improving its bindin<]
affinity to pRb (Sang and Barbosa, 1992a). However, pRb
binding was essential but not sufficient for transformation,
because mutations in E7 that did not impair pRb binding
severely affected transformation (Edmonds and Vousdcn, 1989;
Banks et al., 1990; Chesters et al., 1990; \~atanabc at al.,
1990: Jewers et al., 1992; Phelps et a1., 1992).
The outcome of E7 binding to pRb was clearly demonstrated
in keratinocyte cell system. Inhibition of growth of
keratinocytes by transforming growth factor ('l'GF) -PI is
associated with downregulation of c-!!l:i£ (Pictcnpol ct ill.,
1990a). This growth inhibition was ilbrogated by IIPV-16 E7 and
the pRb binding ability was essentiill for this activity of 87
(Pietenpol et al., 1990b; Munger et al., 1991).
The E7 prote:..n can also interact with other cellular
proteins such as cyelin A, pl07, a pRb related protein, and
plJO (Dyson et al., 1992; Davies et aI" 1993; Tommasino ct
al.,1993).
Immediately towards the C-terminus of the pRb binding
region, between the AAs 30-37, is the casein kinase (CK) II
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phosphorylation region. The serines, 531 and 5 32 , located
within this region are phosphorylated by CK II (Firzlaff et
a!., 1989; Barbosa at a1., 1990). Despite the proximity of
the two regions, pRb binding and phosphorylation by CK II of
E7 ore independent of each other (Munger et al., 1989a;
Barbosa et al .• 1990; Firzlaff et al., 1991). The effects of
mutations of the CK II phosphorylation region
transformation was dependent on whether primary or established
cells were used for the assay and whether the mutations were
deletions or substi tut ~ons. A moderate to severe reduction in
transformation was noticed in various studies (Edmonds and
Vousden, 1989; Chesters at a1., 1990; Storey at al., 1990b;
Watanabe et al., 1990: Firzlaff et 011.,1991; Phelps et al.,
1992) .
The c-tcrminu$ half of E7 has two Cys-X-X-Cys motifs
separated from each other by approximately 29 AAs (Watanabe et
al., 1992b). The Zn··-binding property of E7 has been shown
to be dependent on the integrity of these motifs (Barbosa et
al., 1989). Mutations altering these Cys residues and the
spacing between the two motifs 3everely affected the stability
of the ?rotein and its transforming activity (Watanabe et al.,
1990, 1992b; Phelps et 011., 1992).
HPV-16 E7 has been shown to induce cellular DNA synthesis
(Sato et al., 1989b; Banks et al., 1990a; 1990b; Rawls et al.,
1990). The ability of E7 to induce cellular DNA synthesis was
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enhanced by the growth factor insulin. The induction of DNA
synthesis was dependent on the ability of E7 to bind pRlJ and
release the transcriptionally active form of E2F from the E:2F-
pRb complex (Morris et al., 1993).
The E7 proteins of both the high dsk. and low risk llPVs
have been shown to transactivate the adenovirus E~ cilrly
promoter (Phelps et al., 1988; Storey et al., 19~Oa i Munger ct
al., 1991; Watanabe et a1., 1992a). The ElF binding sites
present in the adenovirus E2 promoter were essential for the
transactivation of this promoter by E7 (Phelps et al., 1991).
Recent studies have shown that, similar to the EiA 125 mHNA
product, the HPV-16 E7 can also dissociate the complexes 01
cellular transcription factor E2F and pRb (Phelps et ill.,
1991; chellappan et al., 1992; Nevins, 1992; Pagano ct a.1.,
1992; Huang et al., 1993). The E7 protein of a low risk 1l1'V,
HPV-6, was less efficient at disl"Upting the E2F'-pRb comp I ex
(Wu et a1., 1993). Similar to tr<lnsform<ltlon, the
transactivating activity of E7 was scverOlly affected by
mutations affecting the pRb binding region (Edmonds and
Vousden, 1989; Watanabe et a1., 1990; Phelps et a1., 1'J9~;
Watanabe et al., 1992a) • Mutations affecting the
phosphorylation of Serll and Ser12 of HPV-16 E7 by CK T I,
reduced, but did not totally eliminate the tranSllctivilt i nr)
activity of E7 (Edmonds and Vousden, 1989; Storey at ul.,
1990; Watanabe at al., 1990; Phelps et al., 1992).
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Transactivation was impaired by mutations affecting other
regions of E7 (Edmonds and Vousdcn, 1989; storey ct al., 1990,
Watanabe et al., 1990).
Extensive mutational analysis of HPV-16 E7 has clearly
indicated that the transfol::1nlng and transactivating activities
of E7 are independent of each other (Edmonds and Vousden,
1989: Watanabe et al., 1990; Firzlaff et a1., 1991; Phelps et
al .• 1992).
1.1.4.3 E~
Several studies have demonstrated an essential role for
El in the process of replication and episomal maintenance of
the BPV-I genome (Groff and Lancaster, 1986; Rabson at al.,
1986; Ustav and Stenlund, 1991; chiang at aI., 1992a, 1992b).
The El ORF of BPV-l encodes a nuclear phosphoprotein of 68-72
kDa (Santucci et a1., 1990; Sun et al., 1990: Blitz and
[,aimins, 1991; Lusky and Fontane, 1991). The El protein of
I3PV-l bears significant structural and functional similarity
to the SV40 and polyomavirus large T antigens. The E1 protein
binds lI'rp through its c-terminus ATP binding domain and
mutations Which affect ATP binding severely interfere with the
activity of this E1 protein (santucci et a1., 1990; Sun et
Cl1., 1990; Blitz and Laimins, 1991). The E1 polypeptide binds
the E2 transactivator protein and the c-terminal region of El
is essential for this interaction (Mohr et al., 1990; Blitz
and Laimins, 1991; Lusky and Fontane, 1991). Although earlier
studies suggested a nonspecific binding of DNA by E1 (Clertant
and seif, 1984; Santucci et a1., 1990; 81 itz and Laim ins,
1991), several recent studies have clearly demonstrated tile
speci!i-=:: binding of E1 to the viral origin of replication
(Wilson and Ludes-Meyer, 1991; Ustav et al., 1991; Yang et
a1., 1991). Further, the binding of El to the origin or
replication was facilitated by its interaction with the E?
transact iva tor protein (Mohr et al., 1990; Blitz and 1.., i nli 11$,
1991; Yang et a1., 1991).
1.1.4.4 E2
The E2 ORF encodes a DNA binding protein which can <lct ,IS
a transcriptional transact ivator and a repressor, dependjng Oil
the context of its binding sites in the LCR. The product or
the E2 ORF binds as dimers to a palindromic sequence,
ACCGN4CGGT (Androphy et a1., 1987b; Dostani et a1., 1908; l.i
et aI., 1989; McBride et a1., 1988). The c-terminal domain 01
E2 mediates DNA binding, and the amino-terminal doma in is
required for transcriptional regUlation (Dostani et al., 1980;
Giri and Yaniv, 1988; McBride et aI., 1989). A truncated rorm
of E2 encoded by BPV-l E2 ORF, lacking the transc.:ri.ptionn)
activating domain acts as a transcriptional repressor,
presumably by competing with the full-length E2 [or DNA
binding sites (Lambert et a1., 1987). By sterically
interfering with the assembly of transcription initiation
complex and binding of essential transcription factor SP1, the
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full-length E2 protein can also repress different HPV
promoters (Thierry and Yaniv. 1987; Bernard et al., 1989; Chin
~t ai., 1989; Romanczuk et al., 1990; Costan! et al., 1991;
McBride et al., 1991; Thierry and Howley 1991). The E2 dimers
can cooperate with each other and with other cellular
transcription factors, such as API, glucocortic-.lid :!:'eceptor
and keratinocyte-specifjc NFI/K factor, to synergistically
activate transcription (Gauthier et al., 1991; Ham at al.,
1991; Monioi et al., 1991).
In addition to its role in transcriptional regulation,
the E2 protein has been shown to be required for replication
of the viral gen\.lme (Lambert, 1991). The binding of E2 near
the origin of replication causes a change in the local
chromatin structure (Moskaluk and Bastia, 1988). This change
in the conformation of DNA might be essential for the
initiation of DNA replication. Another mechanism by which E2
participates in the process of virus genome replication is by
interacting with and targeting the product of the EI ORF to
the origin of replication (Mohr et al., 1990; Blitz and
Laimins, 1991; LUsky and Fontane, 1991). The amino-terminal
transactivating domain of E2 was essential for its interaction
with El (Mohr et al., 1990).
1.1.4.5 E4
Although the E4 ORFs of different PVs have undergone
significant divergence, many physical characteristics of the
l'
encoded proteins are conserved (Doorbar et a1., 1986; 1989).
The E4 ORF encodes an abundant cytoplasmic protein of 10-17
kDa (Doorbar et a1., 1986; Breitburd et al., 1987; Neary at
al., 1987; Brown et al., 1988; Crum et al., 1990; Door-bilr et
al., 1991). In some cutaneous warts containing HPV-l, the 1::1\
protein may constitute up to 20% of the total cellular protein
(Breitburd et a1.. 1987). The mRNAs capable of encoding B4
were readily detected in both parabasal and superficial l;:lycr~;
of the differentiating epithelium (erum et a1., 1990). lIigh
levels of E4 protein was coexpressed in differentiflting
keratinocytes along with the late proteins, Ll and L2 (Doorbar
et al., 1986; Breitburd et a1., 1987; Doorbar at 011., 1909;
Crum et al., 1990). The abundance of £4 protei n in
superficial cells could be related to the replication of the
viral DNA, resulting in amplified levels of DNA templ<ltc for
transcription of E4 message. Although, a role for EN in the
process of virion assembly was suggested by Doorbar et a 1.,
(1986; 1989), recent studies have ruled out this possibility
(Zhou et a1., 1991; Kirnbauer et al., 1992). More recently,
Doorbar et a1., (1991), have shown the specific interaction of
£4 with the cytokeratins, that may result in the collapse of
cellular intermediate filament network.
1.1.4.6 E5
Our knowledge of the E5 protein has primarily emerged
from studies done with BPV-L The BPV-I E5 protein is a
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small, highly hydrophobic, 90191 membrane-associated, 8 kDa
protein (Burkhardt et 01., 1989). ES is the major oncogene of
BPV-! and transforms established rodent cells, such as NIH JT3
and C127, to anchorage independence (Schiller et al., 1986;
Schlegel et al., 1986).
The ability of E5 to interact with growth factor
receptors has been thought to be, at least partially,
responsible for the transforming activity of E5. ES has been
shown to extend the half-life of the internalized epidermctl
growth factor receptor (EGFR), thus prolonging the duration of
the mitogenic signal (Martin et al., 1989). The delayed
turnover of EGFR could be related to the ability of ES to
interact with a 16 kDa protein component of the vacuolar ii'
ATPase (GOldstein and sChlegel, 1990: Goldstein et al., 1991).
E5 can also provide the mitogenic signal t>y a totally
different mechanism, by directly activating platelet derived
growth factor receptor (PDGFR) [petti et al., 1991].
The frequent deletions of the 3' early region ORFs,
including the E5 ORF, in cervical carcinoma cell lines, has
reduced the potential role of HPV-16 E5 in the process of
cervical carcinogenesis. Despite consil1erable divergence in
the AA sequence, the HPV-16 E5 is structurally sin.ilar to the
BPV-l ES (Bubb et al., 1988: Halbert and Galloway, 1988). The
~IPV-16 ES encodes a small, hydrophobic, 10 kDa protein
(Halbert and Galloway, 1988). The HPV-16 E5 is only weakly
"
oncogenic. It can cooperate with the EGFR to transform
established rodent cells and to enhance EGF-mediated mitogenic
signal transduction to the nucleus (Leechanachai at al., 1992;
Pim et al •• 1992). The HPV-16 E5-transformed cells express
higher levels of a-fos ufon treatment with I::GF (Leechanachai
et a1., 1992). c-..f.9§. is a member of a family of transcription
factors called AP-l, The LCR of HPV-IG contains three r.P-l
binding sites and AP-l modulates HPV-16 gene expression from
the promoter p97 (Chan et al., 1990). 'l'hese obs~rvat.i.ons have
suggested a significant role for HPV-16 E5 in the ear.-ly stilgos
of the oncogenic process. In the early stages of infectiot).
the viral genome remains episomal with all the ORl's intact,
inclUding ES. At this stage, E5 could be involved in
initiating the early events of oncogenesis, such as induction
of high levels of viral E6 and E7 oncoprotoins, by
upregulating c~.
1.1.4.7 Ll
The L1 ORF is the most highly conserved ORr among the
different HPVs (Cole and Streeck., 1986; Cole and D<lnos,
1987). This is further reflected by the cross reactivity oF.
antibodies raised against the Ll protein of one type to the 1.1
proteins from a variety of HPVs (Firzlaff at al., 1988).
Expression of Ll protein is restricted to terminallY
differentiated keratinocytes. overexpression uf LI using
heterologous promoters in a variety of cell types results in
"
gC'lf-assembly of this protein into virion-like particles (Zhou
at a!., 1991: Kirnbauer et a1., 1992: Rose et a1., 1993).
1.1.4.8 L2
The L2 ORF encodes a minor capsid protein. Comparison of
the L2 ORF sequences from various PVs indicate that the L2
region is rather poorly conserved. Similar to Ll, the
expression of L2 is restricted to highly differentiated
keratinocytes (Firzlaff et al., 1988).
1.1.5 Regulation of PV gena expression
Al though the oncogenes of HPVs can immortal ize and
transform a variety of cell types when expressed from stronger
heterologous promoters, they shaw strict specificity towards
cpi the I 1al cells when expressed from homologous promoter-
enhancer sequences. Several stUdies have suggested that the
epithelial cell type specific expression of HPVs is related to
cell type-restricted transcri.ption factors or critically
balanced levels of various ubiquitous transcription factors.
All genital HPVs exhibit a similar organization of the
LCR. The genomes of HPVs contain a major promoter located
upstream of the E6 ORr. Upstream of the HPV-16 promoter p97,
at nt position -)2 to -26 with respect to the transcription
initiation site, is a TATA box. Various cellular and viral
transcription factors are known to bind the LCR of HPV-16 and
regulate transcription from the viral promoter p97 (Gloss et
al., 1987; Phelps and Howley, 1987; Chan et al., 1989: Gloss
2.
et a1., 1989a; 1989b; Chan et a1., 1990; Chong et a1., 1990,
Cripe et al., 1990; Gloss and Bernard, 1990; Nakshatri et '-11.,
19901 Romanczuk et a1., 1990; Sibbet and Campo, 1991); Chung ct
al., 1991; Gauthier et a1., 1991; Ishiji et al., 1992; 'I'fln ct
a1.. 1992; Morris et a1., 1993).
Extensive mutational analysis of the HPV-16 LeH h.1S
mapped an epithelial cell type-specific enhancer (Cripe ct
a1., 1987; Gloss et al., 1987; Marshall et al., 1989; Cripe ct
al., 1990; Ishiji et al., 1992). Elements responsive to tile
viral E2 gene product and the steroid hormone glucocorticoid
and progesterone were present in the LCR of HPV-16 (Cripe ct
al., 1987; Gloss et al., 1987: Chan et al., 1989; Mittnl ct
a1., 1993). The viral E2 gene product is a segucncc-spcci J it.:
DNA binding transcriptional modulator that can eitber:' .let i V'lt.C'
or repress transcription from the viral promoter, depend i nq 011
the proximity of its binding sites to the 'l'ATA box sequelll..:e
(Cripe et al., 19B7; Phelps and Howley, 1987; nom,lnczul-: et
al., 1990). steric hindrance with the binding 01
transcription factors to the adjacent motifs or assembl y 01
transcription initiation complex might underlie the basi~ 01
E2-mediated repression (Gloss and Bernard, 1990; J)osttlni ct
al., 1991; Tan et al., 1992).
Twenty-nine different protected regions corrcspontl i ng to
NFl, API, oct-l and several other transcription factor bjnding
sites were observed in the LCR of t1PV-16, by in Y..i.t..r.2 foot-
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printing analysis (Gloss et al., 1939a; Morris at al., 1993).
cooperation between NFl and API has been shown to result 1n
increased transcription from the viral promoter (Chong et a1..
1990). Two API binding sites present in the LCR mediate the
response of HPV-16 to tumor promoter, TPA (Chan et a1., 1990).
It has also been suggested that the API binding sites mediate
the response of HPV-16 LCR to various growth modulatory
factors. Of relevance is a recent study which indicated that
one of the viral oncoproteins, ESt is involved in amplifying
and transducing the mitogenic signal from EGF and PQGF
receptors to c-fos, a component of the transcription factor
APi (f~eechanachai et ill., 1992; Pim et aI., 1992). The HPV-16
LCR responds to growth factors, such as EGf', transforming
growth factor (TGF) , and the morphogen, retinoic acid (Agarwal
et al., 1991; Braun et al., 1990; Yasumoto et al., 1991).
In addition, HPV-16 gene expression is also modulated by
steroid hormones, glucocorticoids and progesterone (Gloss et
a1., 1987; Chan et al., 1989: Lees et al., 1990; von Knebel
Doeberitz et aI., 1991: Mittal et a!., 1993). RegUlation of
HPV-IG gene expression by steroid hormones is of great
relevance, because this virus primarily infects epithelia of
the genital tract. These epithelial cells possess receptors
for sex steroid hormones, estrogen and progesterone and are
SUbjected to profound effects of these hormones (Sanborn et
aI., 1976). Both glucocorticoids and progesterone upregulate
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the HPV-16 promoter p97 (Gloss et al., 1987; Chan et al.,
1989; Lees et a1., 1990; von Knebel Doeberitz et a1., 1991:
Mittal et a1., 1993). This upregulation of HPV-IG gene
expression by glucocorticoid hormones and progesterone forms
the basis of transforming ability of this virus.
The effect of glucocorticoids is mediated through the
91ucocorticoid receptor. Glucocorticoid receptor is ,I
sequence-specific DNA binding transcription factor thCl.t is
normally present in an inactive complex with the heat shock
protein, HSP 90, in the cytoplas:'lic compartment of cel1s
(Beato, 1989; Smith and Toft, 1993). Specific ligand-binding
activates the translocation of and transcr iption by til i:3
receptor (Landers and Spelsberg, 1992). Several studies have
identified glucocorth:oid response elements (GRE) in the f,CH
of HPV-16 (Gloss et al., 1987: Chan et al., 1989: Mittill et
al., 1993). Similar sequences have also bel3n noticed in many
other genital HPVs (Chan et al., 1989). One of the Glms of
HPV-16 identified earlier overlaps an API binding site and was
responsive to both glucocorticoids and progesterone, and
mutations within this sequence lowered the response to
glucocorticoids (Chan et al., 1989: Chan et al., 1990).
Furthermore, this sequence specifically bind.,; the pur.ified
glucocorticoid receptor (Chan et al., 1989). The induction by
glucocorticoids was inhibited by the progestin/glucocorticoid
hormone antagonist. RU486 (Chan et al., 1989; Mittal et al.,
1993) .
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1.1.6 Transcription pattern
PVs generate a wide variety of mRNAs by utilizing
different promoters and following a complex splicing pattern
of a number of splice sites. In the genome of BPV-l, seven
different promoters have been identified (Ahola et al., 19B7;
Baker and Howley, 1987; Stenlund et al., 1987; Choe et al.,
1989). The genomes of HPVs contain a single major promoter
located immediately upstream of the E6 ORF, from which all the
transcripts are initiated. In addition to the major promoter,
an internal promoter is present within the E6 ORF of low risk
HPVs, HPV-l, -6 and -II (Chow et a1., 1987a; 1987b; Smotkin et
al., 1989).
A detailed analysis of HPV-16 transcripts has been
performed by using various techniques. A majority of
transcripts in HPV-16-positiva cervical cancers and cancer-
derived cell lines correspond to the E6-E7 region. In several
different cell lines, the nt 226 splice donor site was spliced
alternately to nt 409, 526 and 3357 splice acceptor sites, to
generate E6*, E6** and E6*"'* mRNAs, respectively (Smotkin et
ill., 1989; Cornelissen et al., 1990; Doorbar et al., 1990;
Johnson et a1., 1990; Schneider-Maunoury et al., 1990; Nasseri
at aL, 1991; Rohlfs et al., 1991; Shirasawa et a1., 1991;
Sherman and A11oul, 1992; J=iherman et a1., 1992). One of the
most commonly used splice donor sites in the genome of HPV-16
1.s the nt 880 site. This site is alternately spliced to nt
2708 and 3357 splice acceptor sites (Doorbar et 031., 1990;
Rohlfs et a1., 1991: Sherman et al., 1992). An infrequently
used splice donor site is the nt 1301 site, which is spliced
to the nt 3357 and 5637 splice acceptor sites (Doorbar at aI.,
1990; Sherman et a1., 1992). The mRNAs corresponding to tho
E2 and L1 regions have also been dE::tected in a few call lines
(Doorbar et al., 1990: Nasseri et al., 1991; Rohlfs et al.,
1991: Sherman and Allou1, 1992; Sherman et a1 1992).
Different species of mRNAs detected in several cell lines ilrc
depicted in the fig. 1.1.
The different species of mRNAs undergo 3' cleavage and
polyadenylation at the viral unknown cellular
polyadenylRtion signals (Doorbar et al., 1990: Rohlfs et ill.,
1991;, smits et aI., 1991; Sherman et a1., 1992). A cellulilr
polyadenylation signal is used in cells in which the IlPV
polyadenylation signal is deleted as a consequence of
integration of the viral genome (Smits et al., 1991). In the
genome of HPV-16, 1 early region (EPl) and 3 late region (1,Pl,
LP2 and LP3) polyadeny1ation signals are present (Seedorf at
a1., 1985). Of the 3 late region polyadenylation signals, LP2
is the most commonly used (Kennedy et <.1., 1990). Alternilte
utilization of these polyadenylation signals may be important,
because an AU rich instability element present upstroam o[ LP2
and LP3 polyadenylation signals might regUlate the stability
of late region transcripts in different cell types (Kennedy ct
a1., 1990).
Figure 1.1 DiagramJll....tic representation of HPV-16 transoripts.
The genomic organization of HPV-16 and the positions of
ORfs indicated by open boxes, are depicted on top. Exons and
i.ntrons are indicated by open boxes and lines, respectively.
Numb~rs below boxes corresponds to HPV-16 nt. The 5' ends of
the last five transcripts were not precisely mapped. The
continuity of transcripts are indicated by arrows. Because
the :1' early region ORFs including the early polyadenylation
5 ignal sequences are deleted in several cell lines as a
L:onscqucnce of integration of the viral genome, many
transcripts utilize cellular polyadenylation signals. Coding
potentials of t.canscripts are indicated on the right.
Abbreviations: LCR, long control region.
The data for the figure is from Smotkin et al., 1989;
Door-bar at al., 1990; Nasseri et al., 1991; Rohl fs et al.,
1<)')J; Sherman and Alloul, 1992: Sherman et al., 1992.
II .o
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~.~.7 Replication of the PV genome
Studies on BPV-l have contributed significantly to
understanding the PV replication, In transformed and
transiently transfected cells, the BPV-l genome undergoes
regulated replication once per cell cycle and is stably
maintained as a multicopy nuclear episome (Lambert, 1991).
The replication of the genome was dependent on the presence of
the viral origin of replication and the full-length E1 and E2
proteins (Sarver at aI" 1984; Groff and Lancaster, 1986;
Rabson at al., 1986; DiMaio and Settleman, 1988: Ustav and
Stenlund, 1991; 'fang at al., 1991). The viral origin of
replication includes an AfT-rich region and the binding sites
for the El and E2 proteins (ustav and Stenlund, 1991; Ustavet
al., 1991; Yang et al., 1991). The El ORF encodes an ATP
binding, phosphoprotein with helicase activity (Santucci et
al., 1990; Sun et aI., 1990; Yang et aL, 1991). The El
protein has been shown to interact with the E2 transactivator
protein, and this interaction facilitates the targeting of E1
protein to the viral origin of replication (Mohr et al., 1990;
Blitz and Laimins, 1991; Lusky and Fontane, 1991; Yang et aL,
1991) .
Little information is available on the replication of
HPVs, primarily because of the lack of a suitable cell system
in which the viral genome can undergo replication. Several
recent studies have demonstrated that the replication of the
2.
genomes of HPV-6, -11, -16 and -18 can be achieved in il
va:dety of cell systems (Chiang et 81., 1992a; 1992b: Oct
Vecchio at a1., 1992; Remm et a1., 1992). The replication was
strictly dependent on the presence of El and E2 gene products.
A mixed combination of El and E2 proteins of different III'V
types supported the replication of homologous as well .IS
heterologous HPV origins, albeit with different efficiencjcs
(Chiang at al., 19928; Del Vecchio at al., 1992).
1. 1. 8 oncogenesis by HPVs
1.1.8.1 Viral factors
HPVs are associated with a variety of proliferative
disorders of epithelia. The role of cutaneous HPVs in the
causation of common cutaneous warts has been very well
established (Rapioi et a1., 1992).
Genital HPVs have received greater attention, beciluso
several experimental and epidemiological studies htlvo
suggested that these HPVa play an important role in gon i tal
cancers, especially cervical cancer that constitutes tl high
percentage of human c~ncers (zur Hausen, 1977; Koutsky et <11.,
1988; schiffman, 1992). The low risk HPVs are the most
frequent types associated with benign genital warts. 'rho i. r
genomes have also been detected in oral and laryngeal cancors
(Gissmann et al., 1982; Mounts and Shah, 1984; de Villier.s ct
al., 1985). Approaching 100\ of cervical cancers contil i n
high risk HPV genomes (Schwarz et a1., 1985; Gergley et tll.,
"
1987; de villiera, 1989; van den Brule et al., 1989; Young et
a1., 1989). Of different types of high risk HPVs associated
with this condition, HPV-16 and -18 are the most common types.
Approximately 55~ of invasive cervical cancers contain the
UPV-16 genome, whereas 15' harbour the HPV-18 genome (Shah and
Uowley, 1990). Several laboratory studies have demonstrated
the oncogenic potenti.al of high risk HPVs. The high risk HPVs
such as HPV-!6, -18 and -33 have been shown to immortalize
human cervjcal and foreskin keratinocytes, which are the
natural target cells for these viruses (Durst et al., 1987b:
Pirisl et al., 1987; Kaur and McDougall, 1988: schlegel et
a1., 1988; Woodworth et al., 1988; Kaur et al., 1989; Pecoraro
at al., 1989; Tsutsumi et a1., 1992; Gilles et al., 1993).
'['he histological abnormalities and the aberrant
differentiation pattern exhibited by these immortalized
keratinocytes resemble various abnormalitieE, present in
naturally infected cells (McCance et al., 1988; Hudson et al.,
1990; Woodworth et aI" 1990; Qi et a1., 1992).
One of the mechanisms by which high risk HPVs induce
immortalization is by deregulating the cell cycle. The tumor
suppressor proteins, p53 and pRb, have been shown to
Mgatively regulate the cell cycle (Ducommun, 1991; Cobrinik
ct a1., 1992; Cowell, 1992; Meek and Street, 1992). Viral
oncoproteins, E6 and E7, interfere with the normal functioning
of these proteins. The E6 protein of high risk HPVs can bind
and selectively target the degradation of pS3 (Scheffner et
aL, 1990; Werness €It al., 1990: Crook €It a1., 1991a). The 1:':7
protein binds and sequesters pRb in a functionally inactive
cOllplex (Dyson €It al., 1989; Munger €It al., 1989a; Barbos.. at
a1., 1990; Gage €It a1., 1990; Heck €It a1., 1992; Sanq ilnd
Barbosa, 1992). The interaction betwesn pRb and E7 also
results in the release of the cellular transcription factor,
E2F, which activates genes c:oncerned with DNA replication,
from a functionally inactive E2F-pRb complex (Phelps at ,,1. ,
1991; Pagano et al., 1992; Huang at al., 19931. Recently,
the association of the HPV-16 E7 protein with the cell cycle
regulatory protein p33cdk2 was demonstrated ('l'ommasino et ., I. ,
1993).
Several studies have suggested that the abi 1 j ty to
interfere with the function of these tumor suppressor and eel I
cycle regulatory proteins is essential for the oncoqcn i c
activity of HPVs (Vousden, 1990; Hunger €It a1., 1992). In
several HPV-positive cervical carcinoma cell lines, only wild-
type alleles of p5J or pRb were detected, whereas in llPV-
negative cervical carcinoma cell lines, these genes were found
to be inactivated by mutations (Crook at 131., 1991b; Schcffnor
et a1., 1991). Interference with the llctivity of thc3c
proteins by the expression of E6-E7 ORFe was sufficient [or.
immortaliz.ation ot keratinocytes (Schlegcl et al., 1988 ;
HaWley-Nelson ct al., 1989; Munger et al., 1989; Inoue at C11. ,
1991; Halbert €It a1., 1991). Maintenance of the transformod
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phenotype of Hpv-transformed cells was dependent on the
continued expression of E7 (von Knebel Doeberitz et a1., 1988;
1991; 1992; Craok et al., 1989; storey et al., 1991). The
oncogenic potential of HPV-16 has also been demonstrated at
the organismal level. Transgenic animals expressing the E6-E7
region of HPV-16 showed a high incidence of germ cell and
neuroepithelial cell tumors (Kondoh et a1., 1991; Arbeit et
al., 1993). Targeting the expression of these genes to the
lens tissue of transgenic animals resulted in altered
epithelial cell growth and differentiation and tumor formation
(Griep et a1., 1993).
The products of other genes, such as El and E2, may play
indirect roles in thn oncogenic process by affecting the
expression of E6 and E7 oncoproteins. rn premalignant
lesions, malignant tumors and tumor-derived cell lines, the
viral genome was found to be integrated with the host DNA.
These integration events resulted in selective retention of E6
and E7 ORFs and disruptions of El and E2 ORFs and frequent
deletions of the J' early region ORFs (Pater and Pater, 1985:
Seedorf et a1., 1985; 'iee et a1., 1985; Durst et a1., 1986;
Hatsukura ct a1., 1986; smotkin and Wettstein, 1986; Androphy
et a1., 1987a; Awady et a1., 1987; Baker et a1., 1987; Chao et
al., 1987; 1988; Seedorf et al., 1987; Shirasawa et a1., 1988;
w:lgatsuma et a1., 1990). The E2 ORF encodes a transcriptional
repressor protein which downregulates the expression of E6 and
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E7 from the viral promoter (Ham et al., 1991; McBride et <\1. I
1991). In keratinocyte immortalization assays, disruption of
El or E2 ORFs resulted in a higher efficiency of
immortalization (Romanczuk and Howley, 1992). Inactivation or
E2, as a result of integration of the viral genome, may lead
to enhanced expression of viral oncogenes E6 and E7 and
augment the oncogenic potential of the HPVs (Sang and lJarbasa,
1992b) •
Recent studies have identified E5 as an oncogene. 'l'he E5
protein may playa significant role in the early stages ol'
tumor induction by enhancing the mitogenic signal of growth
factors such as EGF and PDGF (Leechanachai et al. H192; Pim
et al., 1992; Banks and Matlashewski, 1993).
1.1.8.2 Host factors
The incidence of HPV infection is worldwide (Durst et
al., 1983; Fukushima et al. I Ig85j and high risk HPVs arc
found in both normal and dysplastic cervical tissues (Crum et
al., 1985b; Gissmann and Schneider, 1986; Macnab et al., IgOG:
McCance et al., 1986). However, the high risk UPV-associated
disease process follows a prolonged course and on] y a smilll
proportion of HPV-16-positive dysplastic tissue progresses to
become preneoplastic and neoplaEttic lesions. The long latency
period and variability of the outcome of the infection has
lead to the suggestion that several other genetic changes and
cofactors may be required to precipitate the actual disease
(Vousden, 1989; 2ur Hausen, 1989).
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Several experimental studies are also in agreement with
this suggestion. The genomes of high risk HPVs induced
immortalization, hllt not transformation of primary human and
rodent cells (Durst et al. I 1987b; Pirisi at a1., 1987; Kanda
at al., 1988a i schlegel at al., 1988; Woodworth at al., 1988;
1989; Pecoraro at al .• 1989; Tsutsumi et a1., 1992).
Transformation of HPV-16-immortalized human and rodent cells
was dependent on additional genetic changes, which occurred
spontaneously or were induced exogenously. In contrast to
primary cells, transformation of immortalized rodent cells,
which had undergone certain genetic alterations to become
immortal, was readily achieved by transfection of high risk
IlPV DNA (Tsunoka....a et al., 1986; Yasumoto e1: aL, 1986; Kanda
et a1., 1987; Matlashewski et al., 1987a; Kanda et a1., 1988a,
Vousden et a1., 1988; Yutsudo et al., 1988; Bedell et a1.,
1989). Further, cotransfection with oncogenes, such as EJ-
U§., ....hich is found mutated in a wide variety of cancers, or
v-LM, was sufficient to induce transformation of primary
rodent cells, indicating the need for additional genetic
alterations for transformation (Crook et a!., 1988; Pater et
al., 1988; Lees et a1., 1990; Vousden, 1990; Iol.unger et al.,
1992). similarly, transformation of immortalized human
keratinocytes was achieved either by sequential transfection
with activated EJ-U§ or by maintaining the keratinocytes in
culture for an extended period (DiPaolo et aI., 1989; Durst et
al., 1989; Hurlin et al., 1991: Pecoraro et al., 1991).
Spontaneous secondary mutations or dere~;;lated expression oC
certain genes which arise during prolonged culture could
contribute to transformation. supporting this hypoth(>sis is
the observation that spontaneous transformation of
immortalized BRK cells in culture was i'lccompanied with
increased expression of K-.r.ft.ll (Inoue et al., 1991).
The evidence for the presence of genetic chanIJes ill
cervical cancers comes from sevenal cytogenetic studico.
These changes include deregulated expression and/or mutations
in protooncogenes and antioncogenes and gross chr:-omosomal
abnormalities (Atkin and Baker, )982: Crum et iLl., 1985a;
Durst et al., 1987b: Piri:;i et aL, 1987; Atkin and Unker,
1988; Kaur and McDougall, 1988; \'1oodworth et al., 1990; Inoue
et a1., 1991; Smits et al., 1992; Klingelhutz ot al., 1993).
Recent studies have shown that the viral E7 oncoprotein
enhances cellular genetic instability (Uushida and Vilsumoto,
1991) .
Integration of the viral genome into the cellular qenome
might affect the expression of flankinq cellular (Jenes.
Al though the sites of integration on tho chromosome were
random, disruption of cellUlar genes <lnel their expression Ciln
occur for different integration events near or into these
genes (Durst et al., 1987a; Popescu at a 1., 1987; Schnaider-
Maunouroy et al., 1987; Lazo, 1988; Lazo et al., 1992).
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The resistance of primary cells as compared with the
established cells, to transformation, could be due to
e):tinction of the viral oncogene functions in primary cells
(Bosch et al., 1990; Durst et al., 1991; Miyasaka et al.,
1991; Res! et a1., 1991). The modulation of E6 and E7 by
cellUlar factors may underlie the ability of primary cells to
suppress the tumorigenic phenotype of cell hybrids, which were
derived by fusing IIPV-16- or -IS-positive invasive cervical
cancer cells with normal primary cells (Saxon et al., 1986;
Srivatsan et a1., 1986; Koi et a1., 1989; zur Hausen, 1989;
Stanbridge, 1990; Miyasaka et a1., 1991).
1.1.8.3 Cofactors
Several cofactors such as hormones, ultraviolet (UV)
radiation, environmental carcinogens and infection with other
viruses may enhance the oncogenic potential of HPVs and/or
required for progression of the HPV induced lesions to a more
fully malignant state.
Epidermodysplasia verruciformis is a rare skin condition
characterized by the presence of multiple warts caused by
different types of HPVs. The warts present on areas
frequently exposed to UV radiation show a higher tendency to
become malignant (Galloway and McDougall, 1989; Shah and
Howley, 1990).
It has been suggested that several other biological
agents, such herpes simplex virus (HSV) , human
3.
immunodeficiency virus (HIV), chlamydia and bacteria
associated with vag-ioasis and gonorrhocac may act as C'of ....ctors
for the development of cervical cancer (Galloway and
McDougall, 1989). One of these agents, HSV type 2, can
transform Hpv-imrnortalized human keratinocytes (DiPaolo et
aI., 1990: Hildesheim et a1., 1991).
The chronic use of oral contraceptives has been
established as a risk factor for cervical cancer (lliidesheim
et a1., 1990, Honore et aI., 1991). In experimental studies,
the immortalization/transformation efficiency of high risk
HPVs was enhanced by steroid hormones dexamethasone and
progesterone (Crook et al., 1988: Pater et al., 1988; Durst et
al., 1989: Lees et al., 1990; Pater et al., 1990; Storey et
a1., 1992; Sexton et al., 1993).
Exposure to chemical carcinogens is a well establishod
risk factor for malignant conversion of papillomas. In
experimental systems, the presence of carcinogens facilitated
transformation of HPV-immortalized keratinocytes (Li et al. ,
1992; Garrett et al., 1993; Klingelhutz et al., 1993).
Smoking has been considered to be a risk factor for cerv ical
cancer (Winkelstein, 1990). Accumulation of tobacco
metabolites in vaginal secretions could contribute to the
development of cervical cancer (Sasson et a1., 19B5; Holly et
al., 19B6; McCann et aI., 1992). convincing evidence for
cooperation between HPVs and chemical carcinogens was prav ided
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by 11n .in ~ experiment (Sasaga....a et a1., 1992). The
induction of invasive squamous cell carcinoma of cervix in
mice locally injected .....ith HPV-16 E6-E7-expressing retrovirus
was dependent on the application of tumor promoters and
carcinogens, such as TPA or MNNG.
Oncogenesis due to HPV is a process that probably
requires decades after infection to develop, because genital
infections occur earlier and cancer develops later in life
(zur Hausen, 1991). Cofactors such as UV radiation and
hormones may be prerequisites or corequisites for oncogenesis
due to HPV, whereas co factors such as HSV, tumor promoters and
carcinogens, that have been shown to further oncogenically
insult Hpv-immortalized cells, may be factors in the
progression from HPV-ini tiated premalignant cervical lesions
to the malignant carcinomas occurring later in life.
,.
1.2 RNA PROCESSING
In the process of bQcollling messonger RNA ("RNA), the prc-
messenger RNA (pre-mRNA) transcribed by RNA polymerase II (pol
II) undergoes several posttranscriptional processing events.
These steps include capping, splicing, ). end cleavage and
polyadenylat~.on and transportation of mRNA to the cytoplaslI.
Alternative splicing is of the important
posttranscriptional mechanisms for the regUlation of HPV-16
gene expression. Several species of mRNAs with different
coding potentials are generated from a limited number of
rrimary transcripts by using a number of alternative splice
sites and a complex splicing pattern. My studies indicate
that the nt 880 splice donor site is essential for the
accumulation ot HPV-16 RNA encoding the viral oncoprot.eins.
stUdies with an emphasis on t.he nt 880 splice donor site
constitute the major part of this thesis. Because of the
close coupling of the processes of splicing and )' end
formatlon of pre-mRNA, a brief introduction to the process of
)1 end formation of pre-mRNA is also inclUded. In this
section, the posttranscriptional processing of mammal ian pre-
mRNA is discussed.
1.2.1 CAPPING
The 5' ends of all pre-mRNAs cotranscriptionally acquire
monomethylated, inverted guanosinll! nucleotide,
m7G(5 1 )ppp(5 1 )N, called the "cap" (Shatkin 1976). The cap
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structure has been thought to protect the 5' ends of mRNAs
from exonucleolytic degradation (Green, 1986; Gaille, 1991).
The cap structure serves various other functions, such as (1)
providing a targeting signal for the export of mRNAs, (ii)
increasing the efficiency of splicing and, (iii) enhancing the
translatability of mRNA.
The monomethylated cap structure has been shown to
facilitate the export of mature mRNAs tram the nucleus to
cytoplasm (Hamm and Mattaj, 1990). One of the targeting
signdls for the import of U snRNPs (uridine-rich small nuclear
ribonucleoprotein particles) into the nucleus is their
trimethylguanosine (TMG) cap (Fischer and Luhrmann, 1990; Hamill
et al., 1990; Lamond, 1990; Anderson and Z!eve, 1991).
The cap structure has been shown to influence the
efficiency of splicing (Konarska et al., 1984; Xrainer et al.,
1984; Edery and sonenberg, 1985; Ohno et aI., 1987; Inoue et
aI., 1989). Splicing of the cap proximal, but not the distal,
intron was enhanced in the presence of a cap at the 5' end of
the first exon (Ohno et al., 1987; Inoue et al., 1989).
The 5' cap of mRNAs has an important role in the process
of translation (Shatkin, 1976; Kozak, 1989). Binding of the
translation initiation factor, eukaryotic initiation factor-
(eIF)-<lF Q subunit (eIF-4E) to the S' cap of mRNA is an
essential step for the initiation of translation (Rhoads,
1988; Sonenberg, 1988; Hershey, 1991). Apart from directly
"
facilitating translation, the 5' cap cooperates with the
poly(A) tail to further enhance translation (Gall ie, 1991)
1.2.2 SPLICING OF PRE-mRNA
Splicing is a biochemical process by which the introns of
a pre-mRNA arf! precisely excised and the exons are religated.
Splicing can be broadly grouped into constitutive splicing and
alternate splicing (Smith et aL, 1989a). In constitutive
splicing, all the introns present in a pre-mRNA are excised
without preference for any intran. In alternate splicing, one
or more introns are selectively retained or spliced out.
Alternate splicing is one of the modes by which various
isoforms of proteins with different functions are produced
from the same gene (Andreadis et al., 1987; Breitbart ct ill.,
1987; Bingham et a!., 1988; Baker, 1989; Mattaj and H<lmm,
1989; McKeown, 1990; Maniatis, 1991; Foulkes and Sassonc-
Corsi, 1992). Although, the yeast system has contributed to
our knowledge of the process of splicing, the introduction in
this section is confined mostly to mammalian systems.
several cis-acting elements and ~-acting factors have
been shown to be essential for the splicing of prc-mRNA
(Maniatis and Reed, 1987; Guthrie and Patterson, 1988;
Bindereif and Green, 1990: Green, 1991). These arc described
below in greater detail.
1.2.2.1 Cis-acting elements
1.2.2.1.1 5' splice site
The boundaries of exons and introns are determined by a
set of conserved sequences called 5' (splice donor) and 3'
(splice acceptor) splice sites. The consensus 5' splice site
sequence, (C/A)AG/GURAGU, has been deduced by comparing
several 5' splice site sequences. The majority of mammalian
splice sites do not conform to this consensus sequence.
However, the first 2 nucleotides of the intron, GU, are
invariant among all naturally-occurring splice sites
(Senapathy et al., 1990). Mutation of the 5' splice site
affects the efficiency of splicing, but does not always
prevent 5' splice site cleavage (Aebi et al., 1986; 1987;
Smith et al., 1989a). Often a cryptic splice site is
activated by such mutations (Aebi et al., 1987). Mutation of
the 5' splice site of an internal exon has been shown to
result in skipping of that exon (Robberson et al., 1990:
Talerico and Berget, 1990; Niwa et aL, 1992). The 5' splice
site sequence is complementary to the first 9 nt of the Ul
snRNA (uridine-rich small nuclear RNA), and these two
sequences interact by base-pairing (Zhuar.-l and Weiner, 1986).
The effect of 5' splice site mutation on the efficiency of
splicing can be suppressed by compensatory mutations in the Ul
snRNA indicating that the degree of ..::omplementarity between
the two determines the efficiency of splicing (Aebi et al.,
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1986; zhuang and Weiner I 1986; Zhuang et al., 1987; Mayeda and
Oshima, 1988; Peterson and Perry, 1989: Nelson and Green,
1990) .
1.2.2.1.2 3' splice site
The J' splice site that determines the 3' boundary of the
intran, has the consensus sequence YnNCAG/G (Mount, 1982;
senapathy et al., 1990). The 3'splice site consists of two
elements, the conserved AG dinucleotide and the polypyrimidine
tract (PPT). Mutation of the 3' splice site often results in
activation of a nearby cryptic 3' splice site (Acb! at al.,
1986; Deshler and Rossi, 1991; Belaguli et al., 1992).
Mutations which failed to activate a cryptic splice site lead
to inhibition of the second step of splicing. However, their
effects on the first step of splicing were variable (Ruskin et
aI., 1985; Aebi et aI., 1986; Bindereif and Green, 1906;
Lamond et aI., 1987) . Several heterogeneous nuclear
ribonucleoproteins (hnRNPsj such as AI, C and D, have been
shown to associate with the 3' splice site. Mutations
affecting the conserved AG dinucleotide impaired the binding
of hnRNP protein Al to the 3' splice site (Swanson and
Dreyfuss, 1988). It has been suggested that the selection of
the 3' spice site depends on the process of scanning and the
first AG dinucleotide downstream of the branch point is
selected as the 3' splice site (Smith et al., 1989b).
The PPT is found a few nucleotides upstream of the
conserved AG dinucleotide. This poorly conserved element is
absent in a few introns (Shelley and Haralle, 1987).
repeating GU rich element can functionally substitute for the
PPT (Shelley and Baralle, 1987). Non-snRNP splicing factors,
such as U2 snRNP auxilIary factor (U2AF) and the
polypyrimidine tract-binding protein (PTB) , specifically bind
PP'l' (Ruskin et aL, 1988; Zamore and Green, 1989). Disruption
of the PPT has been shown to interfere with binding of U2
snRNP to the adjacent branch-point sequence (Frendeway and
Keller, 1985; Ruskin et al., 1988; Zamore and Green, 1989).
Several recent studies have indicated that the location and
the extent of the PPT determines the strength of a )' splice
site (Helfl'lan and Ricci, 1989; Smith and Nadal-Ginard, 1999;
Zamore et al., 1992).
1.2.2.1.3 Branch-point (BP) sequence
The DP sequence is generally located 20-40 nucleotides
upstreall of the )' splice site. Although the consensus
sequence, YNYURAY, has been derived by comparing the BP
sequences of several introns, this sequence is rather poorly
conserved among mammalian introns (Senapathy et aI., 1990).
During the first step of splicing, the conserved nucleotide,
/\, of the BP sequence forms a 2' -5' phosphodiester bond with
the invariant nt G of the 5' splice site. In some introns, nt
such as C or U are used for branch formation (Hartllluth and
Barta, 1988; Nobel et aI., Ig88). The branch point sequcnca
is specified independently of the J' splice site ilnd the
sequence context and the proximity to the PPT hiwe been
reported to influence the selection of the BP sequence (Smith
et al., 1989b). The unusually long spacing between the J'
splice site and the BP sequence has been suggested to pInyan
importar,t role in the tissue specific alternative splicing of
tropomyosin mRNAs (Smith et al., 1989b; Helfman at al., 1990).
The efficiency of splicing of an intron is not grei.lt.ly
affected by mutations at the DP scguencc, because such
mutations generally activate a nearby cryptic I3P sequcnce
(Padgett et aI., 1985; Reed and Maniatis, 1985; Ruskin et aI.,
1985). The Bp sequence interacts with the U2 snRNA by base-
pair interaction (wu and Manley, 1989; Zhuilng et al., 1989).
Several studies have suggested a similar interaction of the UP
sequence with U5 snRNA (Hartmuth and Barta, 1988).
1.2.2.1.4 other ill-acting elements
primary transcripts from several geno2ls contain multiple
5' splice sites, 3' splice sites and BP ::;equences. Presence
of such mUltiple elements greatly facilitate alternate
splicing. Several other £iri-acting sequence::; pre::;ent within
introns and flanking exons are known to affect the choice of
splice site and the efficiency of splicing. 'l'hcse clements
act by changing the secondary structure of the RNA, by
providing binding sites for specific ~-acting splicing
factors and by unknown mechanisms. Elements which alter the
secondary structure of the pre-mRNA have been thought to
affect splicing primarily by regulating the accessibility of
splice sites to the ~-acting splicing factors (Solnick,
1985; Eperon et al., 1988; Balvay et al., 1993).
Sequence elements present within the introns of Rous
sarcoma virus (RSV) , HIV-1 and influenza virus pre-mRNAs
regulate splicing and transportation of these RNAs (Chang and
Sharp, 1989; Halim et al., 1989; Lu et aL, 1990; Alonso-
Caplen and Krug. 1991; McNally et al., 1991; McNally and
Beeman, 1992). Similarly, ill-acting elements present within
certain exons of human fibronectin, leukocyte common antigen,
immunoglobulin heavy chain, adenovirus early region 3 and
bovine growth hormone pre-mRNA affect the splicing of flanking
introns (Mardon et al., 1987; Hampson et al., 1989; streuli
and Saito, 1989; Domenjoud et al., 1991; Watakabe et al.,
1993).
The other £1§-acting elements have been shown to play an
important role in developmentally regulated and tissue
specific alternate splicing of various pre-mRNAs. The neuron
specific splicing of c-~ pre-rnRNA was dependent on the
flanking intron sequences (Black, 1991; 1992). similarly, the
tissue specific alternative splicing of p-tropomyosin pre-mRNA
required sequence elements present within the alternately
spliced exon 7 and the adjacent upstream intron (Helfman et
"
al., 1990; Guo et al., 1991). The somatic inhibition of
splicing of the third intron of the Drosophila P element ..... .,s
suggested to be related to the pseudo-5' splice sites in the
S' exon and the third intran (Siebel and Rio, H190; sicbel ct
al" 1992). Sequences present in the female specific exen of
the Drosophila double sex pre-mRNA were essential for the
activation of the double sex female specific 3' splice site by
the products of transformer and transformer-2 genes (Hoshijim<:l
et al., 1991; Ryner and Baker, 1991; Tian and Maniatis, 1992).
1.2.2.2 .'r.nn!.-llctinq factors
1.2.2.2.1 snRNPs
Splicing of pre-mRNA requires a variety of U snRNAs, such
as Ul, U2, U4, U5 and U6 snRNAs. The snRNAs associate with a
common set of 6-10 core proteins and form ribonucleoprotein
complexes called snRNPs. The core proteins specifically bind
a highly conserved consensus sequence, pUllU3.4~lUGPu, present in
snRNAs (Guthrie and Patterson, 1988). In addition to the core
proteins, snRNA-specific proteins are also found in snilNP~
(Smith et aI., 1989a: Anderson and Zieve, 1991; Grcnn, 199.'.).
U snRNAs have a complex secondary structure (Guthrie and
Patterson, 1988: Green, 1991). Several variant forms of U
snRNAs are known to exist and production of some of these
variant snRNAs are developmentally regulated (Mattaj and Hamm,
1989). Temporally regUlated alternate splicing of various
transcripts during development could be related to the
regUlated production of U snRNA isoforms.
U1 snRNP
The U1 snRNP consists of U1 soRNA and three U1 snRNA-
specific proteins. The mammalian U1 snRNA has 160 nt
(Anderson and Zieve, 1991; Green, 1991). The U1 snRNP binds
the 5' splice site and the 5' end of the U1 snRNA is essential
for this interaction (Bindereif and Green, 1987; Zhuang and
Weiner, 1986; Rosbash and Seraphill, 1991; Wassarman and
Steitz, 1992; Cohen et al., 1993). One of the three U1 snRNP-
specific proteins. U1e, potentiates this base-pair interaction
between the U1 snRNA and the 5' splice site of pre-mRNA
(Heirichs et al.. 1990). The differential binding of U1 snRNP
to 5' splice sites is one of the bases for alternative
splicing (Kuo et al., 1991). The alternate splicing of the
axon, E4. of the rat preprotachykinin pre-mRNA was related to
the binding affinity of U1 snRNP to the 5' splice site of the
£4 exon. Increasing the affinity of binding of the £4 exon 5'
splice site to Ul snRNP resulted in inclusion of the exon,
whereas reducing the affinity between the two by introducing
mutations at the 5' splice site resulted in skipping of the E4
exon (Kuo et al., 1991).
]..2.2.2.1.2 U2 8nRNP
The mammalian U2 snRNA has 189 nt (Guthrie and patterson,
1988). The first 110 nt of U2 snRNA are highly conserved
among different species of eUkaryotes. Two U2 snRNA-specific
proteins have been detected in the U2 snRNP (Anderson and
fa
Zieve, 1991: Green, 1991). The U2 snRNP binds t.he IlP sequence
of an intron and this binding is dependent on the presence of
Ul snRNP {Barabino et al., 1990). Non"snRNP proteins, such as
U2AF, splicing factor (SF)! and SFJ promote an efficient
binding of U2 snRNP to the BP sequence (Kl:"amcr, 198B; Rllzkin
et a!., 1988; Zamore and Green, 1989; 1991). l3ilsc-pa.lr
interaction occurs between the 5' end of U2 snRN/\ and the 3'
end of U6 snRNA and this interaction is essential ror
efficient splicing (Datta and Weiner, 1991; WU and Mimlcy,
1991: Wassarman and steitz, 1992).
1.2.2.2.1.3 U4 and U6 snRNPs
The mammalian U4 snRNA consists of 1)9 nt and the U6
snRNA is 107 nt long. The U6 snRNA di f fers [rom other
spliceosomal snRNAs in that it is transcribed by RNA pol III
and laCKS the TMG cap structure and the core protein binding
consensus sequence (Guthrie and Patterson, 1988). In
addition, U6 snRNA contains an mRNA-type intran. It has been
suggested that this mRNA-type intron was inserted into ur,
snRNA erroneously by reverse splicing, because of the
proximity of U6 snRNl\ to the catalytic core of the spl iceosome
(Tani and Ohshima, 1991). The U6 snRNA is highly conserved
among different species of organisms (Brow and Guthrie, 19BB).
The high degree af conservation of both sequence and structure
has suggested an important role in splicinq for this ~;nRNA
(Guthrie and Patterson, 19B8).
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The U4 and U6 snRNPs are found in a U4/U6 snRNP complex.
'l'hese t ....o snRNPs are held together by base-pair interactions
between U4 and U6 snRNAs (Bindereif et aL. 1990). The U5
snRNP associates with the U4/U6 snRNP complex to form a multi-
snRNP complex, which is incorporated into the spliceosome
(Kanarska and Sharp, 1987). In the spliceosome, the U4 and U6
snRNAs undergo unpairing in a process likely to be mediated by
RNA helicases (Lamond "t al., 1988; Green, 1991). Several
studies have suggested a catalytic role for U6 snRNA in the
process of splicing (Guthrie, 1991). supporting this
hypothesis, the U6 snRNA is present in close proximity to the
5' splice site in a spliceosome, as shown by crosslinking to
this region of the pre-rnRNA (Sawa and Shirnura, 19921 Wassarman
and steitz, 1992).
1.2.2.2.~.4 U5 snRNP
The US snRNP is the largest and the most complex of the
snRNPs. It consists of a 117 nt long U5 snRHA and at least
seven U5 snRNP-specific proteins (Bindereif and Green, 1990;
Anderson and Zieve, 1991; Green, 1991). A fraction of U5
snRNP is also found in a triple snRNP complex with the U4/U6
snRNPs (Konarska and Sharp, 1987). This interaction with
U4/U6 snRNP complex appears to be mediatell by the triple snRNP
associated proteins, but not the individual U4/U6 or U5, snRNP
associated proteins (Bach et al., 1989; Utans et aI., 1992).
The U5 snRNA and the U5 snRNP protein, p220, were shown to
interact with the 5' spl ice site sequence of prc-mRNA
(Wassarrnan and steitz, 1992; Wyatt. et al., 1992).
studies have shown that the U5 snRN1'. interacts with both the
5' and 3' splice sites and d.etermines the position
splice site cleavage (Ne\<llllan and Norman, 1991; 1992).
1.2.2.2.2 Non-snRNP splicing- factors
Several non-snRNP splicing factors have been detected by
using different techniques, such as UV crosslink-ing, protein
purification, inhibition of j.n Y..i..t.J:2 splicing by
antibody/immunodepletion, complementation of splicing extracts
with purified proteins and cloning of the corresponding c[)NAs.
Precise functions and the mechanisms of action of a major-ity
of these factors remain to be elucidated.
A number of proteins have been identified Which assocjatc
with the 5' splice site region of pre-mRNA. '1'he bind lng 01'
two proteins, the 27 kDa SPP-l and 37 kDn SPP-2, to the 5'
splice !'lite was independent of U1 snRNP and occurred pl:"ior to
the association of pre-mRNA with the U1 snRNf' (Stolow ilnd
Berget, 1991). In addition, a 55 kDa protein which intel:"ilcts
with the 5' splice site has been detected (Garciil-Blilnco et
a1., 1989). These 5' splice site binding proteins could
either facilitate recognition of splice sites or stilbili.:c the
interaction of U1 snRNP with pre-mRNA.
The PPT/3' splice site of introns is a target folC sl;lvcral
non-snRNP splicing factors. Only a few such proteins arc
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considered here. U2AF has been shown to play an important
role in the asseJlbly of spliceosollle and the process of
spl icing. Depletion of U2AF from .J.n iliX2 splicing extracts
resulted in an inhibition of splicing (Zamore and Green,
1991). U2AF consists of 65 kDa and 35 kCa subunits (Zamore
and Green, 1989). The 65 kOa subunit has three
ribonucleoprotein-consensus domains which are essential for
RNA binding. U2AF binds the PPT/3' splice site region and
this interaction facilitates binding of U2 snRNP to the
adjacent branch site sequence (Zamore and Green, 1989; 1991).
The binding attinity of U2AF is determined by the pyrimidine
content and the lfOl,gth of PPT (Zamore et aI., 1992). The
binding of U2AF to the PPT/J' splice site was shown to be
facilitated by binding of UI snRNP to the dOlinstreall 5' splice
site region (Hoffman and Graboliski, 1992). Several recent
studies have suggested that the modulation of the binding
aztivity of U2AF is an i1l1portant mechanis. for alternative
splicing of pre-mRNAs (Green, 1991; Hoffman and Grabowski,
1992; Valcarcel et al., 1993).
The 62 kDa PPT binding protein (PrBP) binds the PPT of
introns. Mutation of the PPT, which "ffected the binding of
the PTBP, resulted in a lower efficiency of pre-sp1iceosome
complex assembly (Garcia-Blanco et al., 1989). PrBP is a
component of spliceosome and its association with the PPT is
independent of snRNPs and splicing factors (Paton et al.,
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1991). Irnmunodepletion of PTBP and an associated protein,
PTB-associated splicing factor, from splicing extr<l.cts
inhibited splicing (Garcia-Blanco et al., 1989; Paton et al.,
1991; 1993).
Intran binding protein (IBP) is a 70-100 kDa PPT binding
protein mediating the interaction of us snRNP with the 3'
splice site. Despite its interaction and copurification with
U5 snRNP, lBP is distinct from other snRNP proteins (Bindcrcir
and Green, 1990).
A recently identified protein of 88 kOa hilS been shown to
be required for the assembly of the spliceosome.
rrnmunodepletlon of this protein from the splicing extract
resulted in inhibition of splicing and supplementing the
irnmunodepleted extract with affinity-purified paB restored
splicing (Ast et al., 1991).
Several studies have indicated an essential rola for
hnRNPs in splicing. Some hnRNPs, such as AI, c and D, have
been shown to bind the PPT!J' splice site region (Kum<lr ct
al., 1987; Swanson and DreyfUSS, 1988; Garcia-Blanco ct ill.,
1989; Stolow and Berget, 1990). Mutation of the conserved AG
dinucleotide sequence abolished the binding of hnRNP .... l
(Swanson and Dreyfuss, 1988). In Yi.!:..J;:Q splicing of pre-mHNA
was inhibited by the addition of anti hnRNP C antibodies to
the splicing extract or imrnunadepletion of hnHNP C from the
splicing extract (Bindereif and Green, 1990). The
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concentration of the hnRNP Al relative to the splicing factor
(SF) 2 has been shown to .od.ulate alternative splicing of pre-
mRNA (Mayeda and Krainer, 1992; Mayeda et aI., 1993).
By fractionation of nuclear extract, proteins with
essential roles in the process of spliceosome assembly and
splicing have been purified (Krainer and Maniatis, 1985:
Kramer and Keller, 1985; Fu and Maniatis, 1990). Fractions
containing SF1. and SFJ were required for the assembly of
spliceosome and SF2 and SF4 were required for 5' splice site
cleavage and lariat formation (Kramer et al., 1987; Kramer,
1988). sUbsequently, SF4 was shown to convert an assembled
functionally inactive complex into a functional complex (Utans
and Kramer I 1990).
There is also evidence for the presence of non-snRNP
factors which affect the choice of splice sites. The factor
alternate splicing factor (ASF)/SF2 was identified as an
activity required for the assembly and stabilization of
spl iceosolles. ASF/SF2 consists of related 30-35 kDa
polypeptides and selectively promote the splicing of the most
p~oximal 5' splice site to a 3' splice site (Ge and Manley,
1990; Krainer et al., 1990a; 1990b; Go at a1., 1991; Krainar
at al., 1991; Lamond, 1991; Mayeda and Krainer, 1992).
Recently it was reported that the ASF/SF2 belongs to a family
of proteins, called SR proteins, which are involved in
constitutive and alternative splicing (Mayeda et al., 1992;
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Zahler at al., 1992: 1993). Factors which promote the usc of
a distal 5' splice site have also been identified. Distal
splicing factor (DSF), SF5 and hnRNP Al were shown to enh,lIlce
the utilization of a distal 5' splice site (Harper flnd Mtmley,
1991; Mayeda and Kralner, 1992).
1.2.2.3 Assembly of spliceosomes
Splicing of pre-mRNA occurs in a ribonucleoprotein
complex called the spliceosome. Spliceosome, which consists
of five snRNAs (UI, U2, U4/U6 and US) and more than fifty
different proteins, are assembled in fout" different stages
(Reed, 1990: Green, 1991: Guthrie, 1991).
The binding of the VI snRNP to the 5' spi icc 51 to
constitutes the first stage of the assembly process and this
binding is independent of requirement for other snlmps,
splicing factors and ATP hydrolysis (Rosbash and Seraph!n,
1991) •
In the second stage, the U2 snRNP binds the UP sequence.
This binding is an ATP-dependent process and .:ommi ts the pr.e-
mRNA to the splicing pathway. Presence of Ul snRNI' and other.
splicing factors such as U2AF, SFl and SF) promotc stronger.
binding of U2 snRNP (Green, 1991; Hoffman and Crabowski,
1992) .
Incorporation of the pre-assembled U4/UG/U5 multi-snRNP
complex into the spliceosome marks the beginning of the third
stage of the assembly process (Konarska and Sharp, 1987; Utans
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et al.. 1992). The U4/U6/U5 lIulti-snRNP complex associates
with the pre-aRNA-bound U1 and U2 snRNPs (Bindereif and Green,
1987; Wassatllan and Steitz, 1992; wyatt et al., 1992).
In the fourth stage, which immediately precedes the 5'
splice site cleavage, the assembled spliceosome undergoes a
conformational change. Although the base-pair interaction
between the U4 and U6 snRNAs is destabilized, the U4 snRNP is
not released from the complex (Blencowc at al •• 1989).
1.2.2.4 Mechanism of splicing
Splicing involves two successive transesterification
reactions and proceeds in two steps (Green, 1991; Guthrie,
1991). In the first step, cleavage occurs at the 5' splice
site resulting in a linear first axon and an intron-second
exon lariat structure. Formation of 2'-5' phosphodiester bond
between the invariant first base, G, of the intron and the 2'-
hydroxyl group of the conserved A of the BP sequence results
in the lariat structure. In the second step, cleavage occurs
at the 3'spl!ce site with subsequent ligation of the second
exon to the first exon. The intron is released as a lariat.
1'he 2'-5' phosphodiester bond in the lariat intron is cleaved
by a debranching activity and the linearized intron undergoes
degradation (Smith et a1., 1989a; Green, 1991).
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1..2.3 3' END CLEAVAGE AND POLYADENYLATlaN
1.2.3.1 Nuclear polyadenylation
EUkaryotic mRNAs have poly(A) tails at their 3' ~nds.
The poly(A) tail has been shown to confer stability and
facilitate translation of mRNA (Jackson and Standart, 1.990).
The )' ends of eUkaryotic mRNAs, except for histone mRNAs, arc
generated by specific endonucleolytic cleavage of the )' end
of pre-mRNAs and addition of 200-300 A residues by a process
called polyadenylation. The endonucleolytic cleavage occurs
while the RNA pol II is transcribing the template DNA
downstream of the cleavage site. II!. Y.iY2, the )' end cleavage
and polyadenylation are closely coupled. However, these two
processes can be uncoupled in in Y.i..t.1:..Q systems. 'rhe 3' cnd
cleavage and polyadenylation are highly dependent on certain
£.1.§.-acting elements and ~-acting factors which interact
among themselves and with the cis-acting elements.
1.2.3.1.1 Cis-acting elements
1.2.3.1.1.1 Hexanucleot!de AAUAAA sequence
One of the well defined and highly conserved £i..§.-acting
elements required for pre-mRNA 3' end cleavage and
polyadenylation, also called 3' end formation, is the
hexanucleotide consensus sequence, AAUAAA. 'rhis element is
usually located 20-30 nt upstream of the cleavage site. The
percentage frequency of nt in this consensus is Aw/l-u u?sIl.9SIl.?SA9(,
(Wickens, 1'390a). The natural variant of this consensus
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sequence, AUUAAA, is found in approxlaately 12' of IIIRNAs. The
ability of this variant to direct 3' end cleavage and
polyadenylation is comparable to that of the consensus
sequence (Hanley, 1988). Recently, another naturally
occurring variant of the consensus sequence, <:AUAAA, was
detected in the Xenopus a-tubulin mRNA (Rabbitts et 611.,
1992). Mutation of the AAUAAA sequence affected 3' end
cleavage, polyadenylation and mRNA accumulation (Manley,
1988). In.in.Y...i...t..r2 assays in whlch the 3' end cleavage and
polyadenylation were uncoupled, the effect of mutation of the
AAUAAA sequence on the efficiency of polyadenylation was
dependent on the position and the nt sUbstituted (Sheets et
aJ., 1990). A Dlutation at the +2 position was better
tolerated thi'm .utations elsewhere in the hexanucleotide
sequence. In contrast, modification by methylation of the 2'
OH group of ribose of the +2 position nt, but not the +3
position nt, affected polyadenylation (Bardwell et al., 1991).
Apart from underscoring the importance of the AAUAAA
haxanucleotide sequence, the above-mentioned study highlighted
the nature of protein-RNA interactions.
1.2.3.1.1.2 Downstrelllll GUIU rich elements (DSE)
certain sequences located downstream of the cleavage site
are essential for proper mRNA )' end formation. The CSE is
involved in specifying a unique 3' cleavage site. Deletion of
this element resulted in the production of heterogeneous 3'
5.
ends (Manley, 198B). These sequence elements are weakly
conserved and ge.nerally GU or U rich. Several in Y..iY..2 and ill
yiliQ studies have indicated the importance of DSE for
efficient 3' end formation (conway and wickens, 1985; Hart at
a1., 1985; Gil and Proudfoot, 1987; Manley, 1988; Ryner at
al. I 1989a). The SV40 early polyadenylatian signal has a GU-
rich DSE, and the adenovirus E2A transcription unit has a U-
rich DSE. Despite the difference in the primary sequences,
these two elements were functionally interchangeable (Hart ct
al., 1985).
The approximately 40 nt spacing between the AAUAAA
hexanucleotide element and the eSE is fairly well conserved.
Alteration of the spacing, but not the sequence, bet\ot'een these
two elements affected the activity of the polyadenylation
signal (MCDevitt et al., 1986; Gil and Proudfoot, 1987; Heath
et al., 1990; wingley et al., 1990). 1\ systematic study on
the effect of spacing between these two elements was carried
out by Heath et al., (1990). A spacing of 19 nt was optim<l1
for the activity of HSV-l thymidine kinase (tk)
polyadenylation signal. Increasing this spacing to 43 nt or
reducing to 7-9 nt severely affected the function of the
polyadenylation signal (Heath at al., 1990). 'rho AAUAAI\
element and the DSE of human T cell leukemia virus (fITLV) ar.e
separated by 274 nt and the J' end cleavage occur.s
approximately 250 nt downstream of the AAUAIIA sequence.
5.
Looping out and folding of the sequences located in between
the AAUAAA sequence and the DSE brought these two elements
into optimal spacing and facilitated 3' end formation (Ahmed
at ai., 1991). The J' end formation of several other pre-
mRNAs have been shown to depend on a similar looping mechanism
(Brown et ai., 1991).
1.2.3.1.1.3 Upstream elements (UBE)
Recently, certain elements located upstream of the AAUAAA
sequence were shown to enhance the activity of the
polyadenylation signal. A 20 nt USE is present 29 bases
upstream of the AAUAAA sequence of SV40 late polyadenylation
signal (Carswell and Alwine, 1989). A similar USE is present
upstream of the polyadenylation signal of the Ll major late
transcript of adenovirus and this element has been suggested
to promote the preferential utilization of the L1
polyadenylation signal during the early phase of infection
(DeZazzo and Imperiale, 1989). USEs are also present upstream
of the polyadenylation signals of several retroviruses and
retroid viruses and these USEs regulate the activity of the
polyadenylation signal by different mechanisms (Proudfoot,
1991). Although USEs of different pre-mRNAs bear little
sequence similarity, they are functionally interchangeable.
'rhe USE of HIV-l is U-rich and bipartite in n;lture. It can
functionally SUbstitute for the USE of SV40 late
polyadenylation signal (Valsamakis et al. I 1991). Similarly,
..
the USEs of retroid viruses, such as ground squirrel hepatitis
virus and spleen necrosis virus, were also functionally
interchangei!l;ble (Russnak and Ganem, 1990).
1.2.3.1.2 UAla-acting factors
The development of in :!i...t.n! polyadenylation system whIch
accurately reproduces mRNA 3' end forJllat:.ion has greatly
facilitated identification t)f individual factors required for.
this process. Because of the different fractionation
procedures followed by different laboratories, it is possible
that the same factors may have been given diffct'cnt
designations.
One of the factors required for J' end formation j s
poly (A) polymerase (PAP). PAP has been purified from calf
thymus and HeLa cells. It is a 40-50 kDa protein with an N!'P
polyllerizing actiVity (Christofori and Keller, 1989; Gilmartin
and Nevins, 1989; Ryner et a1.. 1989b). 'l'he gene encoding PAP
has been cloned recently (Linger et al .• 1991; Raabe ct ~l..
1991). Puri!ied PAP adds poly(A) tail nonspecifically to uny
RNA sUbstrate. Addition of another tactor to the in :!.ill.2
polyadenylation reaction conferred MUAM sequence dependent
specific activity to PAP (Takagaki et al.. 1988). PAP
required for both 3' end cleavago and polyadcnylation.
The factor that conferred specificity on PAP can bo
further fractionated into 4 factors; specificity factor (SF).
cleavage factors I and II (CF' I and CF II) and cleavage
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specificity factor (CstF) (Takagaki at a1., 1989]_ SF was
required for both J' end cleavage and polyadenylatlon and
bound the hexanucleotide sequence AAUAAA. SF may be
functionally analogous to a f<leter called PF2 described by
Gilmartin and Nevins, (1989). The cleavage factors, CF I and
CF II, ....ere required for the 3' end cleavage reaction. CF I
was shown to associate with the DSE (Gilmartin and Nevins,
1989). CstF consists of 77 kDa, 64 kOa and 50 kOa subunits.
The 64 kDa subunit of CstF can be specifically crosslinked to
the AAUAM sequence-containing RNA substrate (Wi!uz and Shenk,
1988; Takagaki et aI., 1989; wiluz et aI., 1990). An
additional 155 kDa protein has also been crosslinked to AAUAAA
sequence-containing RNA substrates (Moore et aI, 1988). The
functions of this protein has not been established.
llnRNP C has been shown to bind the DSE (Wiluz et al.,
1986). Recently, Quin and Wiluz, (1991), have described
interaction of a 50 kDa protein, DSEF-l, with the GU-r!ch DSE
of lat€~ polyadenylation signal of SV40.
An earl ier study had suggested the involvement of U
snRNPs in the process of 3' end cleavage (Hashimoto and
Steitz, 1986). However, several studies have clearly e;.(cluded
the requirement for U snRNPs for mRNA 3' end formation (Ryner
and Manley, 19B7).
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1.2.3.1.3 Poly(A)some assembly and mRNA 3' end formation
The formation of the )' end of mHNJ\ occurs in <l l<lrqc
ribonucleoprotein complex called the poly (AI5oma. 'l'he
assembly of poly{A) some and the process of mRNA 3' end
formation have been studied in In Y..l...t..!,:Q polYildenylfltion
systems using purified/partially purified fractions. The
assembled poly(Alsome protected the AAUAAA sequence, as well
as those of USE and DSE, from RNase Tl digestion (Humphrey at
a!., 1987). SF, the first factor to billd the prc-uIRNJ\
substrate, binds the AAUAAA sequence. Because of the lower:
affinity of SF to RNA, this binary complex was unst'lble.
However, the binding of CF I to DSE stabilized the interaction
of SF with the AAUAAA sequence. A prcreqllisitc for the
binding of CF I was the prior ils~ociation of SF with MUAAfl
sequence. The AAUAAA sequencQ-bound SF interacted with CstF
and facilitated its binding to pre-mRNA through tho (j~ kDa
subunit. The binding of CstI' to RNA further stilbll izetl the
interaction of SF with the AA.UAAA sequence (Wahle iH.J Keller,
1992). SUbsequent addition of CF II and PAP resulted in
specific endonucleolytic cleavage and poly (A) addit ion
(Gilmartin and Nevins, 1989; Takagal-:i at al., 19B9; 1990).
The mechanism by which DSE-binding proteins, such <.IS DSE~'-l
and hnRNP C, contributed to the process of mRUl\ 3' end
formation was not clear.
The addition of a poly(A) tail to the cleilved J' end
occurred in two phases, (1) the l\AUAAA sequence dependent
addition ot the first 10 1'- residues, and (ii) the AAUAAA
sequence independent elongation of this oli()o(A) primer
(Wickens, 1990a). At the transition between the two phases,
SF dissociated from the AAUAAA sequence. However, it remained
associated with the elongating PAP (Bardwell and wickens,
1990). 'l'ho mechanism by which the activity of PAP is
terminated is not known.
1.2.3.2 cytoplasmic polyadenylation
Temporal expression of several genes during development
is regulated by cytoplasmic polyadenylation. In Xenopus
oocytes, several maternal rnRNAs stored in
translationally repressed state. In mature oocytes, some of
these maternal mRNAs are selectively activated and recruited
into polysomes. Mobilization of these mRNAs into polysomes is
accompanied with changes in the length of poly(A) tails.
Alterations in the length of poly(A) tails occurs in the
cytoplasm. The process of cytoplasmic poly(A) tail
addition/elongation differs significantly from the nuclear
polyadenylation. The 3' end cleava1e is not necessary for
cytoplasmic poly(A) tail elongation. The cytoplasmic polyeA)
tail elongation is catalyzed by a PAP, which appeared to be
distinct from the nuclear PAP (Wickens, 1990b).
Cytoplasmic poly (A) tail elongation of C12, D7 and GIO
rnRNAs required a conserved hexanucleotide sequence AAUAAA and
upstream U-rich element called the cytoplasmic
polyadenylatiun element (CPE) (Fox et al., 1969; Lynn McGrew
et al., 1989; Simon et al., 1992]. Several other IlIRNAs, which
are known to undergo cytoplasmic poly(A) tail elongation
contained a sillilar U-rich element. The CPE of CIa IIIRNA was
functional when placed downstreall of the AAUAAA sequence (I.ynn
McGrew et al., 1989). For Cl2 WlRNA, the spacing between the
CPE and the AAUAAA sequence was found to be illlpOl·tilnt fa,·
temporal regulation of translational activation of this /D.HNA
(Simon et aI., 1992).
Recently, several proteins, which may be involved in the
process of cytoplasmic polyadenylation, were identified. 1\ ~;B
kDa protein was found to associate with the CPE of U4 mRNI\, ilS
determined by UV crosslinking (Paris at el., 1991). 11. 82 kD<I
protein was found to interact with the CPE of CIa ..RNA (I..yon
McGrew and Richter, 1990). The CPE-binding proteins were
present in both immature and mature oocytes, howeveL', only the
proteins from Ilature oocyte were functional in in y.i.1.r2
polyadenylation assays (Lynn McGrew and Richter, 1990; PolriS
et al., 1991). It was suggested that the CPE-bindinq activity
of these proteins may be modulated by phosphorylation. rn all
in ~ polylldenylation assay, both 58 kDa and 82 kim
proteins underwent phosphorylation by pJ4 CdC-2 kinase l1ncJ
this modification was essential for the binding of the::.;e
proteins to CPE (Lynn McGrew and Richter, 1990; Paris ct ill..,
1991) .
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J..3 ANTISENSE (AS) RNA
In s13veral systems, naturally occurring AS RNAs provide
a 10eans for post transcriptional regulation of gene expression
(Helen and Toulme, 1990; Takayama and Inouye, 1990; Nellen et
al., 1992). I have detected naturally occurring AS RNA to
HPV-16 and studied the possible mechanisms by which the AS RNA
can regulate the expression of the E7 oncogene of HPV-16.
AS ntlA contains sequences complementary to the transcript
oC a gene. Both naturally occurring AS RNA and AS RNA
experimentally introduced into various systems have provided
insights into complex processes, such as regulation of gene
expression, DNA replication, signal transduction, cell growth,
development and differentiation. AS RNA technology has
profound implications in diverse fields, such as therapeutics
and agriCUlture (Stein and Cohen, 1988; Toulme and Helene,
1988; Walder, 1988; Helene and Toulme, 1990; Takayama and
Inouye, 1990: calabretta, 1991; Helene, 1991).
1..3.1 Naturally occurring AS RNAs
Naturally occurring AS RNA has been detected in both
prokaryotes and eukaryotes. The functional significance for
the majority of the reported eUkaryotic AS RNA is not known.
Some of these naturally occurring 1\S RNA species
posttranscriptionally regulate the expression of corresponding
genes. This section of the introduction is confined to
euli.aryotic AS RNA.
..
An AS RNA complementary to a portion of the myelin basic
protein (MBP) transcript was detected in the brain tissue of
myelin deficient mutant (mid) mice (Okano at aI., 1986; Popko
et al., 1988; Tosie et al., 1990). The brain tissues of mid
mice express very 10\0' levels of MBP, despite the presence of
wild-type MBP gene. In mid mice, the MDP gene is t,,,',-':cmly
duplicated and the sequences from exons 3 to 7 of the llpstrcOIm
allele are inverted (Akowitz et aI., 1967). 'l'ranscription or
the upstream allele results in AS MBP RNA complementory to
sequences from exons 3 to 7 of sense (5) MBP RNA (Okimo at
al., 1988; Tosie et al., 1990). Formation of an AS HNA-S HNA
duplex interferes with processing and transport of the S MIW
RNA (Okano et al., 1991; Matthieu et al., 1992).
Induction of differentiation of murine erythroleukemia
and melanoma cell lines is associated with the downregulution
of tumor suppressor p53 mRNA and accumulation of p53 prc-mRNA
maturation intermediates. This downregulation of p53 mlHlA is
related to the accumuldtion of three different species of
naturally occurring AS p53 RNA. One of these is a high
molecular weight AS p53 RNA, which accumulates in the nucleus.
Another species of 1.3 kb AS p53 RNA confined to the nuclear
compartment, has sequences complementary to the B1 repetitive
element present in the fi'::"st intron of p53 pre.-mRNA. II famlly
of AS p53 RNA species related to 82 repetitive elements were
also detected in the nucleus and cytoplasm of differentiating
"
cells. These AS RNAs were thought to down regulate p53 mRNA by
interfering with the maturation of p53 pre-mRNA (Khochbin and
I.awrence, 1989; Khochbin at al., 1992).
In Dictyostelium, accumulation of the EB4-PSV mRNA is
developmentally regulated. The EB'! -PSV locus remains
transcriptionally active during all stages of development.
However, the EB4 -PSI/ mRNA does not accumulate until the cells
begin aggregating to establish a prespore-prestalk structure.
Disruption of aggregated cells results in rapid
destabilization of EB4-PSV mRNA. This rapid destabilization
is brought about by a cytoplasmic AS EB4-l'SV RNA which forms
an RNA hybrid with the EB4-PSV mRNA (Hildebrandt and Nellen,
1992) .
Three maternal basic fibroblast growth factor (bFGF)
transcripts of sizes 4.5 kb, 2.3 kb and 1.5 kb, have been
detected in Xenopus oocytes (Kimelman et a1., 1988). The 4.5
kb mRNA encodes the bFGF polypeptide. The most abundant, 1. 5
kb transcript expressed at a level 20-fold higher than the 4.5
kb mRNA, is complementary to the third exon of the 4.5 kb
transcript and forms a duplex with this RNA in~. This
double stranded RNA (dsRNA) is a substrate for the dsRNA-
specific enzymatic activity termed unwindase, which modifies
A into I (Bass and weintraub, 1987; 1988). It has been
suggested that the rapid destabilization of the 4.5 kb bFGF
transcript after oocyte maturation is related to the release
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of unwindase from the nucleus and subsequent modific<\tlon or
this transcript (Kimelman and Kirschner, 1989). Unl ike othOl'
AS RNA species, the AS bFGF RNA encodes il 25 kDa protein,
which is highly conserved among different species of imimals.
The function of this protein is not clear.
Several early response genes, such as c-fos, c-ID.Y£<, N-
l!lYQ, L-~ and c-!!U!..!2, for which expression is rapidly .i nrluced
in response to mitogenic stimuli, were shown to express AS HNA
(Bentley and Groudine, 1986; Nepveu and Marcu, 19B6; Bender at
a1., 1987; Kindy et a1., 1987; Krystal et al., 1988; spicel-
and sonenshein, 1992). However, the AS RNA could not be
detected by commonly used techniques of Northern blotting nnd
in situ hybridization, because the AS RNA was highly unstable
(Bender et al.. 1987; Krystal et al., 1988). Stable
expression of AS c-~ RNA was detected in a murine
plasmacytoma cell line, in which the c-m.Y£ locus had undergone
translocation to the immunoglobUlin alpha heavl' chain constimt
region (Dean et al .• 1983). The stability of the AS c-IDY£. RNA
in this cell line could have been a consequence of:
translocation. using this cell line, the AS promoter
mapped to the second intron of the c-!!U!.£ gene (Spicer and
Sonenshein, 1992). It has been suggested that the AS c-!!lY£
RNA is involved in downregulating c-!!!.Y..G: mRNA expression in
pre-B cells in response to interleukin-3 deprivation (Chang et
al .• 1991).
,.
In contrast to highly unstable AS C-ID.Y£ and L-!!1Y£. RNAs,
the AS N-!!rl£ RNA was stable and accumulated in both the
nucleus and cytoplasm. The promoter for the AS N-:m:i£ RNA was
lo=ated within the first intran. The AS RNA was transcribed
by RNA pol I1 and multiple initiation sites for the AS RNA
ware detected. The A5 RNA underwent polyadenylat ion.
Nonpolyadenylated cytoplasmic AS RNA was complementary to the
first ex on and intran sequences of N-m:i£ RNA and formed an
RNA-RNA duplex with the endogenous S N-!!lY£ RNA (Krystal at
a1., 1990). It was thought that the duplex formation could
interfere with the splicing of N-I!!.Y£ pre-mRNA.
Recently, a 438 nt AS RNA with sequences complementary to
the second intran of C-m:i.£ was cloned from the human colon
cancer cell line (Celano et al., 1992). Unlike the previously
dascribed AS c-Drl£ RNA (Spicer and sonenshein, 1992), the AS
RNA cloned from the human colon cancer cells was transcribed
from a locus different than the c-1llYQ locus. In addition, 120
nt of this AS RNA showed approximately 85% homology to the AS
strands of growth-related genes, s,Jch as N-myg, p53 and
thymidine kinase. This AS RNA was induced by the
intracellular polyamine depleting compound,
difluoromethylornithine, and the induction was accompanied by
concomitant downregulation of the C-l!!:i.£ mRNA. The inverse
correlation between the induction of the 438 nt AS c-.I!ri.£ RNA
and the downregulation of c-!!!y£ mRNA and the complementarity
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between this AS RNA and other growth related gene transcripts
suggested a possible role .I:or this naturally occurring liS RNA
in the regulation of cell <;l'rowth.
The proteins encoded by c-erbA, the cellu] at" homolog o[
the viral oncogene, v-erbA, belong to the family of the
thyroid/steroid hormone receptors and bind the hormone,
triiodothyronine (Evans, 1968). Among the mUltiple forms of
c-gmA, the c-erbAo: is more closely related to the v-orbtl.
Two forms of c-~Aa, c-~Aa-l and c-erbAa-2, have been
detected in rats. Only the c-!ll:!2Aa:-l, but not the c-Q.[Q1Ia-2,
binds the thyroid hormone, T3 (Izurno and Mahdavi, 1~88; La~i'lr
et a1., 1988). A 3 kb AS RNA containing sequences
complementary to the 269 nt of the last exon of the c-~Aa-2
was cloned from a rat cONI'. library (Lazar et a1., 1989). 'l.'he
AS RNA was polyadenylated and encoded a 56 kDa prate in
belonging to the steroid hormone receptor superfamily.
homolog of this AS RNA was also detected in hum<Jn cells
(Miyajima et a1., 1989).
Small, nuclear, nonpolyadenylated AS RNAs complementa ry
to portions of the major dihydrofolate reductase (OlIF'R)
transcript were detected in murine cells. The AS RNA
transcribed from the bidirectional DIlFR promoter had
heterogeneous 5' ends that were complementary to the first 10
nt of DHFR mRNA (Farnham et al., 1985).
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The naturally occurring AS· RNA to the gonadotropin-
releasing hormone transcripts was detected in the cardiac
muscle of rats (Adelman at a1.. 1987). The AS RNA was
alternately spliced and polyadenylated suggesting that it may
code for protein(s). However, no protein(s) encoded by these
AS RNAs have been detected.
The overlap between two transcription units transcribed
in opposite orientations would result in RNAs with sequences
complementary to each other. The transcription of two
'lctj.:lcent genes of a murine locus was shown to produce mRNAs
which overlap by 1J3 nt at their 3' untranslated regions
(Williams and f'ried, 1986). Similarly, an overlap between the
dopa decarboxylase transcription unit and the adjacent
transcription unit of unknown function of Drosophila resulted
in mRNAs with 88 nt overlap at their 3' ends (Spencer et aI.,
1986). An evolutionarily conserved AS RNA complementary to
the 3' reg ions of the DNA excision repair protein-encoding
transcripts of human ERCC-l and the yeast RADIO mRNAs has been
detected (van Duin et aI., 1989). The complete 3'
untranslated region and the last two codons of the RADIO mRNA
were complementary to thE! AS RADIO RNA.
Recently, the naturally occurring AS RNA to the human
thymidylate synthase mRNA was detected in a variety of cell
types and was cloned from the human oral epidermoid carcinoma
cell line (Dolnick, 1993). The AS thyrnidylate synthase RNA
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contained introns. The 1. 8 kb mRNA for th is AS RNA underwent".
polyadenylation and accumulated in the cytoplasm. Four large
ORFs were detected in this AS RNA suggesting that it 11light
encode protein(s). The possible functions and significance of
this AS RNA remain to be investigated.
Several naturally occurring AS RNAs complemcntury to
viral pre-mRNAs/mRNAs have been detected in infected cells.
However, their significance to the life-cycle of the virus is
not understood.
The latency-associated transcript (LAT) is a major USV-l
immediate early region transcript present in the nuclei or
latently infected neurons of mice and humans. 'l'hrcc spec ies
of nanpolyadenylated, colinear LATs of 2.0, 1.5 and 1.45 kb,
have been detected (Rock et al., 19B7: Stevens et al., ] 9irl ) .
The LATs are a part of a larger B.J kb transcription unit.
recent stUdy has indicated that the 2.0 kb LA'r represented a
stable intron generated by splicing of a laqer transcdpt
(farrell et al., 1991). The 750 nt at the 3' end 0[' the 2.0
kb LAT were complementary to the immediate early region gene,
infected cell polypeptide 0 (ICPO). which encodes a potent
transcriptional transactivator. Al though the 2.0 kb LII.'l'
interfered with the transactivating activity of ICPO in iln .in
Y1t..I.2 system, its role in the process of latent infection is
not clearly understood (Farrell et a1., 1991; Fraser et al.,
1992).
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AS RNA corresponding to different ORFs of HPV-16 has been
detected in several HPV-16 positive squamous cell carcinomas.
The AS RNA was detected by in situ hybridization and was
complementary to the early, late and noncoding regions of the
viral genome (Higgins et a1., 1991; Vormwald-Dogan et a1.,
1992). HPV-16 AS RNA is discussed further in chapter 3.
1.3.2 Experimentally-produced and synthetic AS RNA
AS RNA. has been used in several experhnental systems to
selectively block the expression of specific genes (Helene and
Toulme, 1990; Takayama and Inouye, 1990). The AS RNA ....as
generally produced in situ by transient or stahle expression
of the transfected lI.A expression plasmids. Inducible
promoters, such as mouse mammary tumor virus, metallotheionine
and heat shock promoters, provided a better control over the
expression of AS RNA (Helene and Toulme, 1990; Takayama and
Inouye, 1990). Viral vectors, such as retrovirus, adenovirus
and adeno-associated virus vectors have provided a means for
stable and efficient transduction of AS RNA (Helene and
't'oulme, 1990; Takayama and Inouye, 1990; Chatterjee et al.,
1992). Another approach commonly used in the Xenopus system
is the direct microinjection of AS RNA into the oocyte.
Capped AS RNA for microinjection is produced in ti.t..I..Q using
TJ!T7jSP6 RNA polymerases.
synthetic AS nucleic acids, such as oliqoribonucleotide
(ORN) /oligodeoxyribonucleotide (OON) , have been more widely
,.
used in experimental systems (Stein and Cohen, 1988; 'l'oulmc
and Helene, 1988; Walder, 19881 Calabretta, 1991; Helene,
1991; Leonetti et al.. 1993). ODN has several advantages over
ORN. aDN is easier to synthesize and process thilll anN. ODN
is also more stable. Further, DON is more efficient at
blocking the expression of genes, because it elicits I~Nasell
activity, which degrades and destabilizes the RNA portion oC
mRNA-ONA hybrid (Helene, 1991; Leonetti at al., 1993).
can be used to selectively degrade mRNA produced from mutant
alleles, without affecting the Wild-type mRNA (McManaway ct
a1., 1990: Calabretta, 1991; Helene, 1991; Moni." at a I . ,
1992). The uptake, stability and affinity of aON have been
improved substantially by introducing several chern j ca L
modifications into the OON (Stein and Cohen, 1986; 'roulme <Ind
Helene, 1988; Helene, 1991; Leonetti et al., 1993).
be used as a sequence-specific nuclease by coupling it to
chelates, such as EDTA-Fe, phenanthroline-cu and porphyrin-I"c,
which induce strand breakage (TOulmc:! and Helane, 19138; I(elene
and Toulme, 1990).
Ribozymes are a group of sequence-specific catalytic ImA
molecules, which are known to cfltalyze a wide range o[
biological activities, such as the splicing of the group 1
type of intron, maturation of tRNA and replication o[ vi.r.oids
(Cech, 1988a; Symons, 1~a9; 1992). The catalytic function i.s
attributed to the active RNA core. Additional {ianking
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sequences are required for aligning ribozymes to specific
sequences of the tarqet/substrate RNA cecch, 1988b).
Rlb.,zymes can be engineered to recognize and cleave specific
Ciequences on RNA lIolecules. Such engineered ribozymes have
been used as AS RNA to cleave specific RNA, both in Y.i..tJ;:Q and
in Y.iY.2 (Uhlenbeck. 1987; Haselo!f and Gerlach, 1988; Cotten
and Birnstiel, 1989; Eckner et a1., 1<J91~ Zaia et al., 1992).
1. J. 3 Mechanism of action
AS RNA has been widely used to interfere with the
expression of specific gene(s), and this interference
generally depends on hybridization of the AS RNA to the pre-
mRNA or mRNA. The specificity is provided by the sequence
complementarity between the AS RNA and the target pre-mRNA or
mRNA. The work done on AS RNA of prokaryotes has lead to a
considerable understanding of the lIIechanislIl(s) by which AS RNA
affects gene expression and DNA replication (Takayama and
Inouye, 1990). Much of the information on the mechanisJlI(s) of
action of eUkaryotic AS RNA has come froll AS RNA used in
various experimental systems (Denhardt, 1.992). Although, the
detailed mechanislI(s) of action of eUkaryotic AS RNA is not
clear, generally, the AS RNA has boon shown to act at the
posttranscriptional and translational levels to affect gene
expression.
1. 3.3.1 Transcriptional regulation
AS RNA can also act at the level of transcription. An AS
RNA targeted to sequences downstream of the c-.!!!Y.£. prOlnotcr
resulted in decreased transcription from this promoter by
interfering with transcription (Yokoyama and Imamato, 19U7).
1.3.3.2 Posttranscriptional regulation
AS RNA may affect one or more posttranscriptional events,
such as the splicing of pre-mRNA, transport of mRN/\ to the
cytoplasm and turnover of mRNA. My studies ot: naturally
occurring HPV-16 AS RNA have indicated that the IIPV-16 AS Il!'lA
blocks the splicing of the IIPV-16 S RNA at the nt 8UO 5'
splice site.
The generalized inhibition of splicing of pre-mHNAs could
be achieved by targeting the U snRNA. AS RNA complementary to
certain regions of Ul, U2 and U4/U6 snHNA efficiently
inhibited splicing (Blencowe et al., 1989). Inhibition ot'
splicing of specific pre-mRNA species by AS RNA rW.s been
observed in both in Y..i.t..r.:.Q and in.Y..lY..Q systems. '!'he splLcing
of exon 1 to exon 2 of ,a-globin pre-mRNA was inhibiteu .tn
Y.i..t!:Q by AS RNA complementary to 5' and J' splice site regiNls
(Munroe, 1988). AS tissue inhibitor of metalloprotcase ('I'IMP)
RNA, which was produced from a stably transfected plilsmid, WilS
shown to inhibit the splicing of TIMP prc-mRNA 1..n vivo (!'cng
and Denhardt, 1992). Similarly, naturally occurring II.S RNA to
the gonadotropin-releasing hormone and J.U:l2Af.l2 transcripts
appearG!d to interfere with the Pl"oL:cssinlJ or thC'~,l' t ...·o
transcripts (Kelly et ill., 1991; ~lllm'oc ,1ml l.~l:'::H", 19'1l).
Naturally occurring AS N-~ RNA lli'ls uccn thOllC]ht to inhibit
the splicing of the first intron of the S N-!!!y"''<. I~NA.
AS RNA can also lnterfclre with thc trilll~'pDl·t or mHNA to
the cytoplasm. AS RNA targeted to the J' end of IlSV tf.; mlUlA
or to the complete coding region o[ c-my£ mHN1\. re~,Llltcd in th0
retention of respective mHNAs, in the nur..:lelltl (Kim 'lild \~old,
1985; Prochownik et al", 1988). The r.iltufillly occlirrinlJ AS
MBP RNA of mId mice has been sugCJcsted to interfere with thc
export of MBP mRNA (Okano et ill., 199]). In my ~ltlld!CH, t.hc
naturally occurring liS IlPV-16 RNA did not arpC,n" to affect the
transportation of the S HPV-16 RNA [rom the nlll:lcu~; to t.he
cytoplasm.
AS RNA can downregulate gene expre!',sion by dcstill>i I i ~ i nq
its target mRNA. The dOyJnregulation of the lli'V-}(j 1';'/ RNA by
naturally occurring AS E7 RNA was tlot c]eilrly eviLlent in my
studies. The naturally occurring AS RNA to the Dictyost.cl ium
prespore gene, EB4-'PSV mRNA, induced the r'lrJd de(JI',Hlation 01
this mRNA (Hildebrandt and Nellcn, 1992). !;jmi 1,Irly, in
several experimental systems, AS HIM induced the rarid
turnov'~r of target pre-mRNA or mHNA (Helene and '!'ouJmc, l~'HJ;
Bradley et aI., 1992). The induction of instability 01 S rmA
by AS RNA could be due to dsRllA-specific RlIa~c" (Strickland et
al., 1988). The instability of target mRIlA induced by AS Ol.l/l
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has been shown to be mediated by RNasell, an activity which
selectively hydrolyzes the RNA strand in a RNA-DNA hybrid
(Helene and Toulme, 15'90). Ribozymcs and chela ted aON induce
sequence-specific cleavage of target RNA. The cleaved RNA,
which lacks the 5' cap or the 3' poly(A) tail, arc
subsequently degraded by RNases. In addition to these RNases,
a dsRNA-:::pecific unwindase activity present in several cell
types is also known to affect the stability of dsRNA (Bass and
Weintraub, 1987; Rebagliati and Melton, 1967; Wagner and
Nishikura, 1988; Kimelman and K.i.rschner, 1989; Wagner at al.,
1990). 'rhis act.ivity has been shown to nlodify the A residues
into I (Bass and Weintraub, 1988; Bass at al., 1989; Wagner at
al., 1989; Wagner et al., 1990; Nishikura et al., 1991).
1.3. J. 3 Translational regUlation
Generally, AS RNA targeted to the 5' end of mRNA
efficiently down regulates gene expression, by interfering with
the initiation of translation (Helene and Toulme, 1990:
'l'ak3yama and Inouye, 1990). My studies of the naturally
occurrinq lIPV-16 AS RNA have indicated that the AS RNA
interfered with the expression of the viral E7 gene. Becam::e
the AS RNA was complementary to the 5' and 3' and the coding
regions of E7 RNA and formed an AS RNA-S RNA duplex with the
S RNA, it is likely that the lowered E7 expression was due to
interference with the translation of E7 S RNA by the AS RNA.
AS RNA complementary to the coding region of mRNA is less
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effective in blocking translational elongation, bee,luse
helicase activity associated with the elongation complex call
melt the AS RNA-mRNA duplex structure. However, tr<\llsLltiQlhll
elongation can be inhibited by modified DON, which l;all IJll
covalently crosslinked to mRNA (!lelena, 1991). Recently
developed peptide nucleic acids, in which the phosphodicstcr
backbone of ODN is replaced with polyamide bonds, bind mnNfI
with a very high affinity and block translational clongiltloil
(Hanvey ct a1., 1992). Infrequently, AS RNA targeted to the
3' coding and noncoding regions of mRN/\ cCln block translation
in Y..i..Y..Q. (ch'ng et aI., 1989). The mechanism(s) by whleh thls
AS RNA downregulated translation of mRNA was not clcnr.
1.4 OBJECTIVES
Tho objectives of this study wore:
(i) to deline<lte the sequences of HPV-16 required for
transformation ot: BRt< colIs, and
(iil to dctcrminn ::;omc of the possible posttranscriptional
mechanisms, such as RNA splicing and AS RNA, for the
regulation of HPV-16 £7 gene expression.
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CHAPTER 2
SEQUENCES OF HPV-16 REQUIRED FOR T~NSFORMA'rION
iNTRODUCTION
Several epidemiological and experiment.:!.! stud leG h;\Vp
implicated HPV-16 in the etiology of cervical C<1nccr (xur
Hausen and schneider, 1967; Galloway and McDougall, l')ll'J; Lur
Hausen, 1989; 1991). In a majority of cervici'll Cclnccrs 'lnt!
cancer-derived cell lines, the HPV-16 genome was found t.o bC'
integrated with the host cell genome resulting in dj~I:\lpti.01J
of El and/or E2 ORFs an:! deletion of the )1 cnrJy region OHFn
(Matsukura et al., 1986: Durst. et al., 1986; Uakcr ot <11.,
1987; Wagatsuma et a1., 1990). Occasional cases in which the
viral genome occurs in an episomal form have a1Go been not i ceLl
{Durst et al., 1985; Lehn et al .• 1985; 1988; MatsuKu["(l al
al., 1989; Stanley at a1., 19B9; Cullen at ill., 1~91l.
Irrespective of integration, part of the early region of the
viral genome remained transcriptionally active and tho (,<lrly
region genes, E6 and E7, were consistently expressed (P('Itor
and Pater, 1985; Yee at a1., 1985; smotkin <lnd Wettstein,
1986; Shirasawa et 0.1., 1988).
Furthermore, the cloned genome of HPV-16 ciln immorta Ii 7.0,
but not fully transform, primary human and rodent cells (Ourst
et 0.1., 1987b; Pirisi et a1., 1987; Kanda et al., 1968<1;
schlegel et al., 1988; Woodworth et al., 19BB; 19B9; Pecorileo
et al., 1989: Tsutsumi et 0.1.,1992). Both E6 and £7 genas
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were required for immortalization of human cells, whereas E7
was sufficient for rodent cells (Kanda at al., 1988a; Schlegel
et ,)}., 1988; Ilawley-Nelson at 01.,1389; Munger et al.,
191\')h; Watunabe at al., 1989; Inoue et al., 1991; Halbert et
ill., 1':.091). In addition to immortalization, HPV-16 can
transform established rodent cell lines, such as NIH 3T3, 3Yl
and rilt-l cells, and E7 was essential for this activity
(1'sunokawa at 01.,1986; 'lasumoto et al., 1986; Ma~lashewski
at al., 1987a; K<'lnda et al., 1987; 1988b; Noda et al., 1988;
Vousuen at Lil., 1988; Edmond~ and Vousden, 1989; Chesters et
al., 1990; WCltunabe et al., 1990).
IlPV~16 can cooperate with activated oncogenes such as EJ-
.G!..§ or v-iflli to transform primary rodent cells in the presence
of steroid hormone glucocorticoids or progesterone (Crook et
al., 196fl; Puter et a1., 1988; 1990; Lec!:> et a1., 1990). The
immol-tal ization and transformation frequency of HPV-16 were
cnhanced by g.lucocortico:ds (Durst et al., 1989; Storey et
aI., 1992; Sexton et al., 1993). The specific requirement for
qlucocorticoid hormones for transformation of BRK cells by
HPV-16 was demonstrated by Pater and Pater (1991). RU486, an
anti-glucocorticoid, interfered with transformation in a dose
dependent manner (Pater and Pater, 1991).
'l'he requirement for the steroid hormone can be overcome
by expressing the E7 gene from strong heterologous promoter-
enhancer sequences (Matl<lshewski et al., 1987b; Phelps et al.,
198B; Storey et a1., 1988; Edmonds and VOUSdCll, 19B<); H"t.."\nilbe-
et al., 1990; Tanaka et al., 1989; Chesters et ",1., 1990).
Full transformation of immortalized hum"n i;lnd rodent cell::; ,~.1t1
be achieved by sequential transfection with <lCtiViltcct EJ-!:-,H"l
or extensive passaging of immort.alized cells or by exposure to
chemical carcinogens (DiPaolo et al., 1989, Durst ct al.,
1989: Hurlin et a!., 1991; Inoue et al 1991; Li at oJ., 1997.;
Garrett et a!., 1993; Klingelhutz et a!.. 1993). The la!>t two
methods may be analogous to exogenous introduction of
ac,:tivated oncogenes, because ext:ensive passaging of
immortalized cells may result in self.!ction of occiwiollill cells
with additional mutations conferring the distinct growth
advantage required for transformation. Thus, the requirement
for more than one Gncogenic insult is consistent with tho
hypothesis of mUltistep carcinogenesis.
In this chapter, I have examined the sequences 01 J[f'V-16
required for transformation of BRK cellG in the context o[
heterologous promoter-enhancer sequence and homologous mcssugc
processing signal sequence-containing plc1srnids. 'l'wO sepilrilte
regions of HPV-16, the E7 ORF and a cis-acting region Clunking
this ORP were essential for transformation. These stud iog
highlighted the importance of splice sites present within the
E6 (nt 226) and E1 (nt 880) ORFs for HPV-1G eilrly gene
expression and transformation.
2 . 2 MATERIALS AND METHODS
2.2.1 Construction of recombinant plasmids
For constructio:l of recombinant plasrnids, standard
molecular biological techniques were used (Sambrook et al.,
1989).
2.2.1.1 Expression plaslllids for HPV-16 sequences
All plasmids in this group have the HindIII to EcoR!
fragment (nt 0-2635) of pSV2Cat in common.
Plasmid pAl was constructed by A. Mithal. It was derived
from an intermediate plasmid constructed by ligating the blunt
ended HpalI-Saul (nt 700-4338) fragment of HPV-1.6 to the
common pSV2Cat fragment. Deletion of sequences between nt
2898 BstXI and nt 3763 Ndel sites, blunt ending of the termini
and rei igation resul ted in the plasmid pAl (Fig. 2.2).
Plasmid p07 ~ was constructed by O. Hyslop and described
curlier as p07 (Marshall et a1., 1990). It was constructed by
ligating the blunt ended HpaIl-Saul (nt 502-4338) fragment of
HPV-16 to the blunt ended common pSV2Cat fragment (fig. 2.1).
Plasmid pD72 was derived from pD71 by deleting sequences
between Narl-UincII sites (nt 1312-3208) [Fig. 2.1]. Plasmids
p'i7l, p'i72 , pY73, pY74 and pY75 were generated by deleting
sequences from the common Ndel site (nt 3763) to the Narl (nt
1J12), Ncol (nt 867), Pst! (nt 875), Kpnl (nt 880) and SspI
(nt 1179) sites, respectively, from pD7! (Fig. 2.2). Deletion
of the SspI fragment (nt 1179-3978) from pY71 resulted in pY76
(Fig. 2.1). PlaslDids pY71PX, pY7!SX .lntl pnllo,,1
8;
constructed by inserting translation tcnllin,lt.ion 1inke..,; ,It
the PvuII (nt 685). Ssp! (nt 720) lind RSil] (nt 767) situo;,
respectively, in the plasmid pY71 (Fig. 2. 1). :;111,,1 I do 1ct iOIl!'t
at the KpnI site (nt 880) uf pY71 were introduccl.l by I imitco.l
Bal31 digestion (Fig. 2.4). The ,1 bp deletion <It the "pnl
site in the plasmid pD7KB was introduced by LJlunt cndin'j or
the KpnI termini with T4 DNA polymcrilsc (rig. 7.,4). l.lrgc
deletions in the pY713'6 series were crc;lt.cd by Bill:ll
digestion of NarI-partially cleaved pD?l. Delat ion Ir;HjIRcnt:l
containing E7 were gel-purified aftcr l..:ompLctc diCjc:;tioll with
PvuI and ligated to the smaller Ndel-Pvul fl·... qmcnt u/ \-11>"1
(Fig. 2.) _ All deletions were confirmed by either uidc-oxy 01·
chemical sequencing.
Plasmid pBSSK II{+) 0528 WiJS conr;tructr.d by I iqiltinrJ the
blunt ended Hpall-Ncol (nt 57-867) fr<lqmcnt or IIIlV-t(, at tht:
blunt ended BamHI-XbaI site::; of Ulucl:Ocript, pl\!;~;K 11(1)
(f:tratagene]. Plasndd pSV2E6F;7 was det'ived from pll~;~:K 11(1)
0528 by ligating the IlindIII-SstlI friHJment of. plJ~:SK II (I)
0528 to the HindlIl-BqlII site of UIIFR deleted pSV7.lJllFH
plasmid. Plilsmids pllSSK II(+) 0528 nOli pSVI!EGE" were
constructcd by Qi Sun. Blunt ended ~tul fnt '~1,)() of ~;V~O)­
SstI fragment containing E6-E7 Ollfr: were c lonr:d hc:t~J(:cn the
blunt ended StuI-KpnI sites fnt 519Q or ~jVi\O-nt ij80 of IlI'V-lfj)
of p'i71 to derive the plasmid, pD7:H (Fig. 2.10). HeplildnfJ
..
the 1\52 bp Bbs! fragment (nt 806-1258) Of pD7)! with that of
p07l resulted in p073 (fig. 2.l0).
Plasmid pCMVE7 was derived from an intermediate
r.:onstrlJct, pI3SKS{+)SN, which contains the blunt-ended StuI-
Neal fragment (nt 5190 of SV40-nt 867 of HPV-16) of pY71
cloned at the Sma I site of pBSKS(+). Thl:! HindIII-XbaI
fragment from this intermediate plasmid was cloned at the
corresponding sites of pRc/CMV (InVitrogen) to generate
PCMVE7{f'ig. 2.11). Plasmid pCMVE6E7 was constructed by R.
Mittal by ligating the HindIII-SstI fragment of pBSSK 11(+)
0528 at the IHnciIII-blunt ended Xba! site ot pRcjCMV Vf~ctor
(Fig. 2.11).
Plasmids with the suffix pY72t were constructed by
cloning the blunt ended XhoII fragment (nt 4099-4769) of SV40,
upstream of P,7 at the Stu! site of pY72 in either SC,lse
l"iW72t4) or antisense orientation (pY72t2) [Fig. 2.11].
2.2.1.. 2 HPV-16 prClmoter-enhaneer based plasmids
The wild type HPV-l6 plasmid has the complete HPV-16
genome cloned at the l3amB! site of the vector pBR322. Small
deletions around the nt 880 in pHKB series were introduced by
limited Bal31 digestion of pHPV-16, part lally-cleaved with
KpnI ilnd rcligation (Fig. 2.5). All deletions were confirmed
by sequencing.
2.2.1..3 Site direc~ed mutag'enes!s
Site dirC!cted Ilutag'enesis was perforlll<!d by tit" Ul",ll:i I
incorporation llIethod of Kunkel, (198!;), using' the Mut..genc kit
(BioRad). The SspI site (nt 1179) of pY71 ilnd pV·/KUI W,l~~
modified into an EcoRI site by the insertion of .In ECOIH
linker. Similarly, the SllaI site of pDSKS(+) WilS modified
into Neal sIte by inserting a Neal linker. 1'hc J12 bp N<..:ol-
EcoRI fragment (nt 867-1179) was cloned into the modi r lC'cl
pBSKS(+). Mutations were jntroduced by using either l'J-mcr or
29-mer oligonucleotides. 'l'he ot 8UO spLice donor site WII:;;
disrupted in the plasmid pY"IlSM1.5 by SUbstitutIng '1'I\A [or the
wild-type AGG (nt 879-881). In the construct pY71SMl.2, the
wild-type splice donor site CCA (nt 884-886) was mutoltcll to
ACT, to convert this splice site into il consensus spl icc dono 1-
site. In the plasaid, pY7lSMJ .9, +2 position or the consensus
spl ice site, T was mutated to G. The wild-type sp lice ::: i te
was regenerated in the deletion plaslIld, pY7KDl. to obta i n
pY7ISH2.1. The mutated NcoI-EcoRl fragments were cloned into
pY71 or pY7KBl at the appropriate sites (Table 2_1).
A 3l-mer oligonucleotide was used to introduce mutationu
at nt positions 222, 226 and 227. The nucleotide "G" at these
positions was mutated to "T". Single stranded DNA rescued
from the plasmid PBSSK II (+) 0528 served as the temp] ilta for
these mutations. A HindIlI-sstl fragment containing the:.e
mutations was cloned into pRc/CMV vector as dc~crj bed earl i or.
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The 452 bp BbsI fragment.s froJII pY71SMl. 5, pY71SM3. 2 and
pY71SMJ.9 were cloned at the appropriate site of pD?:!I to
dcdvc plaslllids pD7::'SM1.5, pD7lSHl.2 and pD7JSH3.9,
respectively (Fig. 2.10)_
All mutat ions were confirmed by dideoxy sequencing.
2.2.2 Cell culture and transformation assays
1\11 cells were maintained in OUlbecco's modified Eagle
medium with 10\ fetal calf serum, unless otherwise spculfied.
Subconfluent BRK cells (ill GO-mm plates) prepared from 5 day5
old rats were transfected with 5 J.lq each of the indicated
plasmids and activated EJ-nu;; accorciing to Chen and Okayama
(1987). Two days after tr..nsfection. the media was changed to
2\ [atill calf s.arum-containing modiull. For HPV-16 promoter-
enhancer based plasllids. this mediulD contained 10-6 M
dexamethasone. SelectH.n was carried out in 2\ fetal calC
seru.-containinq medium for 4 weeks. The total number of
colonies in each plate was counted at the end of .4 weeks.
Handom individual colonies were selected and expanded if
further analysis was required.
2.2.3 RN;\ preparat.ion lind analysis
Cos-l cells in 100-mm plates were transfected with 10 /19
o! the indicated plasmids and harvested 48 hours after
tcunsfection. Total cellUlar RNA was prepared by the rnetbod
of Chirgwin et al., (1979). Five /19 or this total RNA was
ilnalyzed by RNase protection assays as described by Kreig and
Helton, (1987), H~'bridiz.:ltjon loIa~ !lC'I'forrncd .. t !.h"C fOI' I"
hcurs with 100,000 cpm each of E7 ~lIld 1.11'1)(' 'I' ,lI~tiqC'n (01' CAT)
probes and RNase digestion was done ~lt ~O"C (01" 9n llIinulc:',
with 700 U of RNase Tl pcr mt. RN"sc rC'l:li:..:t,mt hybrhb 1oI,'rl'
resolved on 5' denaturing poJyacryJi'1miuc-lIrcil Dequl'llcinq 'Iel~~.
Laser densitometry was used for qu,mtitilting the ~ign;II".
The RNA probes used in these experIment:; werc G('llel',ltl~tl
from the corresponding DNA I'ra'1ment~\ tl'1ilt 1'1<'1'(' c:lull(',1 illt:O tILl'
vector Il1uescript KS/:.>K (! /-) A frilrJlllcmt ol pY"/1 11"01\1 till'
Stu1 site of SV40 (ot 519U) to till' ~;*;pl nit,! 01 II1'V-ll. (Ill
720) was used for the E7 probe, 'J'he 1-:6 jlrollc 101,\:: ,ll'l·iv•."] 11'0111
Hpa11-Pvu11 (nt 57-553) fragment of 1l"V-IC.. A I'd bp ll:;d!
fragment (nt 3072-)225) of SV40 wag w;eu to l]l'I1C'I',lte 1,IPIe 'I'
antigen probe. The Cat probe corrcl~poodcll to the Illndlll-
fcoRI (nt 5018-4768) frayment of pSV;'Cilt.
2,2.4 Actinomycin D chase experiments
Focty eiqht hours after transfection with the im.lic.\t.."l
plasmids, actinomycin 0 was ..clucd "t il concantr'ltiun 01 " /1<1
per ml to the culture meditl <lnd the tot;d l:cllul"r WIA w;,:;
harvested after 0, 0.5, 1, 2, J, 4, !> IInu 6 huur:; Fivc /1'1 oj
total RNA wa:; analyzed by RNa~c protection 'll::;,ly:; with the J~"I
probe. '1'0 deter~,lne the stnbil ity of E7 WIll in the pn~:;\!llf.':fJ
of st~roid hormones, actinomycin D wa~ cu..lU<JU to th<..l pl01
plasmid tlCansformed BHK cells I? hour::; a(ter till:) auuition 01
the indicated hormones. Twenty Wj of tot" 1 HIlA Iwrv,!::;tc(j
after 0, I, 2, 4, 6 nnd 8 hours was analyzed by dot blot.
assays with nick translated E7 probe as described by Sambrook
et al., (1989). The E7 probe for dot blot assays ",'as the
smaller stuI-KpnI fragment of the plasmid pY71. The blots
were stripped ami reprobed with the BamHI fragment containing
v-actin probe after nick translation.
2.2.5 Nucloar runoff assays
Nuclear runoff Ql/periments were performed as described by
i\usubal at al., (1990). Approximately Sxl0" Cos-l cells were
transientlY transfected with either pY71 or pY72. Nuclei from
these cells were i.::;;olated 48 hours after transfection by using
a Dounce homogenizer. Nuclei were incubated with 100 t4Ci of
{1l_J2pjUTP for 30 minutes at 300 e and treated with protease 1<.
l\ppro)(imately 10" cpm ,}f labelled RNA extracted from these
nuclei were hybridized for 36 hours at 6SoC with 5 /Jg of
genolll:c HPV-l6 and SV40 DNA immobilized on nitrocellulose
filters. Filters were washed thrice in 2xSSC at 6Soe and
treated with 80 /.1.g of RNase A. Filters were dried and
auto radiographed .
2.3 RESULTS
2.3.1 Transformation by SV40 promoter-enhancer based
deletion plasmids
It had been shown earlier that the HPV-16 can cooperate
with th, activated EJ-na oncogene to transform primary SRI<
cells in the presence of the glucocorticoid hormone,
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dexamethasone (Crook et al., 1988: Pater et al., 1988: Lees at
al .• 1990). The lower transformation efficiency of the whole
HPV-16 plasmids prevented reliable cvaluotion of tllQ
contribution of different sequences of the viral genome [or
transformation. This deficiency can be overcome by expressing
the HPV-16 sequences from a strong heterologous ;'lromotCl-"-
;;nhancer. The SV40 early promoter-enhancer, which is active
in a wide variety of cell types, was chosen for tid s purpose.
The expression from this promoter. was independent of
glucocorticoid hormone requi.rement. To map the raglans of
HPV-16 essential for transformation, a number of plasmjds with
deletions ilnd translation termination linker insertions were
constructed and tested for their ability to transform URK
cells.
The plasmid pD73, which expr~ssed only the early region
ORFs, was transformation competent, suggestiny that the eilrly
region sequences of the viral genome are sufficient for
transformation (Fig. 2.10).
Deletion of the complete E6 ORF sequences in the plasmid
pD71 resulted in a slight increase in transformiltion (Fig.
2.1, 2.10). The possible reasons for the increilscd
transformati.on for this plasmid are discussed later. 'rho.
commonly used nt 226 splice donor site is present within the
E6 ORF. In addition, a putative cryptic splice donor site is
present immediately upstream of the nt 226 splice donor site
Fiqure 2.1 Transformation of BRK cells by HPV-16 expression
plasmids.
11.11 of the plasmids are in the pBR322 vector and
expressed from the SV4Q early promoter-enhancer. The thin
lines represent the HPV-16 genome and the numbers below lines
indicate the HPV-16 nt sequence. The black boxes represent
deletions. The vertical lines within the E7 ORF sequences
indicate translation termination linker insertions. The names
of plasmids are shown to the left. The total number of
colonies in eight GO-mm plates are presented to the right for
duplicate experiments. The abbreviations used are: ATG, E7
start codon; TAA, E7 stop codon; EP, early polyadenylation
signal; TTL, translation termination linker.
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(Sedlnan at a1., 1991). Alternate splicing 01.' the nt
splice donor sit", to the nt 409 and 526 splice acceptor sites
generates E6* and E6** mRNA species (Smotkin and wettstein,
1986; smotkin et a!., 1989: Cornellisen et a!., 1990; Doorbar
et a1. I 1990; Johnson et a1 .• 1990; Schneider-Maunoury at al. ,
1990; Snijders et al., 1990; Rohlfs et a1., 1991; Sedman et
al., 1991; Sherman and Alloul, 1992; Sherman et al., 1992).
Results of transformation experiments for the plasmid pO?!
indicated that neither E6*, E6** nor intact E6 were required
[or the transformation of BRK cells. Further, they also
suggested that the integrity of the nt 226 splice dono't' site
was not essential for transformation. Several other studies
have indicated that the E6 ORF sequences are dispensable for
transformation of BRK cells (Vousden, 1990; Munger et a1.,
1992) •
To determine the reqUirement for the other early region
sequences for transformation of BRK cells, plasmids mutated in
these sequences were used. The large deletiOll between nt
1312-3208 affecting the El and E2 ORF sequences in the plasmid
p072 did not affect transformation (Fig. 2.1). Transformation
was not affected by a further deletion of 555 bp of E2 ORF
sequences (nt 1312-3763) in the plasmid pY71 (Fig. 2.1). The
plasmid pY71 is also deleted for the E4 ORF sequences.
Insertion of translation termination linkers within the E7 ORF
of the plasmid pY,l, at nt 685 or 720 or 767, totally
abolished transfornation (Fig. 2.1).
"
Al thouqh thesa
translation termination linker insertion plasmid clearly
denonstrated the requirclJCnt for £7 ORf" !>cqucnccs (or
t.ransformation, they did not elilllinatc the pos~.iblc
requirements for the £5 oRr and the 5' end sequences of the EI
ORF for transformation, because these sequences wore also
present in the plasmid pY71. Saveral recent studies have
identified ES as an oncoprotein for rodent cells (Lcptilk at
al., 1991; Leechanachai et al., 19<J'.; Pim ct nl., 19<)2; Bankr·:
and Mi;ltlashewski, 1993). 'fhe requir.ement for the 1':5 OIH'
sequences for transformation was analyzed by del cting the 1::5
ORr sequences in the plasmid pY76. 'fhe deletion cxt_cndin'1 to
nt 3973 in the E5 ORF did not affect trilns[orlll,ltion
significantly (F i9. 2.1).
The requirement for trans format ion of the 5' reel i on
sequences of E1 ORF' present in the pla~JlIid pY71 wa:::
investigated by deletion lRutagenesis of this region. 'I'he
additional deletion between nt 1179 and lJ12 in the pla"mid
pY75 did not affect transformation (Fig. 2.2), A further.
deletion of the J12 bp between nt 867-1179 in the plasmid pyn
totally abolished transformation (Fig, 2.2). 'rhe plasmidc.
pY74 and pY73. with deletions extending to nt 875 or AOO.
respectively, were also transform<ltion incompetent (FiC). 2.2),
In the context of the whole HPV-16 genome. simililc doletions
of the 5' region sequences of E1 were reported to oj iminato
Figure 2.2 Transformation by HPV-16 expression plasmids with
deletions in the E7 3' flanking region.
All of the plasmids are in the pBR322 vector and
expressed from the SV40 early promoter-enhancer. The thin
lines represent the HPV-16 genome and the numbers below lines
indicate the HPV-l6 nt sequence. The black boxes represent
deletions. The names of plasmids are shown to the left. The
total number of colonies in eight 60-mm plates are presented
to the right for triplicate experiments. The abbreviations
used are: !lTG, E7 start codon; TAA, E7 stop codon; EP, early
pol yadenylation signal.
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transformation (Pater et a1., 1992b). It \o,'a5 unlikely that
the truncated EI gene product encoded in the plasmid pY71 was
essential for transformation, because several studies have
shown that the E7 ORF sequences are necessary and sufficient
for transformation of BRK cells in EJ-ras cooperation assays
(Vousden, 1990; Munger at a1., 1992). In those studies
heterologous promoter-enhancers and message processing
signals, such as splice sites and polyadenylation signal
sequences, were used for the expression (If HPV-16 sequences.
Because the expression plasmids used in my studies did not
possess heterologous splicing signals, it was (Jossible that
this function was provided by the El ORF sequences present in
the plasmid pY71. The loss of transformation for the
plasmids, pY72, pY73 and pY74, could be related to deletion of
nuch cis-acting EI ORF sequences. The evidence for the ili-
acting nature of the E7 J' flanking sequence was; obtained by
cotransfecting pY72 with the El-encoding plasmid, pAl, and EJ-
!1!§. If the product of the El ORF was required for
transformation in addition to E7, cotransfection of plasmids,
p\'72 and pAl, would be expected to restore transformation.
Plasmid, pAl, failed to complement pY72 in cotransformation
experiments, indicating that these El ORF sequences are ~­
acting ~Fig. 2.2). These results clearly indicated that in
addition to the E7 ORF sequences, the E7 )' flanking sequences
between the nt 880 and 1179 are reqUired for transformation
(Belaguli et al" 1992).
2.3.2 The E7 3' :flanking sequences required :for
transformation
To determine the minimum size of the E7 )' flilllking
region required for tr.ansformation, various constructs with
progressive unilateral deletions towards the E7 ORF were llsed
in transformation assays. The exonuclease 6a131 WilS used to
introduce deletions into the plasmid pY71. The progr.essive
deletions extending from nt 1312 to 954, in pY713 '47, !I15,
,617, ,61, 429, 416 and .6.1.2, did not affect the transforming
ac':ivity (Fig. 2.3). No change in the frequency of
transformation attributable to progressive deletions was
observed, implicating the requirement of a narrowly defined
region. A further deletion extending to nt 876 in the plasmjd
pY713'42 totally abolished transformation (Fig. 2.3). '1'0
identify precisely the nature I)f this sequence, smaller
deletions were introduced into the plasmid p'i71 around the nt
880. Deletions of 4 bp in p'i7RBl, 9 bp in pY7KD5 and 18 bp in
pY7RB7 totally abolished transformation (Fig. 2.4). Deletions
in these plasmids overlap a previously-identified splice donor
site at nt 880 (Smotkin et al., 1989). An additional Gplice
donor site located at nt 1301 was present in these plasmids.
However, the function of this less frequently utilized splice
donor site might have been impaired by the deletion between nt
1312 and 3763.
Figure 2.3 Transformatioll by E7 expression plasmi4s with
pro'j'ressive unilateral d.eletions in th.ir E7-3' nankinq
region.
All of the plasmids are in the pBRJ22 vector and
expressed from the SV40 early promoter-enhancer. The thin
1 ines represent the HPV-16 genome and the numbers below lines
indicate the HPV-16 nt sequence. The black boxes represent
deletions. The nall'.es of plasmiits are shown to the left. The
tetal number of colonies in eight 60-mm plates are presented
to the right for triplicate experiments. The abbreviations
used are: ATG, E7 start codon; TAA, E7 stop codon; EP, early
polyadcnylation signal.
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Fig~::e 2.. Transformation by E7 expression plaslllids
with small deletions around the nt 880 splice donor site.
All of the plasmids are in the pBRJ22 vector nnd
expressed from the SV40 early promoter-enhancer. 'rhe thin
lines represent the HPV-16 genome and the numbers below lines
indicate the IIPV-16 nt sequence. The black boxes represent
deletions. The names of plasllids are shown to the l~ft. The
t:otlll number of colonies in eight 60-llIm plates are presented
to the right for ~riplicate experiments. The abbreviations
used arc: ATe, E7 start codon; TAl., E7 stop codon; EP, early
polyadenylation signal.
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Effect of nucleotide 880 splice donor site mutations
on transformation
site directed mutagenesis of the nt 880 splice donor site
carr led ':Iut to examine the role of this splice site ill
transformathm. The mutation that disrupted this splice slte
by substituting taa in the wild-type sequence (pY71SMl.5) also
e1 imina ted transformation (table 2.1). Mutating the Wild-type
splice gite into a consensus splice site (pY71SM3.2) resulted
in higher frequency of transformation with 1.5-2 fold more
colonies appearing at 2 to 3 weeks after transfection (data
not shown). However, this difference was not apparent at Ij
weeks after transfectiun when the number of colonies were
counted, because of the appearance of secondary colonies for
the wild-type plasmid (table 2.1). A single base substitution
at the .... 2 position of the consensus splice donor site (plasmid
pY71S~().9) markedly reduced the transformation efficiency of
p\'71SMJ.2 (table 2.1). In addition, regeneration of the wild-
type splice site by inserting the taae sequence into a
previously transformation incompetent splice site deletion
mutant, pY7KB1 (Fig. 2.4) to derive pY71SM2.1, restored wild-
type transforming activity (table 2.1). These results confirm
that the integrity of the nt 880 splice donor site is
essential for efficient transformation.
Table 2.1 Transformation by nt 880 splice 9ite-specitic
mutants.
Wild-type and splice site mutated plasmids are indicated
in the first column. In the second column, the splice site
sequences from nt 878-886 for these plasmids lire shown. 'rotal
number of colonies for each experilllent is frolll eight 60-t1nl\
plates for triplicate experiments counted 4 wcckG after
transfeet ion .
Transformation
Plasmid 5' Splice Site Sequence Expl. 1 Expl. 2 Expl. 3
pY71 5' CAG GTACCA 3' 144 104 122
pY71SM1.5 CTAATACCA 0 0 0
pY71SM3.2 CAGGTAAGT 156 121 135
pY71SM3.9 CAGGGAAGT 28 13 16
pY71SM2.1 CAGGTACCA 133 115 113
'.7
2.3.4 Effe;::l; of splice acceptor si tes on transfontation
Analysis of £7 mRNA from several prcll'lalignant and
malignant cervical carcinOJ').a cell lines, imJllortalizcd human
cell lines and transforlled rodent cell lines hilS indicated
alternate splicing of the nt 880 splice donor s1 to to nt 2706
or 3357 splice acceptor sites (Smotkin and \~cttstcin, 1986;
Tanaka et aI., 1989; Doorbar et lIl.. 1990: Rohlfs ct a1.,
1991; Sherman at al .• 1!J92). Deletion of the nt n08 <lnd the
nt 2708 and 3357 splice acceptor sites [rom the plasmids, plYI?
and pY71, respectively, did not affect the tram:(orm,lUoll
efficiency of these plasmids (f"ig. 2.1). Thc~c rccults
indicate that neither of the two reported authentic sfll icc
acceptor sites of the early region lire required (or
transfonJIation. This data is also suggestive of the presence
of a cryptic splice acceptor site within the early region of
HPV-16. Deletion of all the authentic splice acceptor sites
may result in activation of this cryptic splice ~itc. 'I'hj!j
cryptic splice site may be located between nt 39"18 and "336,
because nei ther of the authentic spl ica acceptor sj tes
present in the plasmid ~.Y71.
2.3.5 Effect ot nt 226 and 1301 splice donor sites
on transformation
Disruption of the nt 880 splice site in pY71 r.eslilted in
total loss of transformation. The effect of disruption of
this splice site could be different for plasm ids which have
lOB
other authentic splice donor and acceptor and potential
cryptic splice sites. To address this possibility, the nt t.80
splice donor site was mutated in the early region expression
plasmid, pD7KB, and the whole HPV-16 plasmid!>, pHI<Bl, pHKB5
and pflKIH. Deletion of 4 bp in the plasmid pD7KB totally
abolished transformation (Fig. 2.4). similar deletions in the
context of whole HPV-16 genome plasmids, pHKBl, pHKB5 and
pHKB7, resulted in a significant reduction, but not total
abolition, of glucocorticoid dependent transformation (Fig.
2.S). Taken together, these results indicate the specific
requirement for the nt 880 splice donor site for efficient
transformation.
2.3.6 Effect of nucleotide 880 splice donor site mutations
on E7 RNA levels
To investigate the molecular mechanism by which the
.integrity of the nt 880 splice site affects transformation
function of E7, the levels of E7 message generated by various
transforming and nontransforming plasmids were compared by
RNase protection assays. Since BRK cells were not transformed
by the splice site mutants, assays used total RNA from
transiently 'transfected Cos-l cells. Transformation competent
plasmids, pY7l and pY75, generated a-fold higher levels of E7
message than the nontransforming plasmids, pY72 and f1Y73.
This was demonstrated in densitometric scans of autoradiograms
from three independent e>:periments. A typical autoradiogram
:Figure 2.5 Transformation by whole HPV-16 pll1slIids with small
delet.ions around the nt 880 splice donor sit-e.
All of the plasmids are in the pBR322 vector and
expressed from the homologous HPV-16 promoter-enhancer. 'l'he
genome and the ORFs of HPV-16 are shown in the diagram at the
top. The arrow indicates the transcription initiation site.
The thick lines represent the HPV-16 genome and nU'Iilbers below
lines correspond to HPV-16 nt sequence. The vertical black
boxes represent deletions. The nalles of plasJlids are shown to
the left. The total number of colonies in eight 60-rm plates
are presented to the right for duplicate experiments.

is shown (Fig. 2.61..). Plasmid pY75, which had a deletion o(
136 bp in the E1 ORF, produced 1.4-fold higher levels of E7
RNA, compared with the wild-type pY71 (Fig. 2.GA). 'rho
nontransfonllng plasmid pY72, which had a large deletion 1n
the E7 3' nanking region, produced levels of E7 RNA
comparable to that of another nontransforming plasmid, pY7KBI,
which has only 4 bp deletion at the splice site (Fig. 2.GB).
This indicates that the smaller size of the E7 nNA generated
by pY72 is not the reason this plasmid is nontransCor.ming.
ThE' splice donor site mutant pY7lSM1.5 gonerated 10-fold lowor"
levels of E7 RNA than the parental plasmid pY71 (Fig. 2.GC).
This mutant precisely defined the sequenco essential for both
transformation and E7 RNA accumulation. Verifying that
potential second site ..utations are not involved, the plasmid
in which the wild-type splice site was regenerated
(pY71SM2.1), produced near-wild-type level of E7 RIM (Fig.
2.6C). In addition, the mutant containing the consensus
splice donor site !'equence had a loS-fold higher level of 1-.:7
RNA (fig. 2.6C). These results clearly indicate that the nt
880 splice site is indispensable for transformation ilno
efficient E7 RNA accumulation.
That the presence of other authentic splice donor site
at nt 1301 and acceptor sites and potential cryptic splice
sites could not functionally substitute for the nt 880 splico
site, was shown by the plasmid pD7KB. Deletion of -1 bp from
Figure 2.6 A, Band C RNase protection assays for pY7 series
of plasmid.
Fil/e Jig of total RNA from CaSki cells or Cos-l cells
transfected with the pY7 series of plasmids was analyzed by
RNase protection assays for E7 RNA. The E7 probe corresponds
to the StuI (nt 5190 of SV40) to SspI (nt 720 of HPV-16)
fr.agment of pY71. constitutively expressed SV40 T antigen was
used as an internal control and the T antigen probe was
derived from the RsaI fragment (nt 3:>n-U86) of SV40.
Control lones and lanes for RNA from transfected Cos-l cell'J
ore indicated on top: probe, undigested E7 and T antigen
probes: CaSki, RNA from CaSki cervical carcinoma cells; Cos-I,
HNA from untransfected Cos-I cells: tRNA, E. coli tRNA.
Molecular size markers are sho...,n on the right. Protected E7
and T antigen fragments are indicated by arrow heads. CaSk!
1':7 RNA fragment is smaller since it lacks SV40 sequences
present in the probe and pY7 series of plasmids.
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the splice site in the plasmid pD7KB, that resulted in loss of
transformation, also lead to a substantial reduction in the
levels of £7 RNA (Fig. 2.7). This observation highlighted the
specific requirement of the nt 880 splice site for
transformation and £7 RNA accumulation.
Essentially, similar results were obtilined in experiments
in which the cotransfected pRSVCat was used as an internal
control, instead of the constitutively expressed T-antigen
(da ta not shown).
2.3.7 Requirement for the nucleotide 8ao splice donor site
for the stability of E7 RNA
Splicing is an essential process for the production of
many mature mRNAs. The lower levels of E7 RNA accumulation
for splice site mutants could be due to either lower levels of
synthesis or higher rates of degradation of this RNA. It is
more likely that the mlltations at the splice site af:'ect the
stability of E7 RNA. Actinomycin D chase experiments were
performed to compare the half-life of E7 RNA produced by the
wild-type plasmid pY71 and the ~plice site deletion mutant
pY72. Constitutively expressed T antigen of SV40 was used as
an internal control. The E7 RNA produced by the wild-type
plasmid pY71 was stable in the (} hour chase period with a
half-life of approximately 4.0-4.5 hours. In contrast, the E7
RNA produced by the splic(.· site deletion mutant pY72 was
highly unstable, and no signal could be detected beyond 0 hour
of the 6 hour chase period (data not shown) .
Fiqure 2.7 RNase protection assays for p071 and pD7KB
piasaids.
Five IJg of total RNA frolll CaSki cells or Cos-l cells
transfected witt- the p07l (D71) and pD"lKB (D7KIl) plasmids WilS
analyzed by RNase protection assays for E7 RNA. The E"l probe
corresponds to the StuI (nt 5190 of SY·IO) to SspI (nt 720 of
HpY-16) fragment of pY71. constitutively (>xpressed SV40 '{'
antigen was used as an internal control and the '1' antigen
probe was derived from the RsaI fragment (nt 3072-3266) of
SV40. Control lanes and lanes for RNA from trllnsfecled Cos-l
cells art:! indicated on top: probe, a mixture of undigested E7
(upper band) and T antigen (lower band) probes; CaSk!, ImA
from CaSk! cervical carcinoma cells; Cos-I, RNA [roll
untransfected Cos-l cells: tRNA, E. coli tRNA.. Molecular S-ll'.C
markers are shown on the right. Protected E7 and T antigen
f't'aqments are indicated by arrow heads. CaSki £7 RNA fragmcnt
is smaller sir,ce it lacks SV40 sequences prescnt in the probe
and pY7 series ot plasmids.
Figure 2.8 Nuclear runOff assays for wild-type and splice
site deletion mutant E7 expression plasmids.
Immobilized HPV-l6 (E7) and SV40 ('1') llNA were hybridized
with labeled RNA extracted from the nuclei of SOla cells (lilne
1), Cos-I cells transfected with pY71 (lane 2), pY72 (lane J)
and untransfected Cos-1 cells (lane 4).
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To show that the deletion of the F.7 J' flanking region
including the nt 880 splice site did not affect the rata or
synthesis of E7 RNA, nuclear runoff analysis was performed in
Cos-l cells transiently transfected with either pY71 or pY"".
Relative to the internal control T antigen, sYllthc~is of ~:'J
was comparable in both pY71 and pY72 transfectcd nuc.lci (Fig.
2.8). Taken together, the results of actinomyc-in D chase nl)1.I
nuclear runoff experiments indicate th"t the lower 1('vc10 of
E7 RNA accumulated by splice site mutants is dllQ Lo
destabilization and higher rateo of degradfltion oC 1::"/ HNA.
2.3.8 Effect of steroid hormones on the stability of E7 RNA
The disruption of the nt 880 splice donor site in the
context of SV40 promoter-enhancer based E1 l!xpre5sion pli.l£'mic.J~
totally abolished transforllation, whereas similar mutations in
the context of Whole HPV-16 plasnids siqnificantly rel.luccd,
but did not abroqatc, transformation. There was a derinlt(~
correlation between the ability of the SV40 prOllloter-cnhancc;or'
based E7 expression plasmids to transform nRK cell sand
qenerate stable E7 RNA. (Belaguli et al 1992; Pater ct ai"
1992b). The whole HPV-16 plasmids .... ith mutations at their lit
880 splice donor site may still be able to produce .,"/ lUI .... <It
levels sufficient for a low frequency of tram;f.onn<.ltioll.
Although, the transformation assays were very similar lor both
types of plasmids, they differed with respect to the
requirement for the steroid hormone dexamethasone for
transformation. Dexamethasone was used only for assays with
whole IIPV-16 plasmids. The E7 RNA generated by the splice
si te mutant HPV-16 plasmids may be stabilized to a certain
extent under the influence of steroid hormones used in
trilnsformiltion assilYs. Alternately, splice sites located
within the E6 and E1 DRFs could compensate for the loss of nt
sao splice donor site. Steroid hormones have been shawn
previously, to stabilize many mRNAs posttranscriptionally
(Nielsen Clnd ShClpiro, 1990). To address this possibility, a
number of cell lines stably expressing the early regions of
IIPV-16, except the E6 aRF sequences, were derived by
cotrClrlsfecting the plasmids p071 and E,J-.r..i!...§ into BRI< cells.
Aftcl."" blacking tl.""Clnscription with actinomycin 0, the half-life
of E7 RNA expl.""essed in pooled cell lines was measured by dot
blot assays with nick translated E7 probe. Actinomycin 0
chase experiment.. were pc:""formed in the presence and absence
of dexamethasone alone or in combination with progesterone.
The E7 signuls were quantitated by densitometric scanning and
norm<llized to the internal control y-actin. Addition of
hormones rasulted in slightly lower levels of E7 RNA.
Irraspective of the presan...~ or absence of hormones, the E7
RNA decayed with an appro>:imate half-life of 3.5 hours and no
'-'ppill.""ent differences in the half-life of E7 RNA was observed
(Fig. 2.9). Results of these experiments indicated that the
st~roid hormone dexamethasone, alone and in combination with
Figure 2.9 Actinomycin 0 chase experiments.
Total RNA from pO?! transformed BRK cells treated with
and without the indicated hormones were harvested at 0, 1, 2,
4, 6 and 8 hours after the addition of actinomycin D. Twenty
p.g of RNA samples were analyzed for £7 RNA by dot blot assays.
The E7 probe for dot blot assays was the smaller StuI-KpnI
fLdqrnent of the plasmid pY7L The blots were stripped and
reprobed with t.he BamHI fragment containing y-actin pr.obe
after nick translation. Time in hours is shown on the top.
The abbreviations used: CaSki, total RNA from CaSki cervical
carcinoma cells; N.BRK, total RNA from normal baby rat kidney
cells; £7 probe, the dot blots probed with the E7 probe; hetin
probe, the dot blots reprobed with the y probe; -, no hormone
added; 0, dexamethasone; D+P, combination of dexamethasone and
progesterone.
The dot blots were scanned by laser densitometry and the
results for duplicate experiments corrected for RNA loading
were plotted for graphical representation of results on the
bottom panel. Time in hours were plotted along tho X-axis and
the optical density (0.0) values were plotted along the '1.-
axis.
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progesterone does not contribute to the posttranscriptional
stabilization of E7 RNA. Thus, it is unlikely tl1at
posttranscriptianal stabilization of E7 RNA by steroid
hormones was responsible for the transforming ab,ility of IIPV-
16 splice site mutants.
2.3. 9 Effect of E6 splice sites on transforlltlltion
Al though the deletion analysis had made any role for Eli
splice sites in transformation unlikely (Pater at a1., 1992b),
the presence of these splice sites in the E6-E7 mRNl\. produced
from pHKB constructs, pHRS7, pHKBS and pHRDI, might have
contributed to the stabilization of these mRNAs and the
ref1idual transforming ac-::ivity of these plasmids (Fig. 2.5).
To study the role of E6 splice sites in transfcrmation, the
plasmids of the p073 series were lOsed (Fig. 2.10). 'rhe p073
series of plasmids mutated for the nt BBO splice donor si.tc
were constructed by transferring the restriction fragments
containing point mutations at this splice donor site [r.om the
previously-described pY71SM series of plasmids (Bel<lguli at
a1., 1992). The plasmid p07JI has a deletion of 45 bp (nt
B63-B87), spanning this splice site, whc.reas constructs
pD73SM1.5, p073SM3.2 and p073SM3.9 have similar mutations as
pY71SM1.5, pY71SM3.2 and pY71SM3.9, respectively (Fig. 2.10).
All these plasmids were tested for their transforming
activity. Construct pO?3 was less efficient in transformation
compared with the plasmid p071 (Fig. 2.10). The efficiency oC
Figure 2.10 Transformat.ion of BRK cells by pD73 series of
plasmids.
All of the plasJllids are in the pBR322 vector and
expressed from the SV40 early promoter-enhancer. HPV-1G
sequences are indicated as lines and the HPv-16 nt numbers are
shown below the lines. Wild-type and mutated nucleotide 880
splice site sequences are shown above the lines with lower
case letters for mutated nt. Abbreviations used are: EP,
early polyadenylation signal; 863-887.1, deletion between nt
663 and 8B·'. Total number of colonies in each duplicate
experiment are from ei9ht GO-mm plates. The percentage
transformation frequencies for plasmids compared with the pD73
plasmid are indicated on the right.
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transformation of the plasmid, pD73SM3. 2 , was slightly higher
than the pO?J construct and comparable to that of the pO?l
plasmid (Fig. 2.10). The plasmids pO?3I and pD73SM1.5 with
their nt 880 splice sites disrupted and the plasmid pD73SM3. 9
with a sUboptimal nt BfO splice site, were transformation
competent. HowElver I the efficii!ncies of transformation were
greatly reduced for these plasmlds (Fig. 2.10).
To confirm these observations regarding the E6 splice
sites, the E7 ORF and E6-E7 ORFs were expressed from the CMV
immediate early promoter-enhancer. The CKV vector used for
this purpose did not have any splice signals upstream of the
bovine growth hormone polyadenylation sIgnal. Only pCMVE6E7,
which has sequences encoding both E6 and E7,
transformation competent, whereas pCMVE7 was transformation
incompetent (Fig. 2.11). The E6 ORF present in the plasmid
pCMVE6E7 could have acted by providing either the E6 gene
product or the functional E6 spl ice signals. However, the
possibility that the E6 gene product might have conferrerf the
transformation phenotype on this plasmid was unlikely.
Disruption of the nt 226 splice donor site and a potential
ct"yptic splice donor site immediately upstream of it, in the
plasmid pCMVE6ME7, resul ted in the total loss of
transformation, highlighting the requirement for the
functional E6 spl ice sites, rather than the E6 gene product
for transformation (Fig. 2.11).
Fiqura 2.11 Transformation of BRK cells by pCHV and pY72
series of plasmids.
The pY72 series of plasmids are in the p13H322 vector i.\Ild
expressed from the SV40 early promoter-enhancer. HPV-16
:~equences are diagrammed as open boxes with the IIPV-16 nt
numbers shown below. Black bo:xes in the pCMV series of
plasmids represer.ts the bovine growth hormone gene
polyadenylation sequences. In pY72 series of pl<1smids, bo)(cd
arrows indicates the presence and orientation of SVI\O small t
intron containing sequences. The deletions are indiCllted by
thin lines. Abbreviations used are: E7, E7 ORF; E6, 1::6 ORF;
SSM, E6 splice site mutation. Total number of colonies in
each duplicate experiment are from eight 60-mm plates.
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2.3.10 Effect of heteroloqous splice s1tes on
transformation
To exallline whether heterologous spl icc sign.:lls could
substitute for the E6 splice sites, the SVIIO smilll t I.ntroo
was cloned in both S and AS orientations up:;trc'u. of E7 j n the
transformation deficient plasmid, pY72. 'I'his heterologous
intron restored transformation, only when prescnt in S
orientation in the plasmid p¥72t4, but not in II.S orientation
in the plasmid pY72tl (Pig. 2.11). Ilowcvcr. the
transformation efficiency of p'i72t4 \oH1S lower compilrcd wIth
the wild-type plasmid p'i71.
Considered together. these results indiciltc that
transformation by HPV-16 E7 is dependent on the presence of
functional splice sites. The presence of functional EG splice
sites in the pHKB series of plilsmitls could ho1VC been
responsible for their residual transrorming activity.
2.].11 Effect of E6 and heterologous splice sites on £7
RNA accumulation
The presence of either E6 or heterologous splice sites
u~stream of E7 was sufficient to confer transforming ability
to plasmids ....ith mutations at their nt 880 Dplice sites.
Since a good correlation had existed bet....een the prc[.lencc 0('
functional splice sites and the stability 01' El UNA, it
appeared likely that the EG or heterolofJolis spl ice sit(ls
present in these piasillids also contributed to the
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stabilization and accumulation of E7 RNA. To investigate this
possibility, total RNA from Cos-l cells transiently
transfected with E7 or E6-E7 expression plasmids was analyzed
by RNase protection assays. As was reported earlier (Pater et
al., 199/.b), mutations at the nt 880 splice donor site in the
plasmid pD7KB, which lacks the upstream E6 ORF I resulted in a
large reduction in the steady state E7 RNA level, as compared
with the wild-type plasmid pD71 (Fig. 2.7). The nt 880 splice
site mutants, pO?)I and pD7JSM1.5 generated lower levels of E7
RNA when compared with pO?) and pD73SM3.2 (Fig. 2.121\). TI'''
plasmid pD73SM3.2, with a consensus nt 880 splice donor site,
produced slightly higher level of E7 RNA as compared with the
plasmid p073 (Fig. 2.1210.). The plasmid with a suboptimal nt
aao spl ice site, pD7 3SM3. 9, gave rise to intermediate levels
of E7 RNA (Fig. 2 . .1210.).
Similarly, the transformation competent plasmid, pCMVE6E7
accumulated higher levels of E7 RNA than that of the
nantransforming pCMVE7 plasmid (Fig. 2 .12B). Disruption of
the nt 226 splice site that eliminated transformation for
pCMVE6ME7, resulted in lower levels of E7 RNA, compared with
pCMVE6E7 (Pig. 2.126).
Presence of SV40 small t intron upstream of E7, in the S
orientati.on, but not in the AS orientation, stabilized the E7
RNA. 'l'hL're was a high level of E7 RNA for the transformation
competent plasmid, pY72t.4, which has the SV40 small t intron
Figure 2.121\ RNas~ protection assays for pO?3 series or
plasmids wi th the E7 probe.
Five p.g of total RNA from CaSki cells and Cos-l cells
transfected with the indicated plasmids were analyzed by RNase
protection assays with the E7 probe. The E7 probe corresponds
to the stu! (nt 5190 of SV40) to Ssp! (nt 720 of IlPV-16)
fragment of pY71. Cotransfected plasmid, pRSVCat was used as
an internal control and the Cat probe corrasponds to nt 5016-
4766 of pSV2Cat. Control Innes and lanes for I~NII from
transfected Cos-I calls are shown on top: probe, a mixture of
undigested Cat (upper band) and E7 (lower band}; eLlsl:i, HNlI.
from CaSki cells; pSV2CIIT, RN/\ from Cos-l cells trLlnsfocted
with the plasmid pSV2Cat; tRNA, E. coli tRNlIi M, llpaII-
digested pBR322 molecular size markers. Protected eN!' (Ind £7
fragments are indicated by arrowhe<lus.
Figure 2.12B RNase protection assays for pCMV series of
plasmids l... ith the E7 probe.
Twenty p,g of total RNA was used for assays. Other
conditions and labels are as in figure 2 .12A.
Figure 2.12C RNase protection assays for pY72t series of
p1asmids.
Constitutively expressed SV40 'r antigen was used as
internal control and the T antigen probe was derived from the
RsaI fragment (nt 3072-3286) of SV40. E7 and T antigen
signals are denoted by arrow heads. T antigen signals were
clearly visible in darker ey.posures. Other conui tions and
labels are as in figure 2. 12A.
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containing sequences in the S orientation. 'I'll(! transformation
incompetent plasmid, pY72t.l, with the Solmc SV.10 sequence::. in
the AS orientation, had undetectable lcvl!l~: of E7 RNA (Fig.
2.12C) .
2.3.~2 splicing of E6 introns
As the presence of the E6 splice sites mil]ht have
compcr.satcd for the loss of nt 880 splice donor Gite that was
required for E7 RNA accumulation and trit!U;(ol-mntion, it Wil:: 01
interest to determine whether spI ic i ng invo [. vi neJ the E(, ~;pl icc
sites was occurring. For the nt BOO spl icc f".itc mllt,-ltiollP,
resul ting in reduced transfermat ion efficiency ([.' iq. 2. Ill) ,
the deletion mutation in the plasmid pi:'l)J und the t,li.l
mutation in the plasmid pD7JSMl.5 lead to il smal.! reductioll of
the RNA for the promoter-proximal, ~;6EXI c)(on anti .:l
sUbstantial reduction for the 3', more E7 onr-proxi ma I, EM:X2
exon (Fig. 2 .13A). 'rhe Cl1V construct, pCMVE6Ml-:7, tlwt "",15
completely defective for transformation due to iJ mlltilted nt
226 splice site, was completely defective for:- the stable
production of spl iced and unspl iced E6 RNII (F ig. 2.1 )F3j •
2.4 DISCUSSION
Several epidemiological studies have impl iciltcd 1l1'V-Hi as
one of the important etiolo<Jical agents for cervical cancer.
supporting these observations is the experimental eviLlencc
that this virus can immortalize it's natural targot cell:',
Figure 2.13 RNase protection assays for pO?3 and pCMV series
of plasmids with the E6 probe.
Five I~g of: total RNA from CaSki cells and Cos-I cells
transfected with the indicated plasmids were analyzed by RNase
protection assays with the E6 probe. The E6 probe was derived
from the HpaII-PvuII (nt 57-553) fragment of HPV-16.
Cotransfccted plasmid, pRSVCat or pSV2Cat was used as an
internal control and the Cat probe corresponds to nt 5018-4768
of pSV2Cat. Control lanes and lanes for RNA from transfected
Cos-l cells are shown on top: Probe, a mixture of undigested
E6 (upper band) and Cat (lower band); CaSki, RNA from CaSki
cells; PSV2CAT and RSVCat, RNA from cos-l cells transfected
with the plasmids, pSV2Cat and pRSVCat, respectively: tRNA, E.
Coli tRNA. I..abels are: E6 EX1, £6 exon 1; E6 EX2, E6 exon 2;
US, unspliced £6 RNA. The US and E6 EX1 fragments for CaSki
are smaller because th~ transcription is initiated from the
p97 promoter and the transcripts lack sequences between nt 57
and 97.
1\. pO?3 series of plasmids.
pCMV series of plasmids.
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primary human keratinocytes, in culture (Durst at al., 1987b;
Pirisi at a1., 1987; Schlegel et a1., 1988; Pecoraro et a1.,
1989; Woodworth et al., 1989). In addi ticn, HPV-16 can fUlly
transform established rodent cells (Tsunokawa at al., 1986.
Yasumoto at a1.. 1986; Matlashewski et a1.. 1987a). HPV-16
can also cooperate with activated oncogenes such as EJ-ras and
v-fos to transform primary rodent cells in the presence of the
glucocorticoid hormone, dexamethasone (Crook et al., 1988;
Pater et a1., 1988; Lees et a1.. 1990). In human cell
systems, the immortalizing activity of HPV-16 was localized to
E6 and E7 ORFs (Schlegel et a1., 1988; Hawley-Nelson et a1.,
1989; Munger et al., 1989b; Halbert at al., 1991). Several
studies have established that E7 is the major transforming
gene for rodent cells, but these studies utilized strong
heterologous promoter-enhancer sequences and message
processing signals for the expression of HPV-16 genes (Kanda
et al., 1987; Kanda et al., 1988b; Phelps et al., 1988;
Vousden et al., 1988; 'fanaka et al., 1989: Chesters et al.,
1990). However, the requirement for the homologous message
processing signals, especially the splice site sequences, for
the efficient expression of HPV-16 oncogenes, has not been
determined to date. I have examined the requirement for the
early region sequences of HPV-16 for transformation in the
context of E7 expression plasmids, with an emphasis on the nt
880 splice donor site.
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Deletion of the E6 ORr sequences did not affect
transformation for the plasmid pO?1 and several other SV40
promoter-enhancer based plasmids. In contrast to the results
obtained for the SV40 promoter-enhancer based plasmid, pDJl,
for the CMV based E7 expression plasmid, pCMVE7. the £6 OI~F
sequences were essential for transformation. It has beon
reported earlier that the E6 ORF seguences of i1PV-16 Ciln
transform established rodent cells (Sedman et a1., 1991) and
immortalize BMK cells in EJ-U§ cooperation assays (storey and
Bank~. 1993). Although the E6 ORF sequences are rllquired for
efficient immortalization of primary human keratinocytes,
which are the natural targets for this virus, (Schlegel at
al., 1988; Hawley-Nelson et al., 1989; Munger et al., 1989b;
Watanabe et al" 1989; Halbert et a1., 1991), several studies
have established that the E6 ORF sequences are dispensable for
transformation of BRK cells in EJ-ras cooperation assays
(Vousden, 1990; Munger et al., 1992). Further studies for the
CMV based E7 expression plasmids clearly indicated that the
splice sites present within the E6 ORF sequences, but not the
E6 gene product Rfi./iSl, were required for transformiltion. 'Phe
high risk group of HPVs, including HPV-16, produces low levels
of full length E6 and comparatively higher levels of a variety
of spliced mRNAs referred to as E6'" and E6'~"" (Schneider-
Gadicke and Schwarz, 1986; Smotkin at a1., 1989). Ability of
only high risk HPVs to produce such spliced transcripts
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suggested an important role for their products in the process
of tumorigenesis (Smotkin et a1., 1989). Two recent studies
have indicated that the E6* and E6** are not required for
immortalization of primary human keratinocytes (Halbert et
a1., 1991; Sedman et a1., 1991).
The E2 ORF of HPV-16 encodes
transcriptional modulator protein, which
DNA binding
either
down regulate or upregulate the viral promoter, depending on
the context of E2 binding sites (Ham et al., 1991; McBride et
a1.. 1991). Similar to the E2 protein of BPV-I, the HPV-16 E2
protein is also required for replication of the viral DNA
(Lambert, 1991; Del Vecchio et a1., 1992; Chiang et a1.,
1992a). In addition, several recent studies have assigned a
significant role for E2 in the process of immortali2ation and
transformation. Disruption of the E2 ORF sequences in the
context of the whole HPV-16 plasmids. resulted in enhanced
transformation of human fibroblasts and immortalization of
primary human keratinocytes (Smits et a1., 1988; Romanczuk and
Howley, 1992). In contrast, mutations in the whole HPV-16
plasmids did not Clffect the glucocorticoid dependent
tr"nsformation of BRK cells in EJ-ras cooperation assays
(Pater et al., 1992b). The E2 ORF sequences were shown to be
essential for immortalization of primary human keratinocytes
but not for transformation of BRK cells (Storey et a1., 1992).
Recently, it was shown that the coexpression of E2 from a
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strong heterologous promoter and the whole HPV-16 sequences
results in an increase in the frequency of transformation of
BRK cells (Lees ~t al. I 1990). The discrepancy regarding the
role of E2 in immortalization/transformation is not clci'lr. It
could be related ttl the differences in the assay systems imd
the level of expression of E2 protein. In the context of SV40
promoter-enhancer based f1PV-16 early region plasm ids, E2 ORF
sequences were not required for transformation of BIH< cells.
Similar results have been reported from several laboratories
(Vousden, 1990; Munger at aL, 1992).
Plasmids pY71PX, pY71SX and pY71RX implicated 1::::7 as the
major transforming gene of UPV-16 (Fig. 2.1). Several other
studies in which E7 ORF sequences were expressed from strong
heterologous promoters have also indicated that E7 is
necessary and sufficient for transformation (Phelps et <,:1.,
19881 St"rey et al., 1988: Vousden et al., 1988; Edmonds and
Vousden, 1989: Tanaka et al., 1989; Watanabe et al., 1990).
The oncogenic potential of HPV-16 E7 protein has been shown to
be closely related to its ability to complex with <Inti
interfere with the activities of the tumor suppressor protein,
pRb, and various other cellular proteins such as cyelin A,
plQ7 and pDQ \::dmonds and Vousden, 1989: Watanabe at al.,
1990; Dyson et al., 1992; Munger et al., 1992: Phelps at al.,
1992; Sang and Barbosa, 1992a: Davies et al., 1993; Tommasino
et al., 1993). The loss of transformation for the plasrnids
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pY71PX, pY71SX and pY71RX could be related to the instability
of the truncated E7 proteins encoded by these E7 mutated
plasmids, because similarly truncated E7 proteins have been
shown to be unstable (Watanabe et a1., 1990).
Several recent studies have assigned a role for E5 in the
transformation of established rodent cells (Leechanachai et
al., 1992; plIO et al., 1992; Banks and Matlashewski, 1993).
Similar to the E5 protein of SPY-I, the oncogenic potential of
the !/PV-16 E5 protein is likely to be related to its ability
to potentiate the EGFR and PDGFR-medlated signal transduction
to the nucleus (Banks and Matlashewski, 1993). Comparison of
the transforming activities of the plasmids pY71 and p'i76
suggested that the contribution of E5 ORF sequences for
transformation was not significant (Fig. 2.1). This could be
related to the weak oncogenic potential of HPV-l6 E5 protein.
The other possibility is that th~ E5 ORF sequences prescnt in
the plasmid pY71 may not be expressed efficiently, because of
the lack of proper message processing signals for the E5 RNA.
Recently Romanczuk and Howley, (1992), have correlated
disruption of EI ORF in the context of the whole HPv-16 genome
with an increase in the frequency of immortalization of
primary keratinocytcs. various studies have shown tr,at thti.
product of this highly conserved ORF is required for
replication and maintenance of the viral genome (Lambert,
1991). The El gene product can interact with and form a
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complex with the £2 transactivator protein and thi!>
interaction facilitates targeting of El to the viral origin oC
replication (Lambert, 1991). Because Dlany of the £.i2-actln<.J
elements present in the LeR of HPV-16 are required for tt.e
regulation ot transcription and replication and some of these
sequences overlap with each other, it is possible that El
participates in transcription of viral genes essential 1'01'
transformation, in presently undefined ways. This could be
responsible for the observed increase in the frequency of
immortalization tor El mutated plasmids (Romanczuk and Ilowley,
1992). The El ORF sequences were not required for the
glucocorticoid dependent transformation of DRK cells by whole
HPV-16 plasmids. however, the integrity of the nt 880 spl icc
donor site present within the £1 ORF sequences was essential
for efficient transformation (Pater et al., 1992b). 1'hc
requirement for the nt 880 splice donor site for
transformation is discussed later. In BRK cell system, in the
context of SV40 prollloter-enhancer based expression plazaids,
the majority of £1 ORF sequences were not required for
transformation (Fig. 2.1). 'l'he E1 ORF sequences present in
the plasmid pY71 were required in £..i.§.-contiguration Cor
transformation and deletion of this sequence resulted in loss
of transformation. The evidence for the ~-actinq nature of
this sequence was provided by the plasmid pAl (Fig. 2.2).
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That the deletion of this ill-acting J' flanking region
resulted in lower levels of E7 RNA and complete loss of
transformation, suggested the presence of either a
transcriptional enhancer or an mRNA stabilizing element(s)
....ithin the 3' flanking region. The possible presence of a
transcriptional enhancer for E7 expression was clearly
el iminated , since comparable levels of E7 RNA synthesis were
found for the transforming construct p'i71 and the
nontransforming construct pY72 by nuclear runoff experiments
(Fig. 2.8). Further, there was no evidence for the presence
of an mRNA stabilizing element within this region, based on an
analysis for homology to known structural or sequence
elements. 1\ previously mapped splice donDr site was present
within this region (Srnotkin et al., 1989).
'l'he results obtained from various constructs demonstrated
that it is the integrity of thi!i= splice donor site that
determines the level Df E7 RNA and the transformation
~ompetency. This interpretation is supported by the following
observations. (i) Deletion of as few as <I bp in pY7KBl or
mutating the conserved 3 bp of the splice donor site in the
plasmid pY7lSMl. 5 completely eliminated transformation and
greatly reduced £7 RNA levels (Table 2.1, Fig. 2.4, 2.6B,C).
The splice site sequence in these mutant plasmids does not
conform to the GT-AG rule observed for 100% of naturally
occurring splice junctions (senapathy et al., 1990; Jackson,
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1991). Similar substitutions in ot.her splice donor sites have
been shown to inactivate the splice site. (ii) Regeneration
of the wild-type sequence in a previously transformation
incompetent deletion plasmid pY7KBl restored both near wild-
type levels of transformation and E7 RNA Cl'able 2.1, Fig.
6B,C). (iii) Mutating the ....ild-type splice donor site to a
consensus splice site resulted in a 1. 5-fold higher level of
E7 RNA, a slightly higher frequency of transformation and the
early appearance of transformed colonies (Table 2.1, 1'1g.
2.6C) • The consensus splice donor sequence is fully
complementary to the first 9 nt of U1 snRNA and the degree or
complementarity between the splice donor site sequence and the
VI snRNA has been shown to determine the eff icicncy of
splicing (Nelson and Green, 1990). Thus, the higher froquency
of transformation and earlier appearance of transformed
colonies for the consensus splice site sequence plasmid,
pY71SM3.2, could be related to a higher efficiency of g"j RNA
processing, resulting in greater accumulation of E7 mRNA.
(iv) A single base substitution at the +2 position of the
consensus splice donor site signi f icantly reduced the
efficiency of tr;.lns(ormation (Table 2.1). (v) The plasmid
pY72 could support transformation when the heterologous SVI\O
small t intron was provided in the transcription unit in the
sense orientation (Fig. 2.11). Taken together, this datil
indicates the crucial role of the nt 880 splice donor site for
efficient E7 RNA accumulation and transformation.
The pY7 and pD7 series of plasmids mutated for the nt 880
splice site were transformation deficient. In contrast, whole
IIPV-16 plasmids containing similar mutations retained a low
transforming activity (Belaguli et al., 1992; Pater at al.,
1992b). Disruption of either the nt 226 or 1301 splice donor
s::'les did not affect transformation in the presence of wild-
type nt 880 splice site (Pater et al., 1992h). considering
the requirement for the steroid hormone dexamethasone for
transformation by HPV-16 plasmids, a hypothesis suggesting a
role for dexamethasone in posttranscriptional stabilization of
E7 mRNA was considered. This hypothesis was consistent with
several other studies, in which glucocorticoid hormone was
shown to stabilize various mRNAs (Paek and Axel, 1987;
petersen et al., 1989; Nielsen and Shapiro, 1990; Mendelson
and Boggaram, 1991; pilkis and Granner, 1992). My
experimental results failed to provid~' support for this
hypothesis, because no apparent difference in the half-life of
E7 RNA was noticed in the presence of dexamethasone, alone and
in combination with progesterone (Fig. 2.9).
The alternate explanation that the nt 226 or 1301 splice
sites present in the nt 880 splice site mutated HPV-16
plasmids functionally compensated to a certain extent for the
loss of the nt S80 splice site appeared unlikely, because the
disruption of either the nt 226 or 1301 splice sites did not
affect transformation (Pater et aI., 1992b). However, it was
'"
possible that the presence of a dominant nt &80 spi icc site
screened the effects of disruption ot other splice donor
sites. The ability of E6 splice sitas to compensate for the
loss of nt 880 splice site was demonstrated by the plasllids
pO?)I and pD73SHl.5. The presence of E6 splice sites in those
plasmids which WGee mutated for the nt 880 splice site was
sufficient to partially restore transtormation (Fig. 2.10).
As was previously observed, a good correlation between
the ability to produce stable E7 RNA and transform BRK colIs
was also observed for the pO?) series plasmids (Fig. 2.121\).
PlasmidF., pO?)I, pD73SMl.5 and pD73SM).9. which a.::cumulatcd
lower levels of E7 RNA compared with the wild-type plflsmid,
pO?3, showed a lower frequency of transfor;TlIatjon (Fig. 2.10,
2.12A). Similllr plasmids, pY7SMl.5 and p07KB, lacking the
upstream E6 splice sites, were unable to generate stable 1::7
RNA a.nd transform BRK cells (Belaguli et al., 1992; Pater et
al., 1992b). Irrespective of the presence of sequences for
two spliceable introns. the tnmsforlll<!ltion efficiency of the
plasmid p073 was slightly lower compared with the plasmid
p071, which has sequences for only one spliceablc intron (~·ig.
2.10). A likely explanation is that the EO' RNA produced from
the p'i71 and p071 plasmids are transln.ted only into F.7
protein, Whereas the E6-E7 polycistronic RNA ploduced from
p07J and p073SMJ.2 is used for translating the E6", E6"". ECt
and E7 proteins. In addition, the alternate splicing of che
nt 226 splice donor site to splice acceptor si~es present
downstream of the £7 ORF sequences, resulting in E7 axon
skipping, may lead to lower levels of £7 RNA and £7 protein
for the pon plasmid. A slightly higher level of E6-E7 RNA
produced frolll the plasmid p07JSM3.2 JlIay compensate for the £7
exon s)dppinq and a lower level or 1::7 synthesis.
For the p073I and pD73SH1.5 plasmids comptlred with the
p073 plasmid, the levels of £7 RNA detected with the £7 probe
wet"e substantially lower (Fig. 2.12A). However, with the E6
probe, only a slight reduction in the promoter-proximal £6
exon (£6 EXl) ""as observed for tho&1e nt 880 splice site
mutated plasmids (Fig. 2.13A). The splicing or this promoter
proximal axon to the nt 409 splice acceptor site (and probably
to the nt 526 splice acceptor site) of the second exon was
severely i.paired for the pOn1 and pD73SM1.5 plasllidti.
Because the early region E6 and E7 RNAs of HPV-16 transcribed
frofll the promoter p97 are polycistronic, a slight reduction in
the promoter-proximal E6 EXI exon and a substantial reduction
in the E7 ORP sequences-containing second exon, suggests
skipping of this £7 ORF sequences-containing second exon. In
support of this, it has been 6ho'fin that the mutation of the 5'
splice site of an internal exon results in skipping of that
internal eKon (Robberson at al., 1990; Talerico and Berget,
1990: Niwa et al., 1992). The hypothe!;1S that more of the E7
eKon is skipped for the plasmids, p073!, pD73SH1.5 and
14'
pD7JSM3.9, as compared with the plastlid pO,,) by splicing of
the nt 226 splice donor site to splice acceptor sites loci\tcd
downstream of £7 ORF sequences can be tested by usinq probes
spanning the nt 2708 and 3357 splice acceptor sites. That the
nt 880 splice site mutations for the pO?) series of plasllIids
results in E7 exon skipping is further supported by r.-aBults or
RNase protection experiments for the suboptimal nt 880 spl icc
site containing pD73SM3.9 plasmid. For this plasmid, there
was no detectabla reduction for the promoter-proximal F:6 I~Xl
exon RNA (Fig. 2.1311.). However, a 2-) fold reduction for the
87 RNA reSUlting from the £7 exon skipping, possibly bccaUtiu
of impaired splicing of the promoter-proximal E6 EXl eXOll to
the E7 ORF sequences-containing second intron, WilS observed
for this plasmid (Fig. 2.12A). The possibility thilt for most
of the RNA for the nt 880 splice donor site mutilted plYl]
plasmid series, the nt 226 splice donor site was spliced to nt
526 splice acceptor site and that the protected RNA fragment
corresponding to this more £7 proximal axon was not detectcu
with the E6 probe used in the RNase protection assays, was
also eliminated by the pD73SMJ.9 plasmid. No reduction for.
the E7 RNA would be expected if the majority of the nt 7.7.6
splice donor sites are spliced to the nt 526 splice acceptor
sites. The substantial reduction for the E7 HNA in the
absence of any reduction for the £6 EXl oxon and impairod
splicing of the nt 226 splice donor site to the nt 409 spliCe!
14'
acceptor site for the pD7JSM3.9 plasmid indicated that the nt
880 splice donor site mutations resulted in E7 exon skipping.
Thus, the low frequency of transformation for pD?3 series of
pl<'lsmids mutated for the nt 680 splice site appears to be a
consequence of E7 cxon Skipping. This interpretation does not
eliminate the importance of the E6 splice sites fer
stabilization of £7 RNA, because the mutation of the E6 splice
donor sites in the pCMVE6ME7 plasmid resulted in loss of E6
and £7 RNA accumulation and transformation (Fig. 2.11, 2.128).
The importance of alternate splicing for the regUlation of
IlPV-16 gene expression is further discussec1 in chapter 4.
The finding that the E6 intron of HPV-16 plays a role in
stabilizing the early region polycistronic mRNAs was clearly
demonstrated with plasmids pCMVE7, pCMVE6E7 and pCMVE6ME7
(Fig. 2.128, 2.13B). The E6-E7 RNA accumulation and
transformation was dependent on the presence of the functional
E6 splice sites for the plasmid pCMVE6E7. The identity and
source of the additional bands observed for the plasmids
pCr~VE7 and pCMVE6E7 are unclear (Fig. 2.128, 2.13B). For the
plasmid, pCMVE7, this band does not represent a specific
s.ignal. because this band was not seen in experiments in which
SV40 large T antigen was used as an internal control instead
of Cat (data not shown). Results obt.alned from these p1asmids
also indicate that the requ irement for an intron in thE= E7
transcription unit can not be overcomE' by employing the
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strong, heterologous promoter-enhancer and polyadcnylation
signal sequences. previously, the efficient CMV promoter was
shown to relieve the intran requirements of another. gono
(Neuberger and Williams, 1988).
However, heterologous sequences containing the SVI\O small
t intran functionally substituted for the nt 226 and SHO
splice sites. Presence of this intran upstream at' 10 in tho
sense orientation in the plasmid pY72t4 but not in the
antisense orientation in the plasmid p'i72tl, stabilized [>7 HNJ\
and conferred the transformation phenotype to a previously
transformation incompetent plasmid, pY72 (Fig. 2.11, 2.12C).
'fhe transformation efficiency of the plasmid p't72t4 was lower:
than that of the plasmid pY71, although it produced
consistently higher levels of E7 RNA (Fig. 2.11, 2.12C). 'I'he
presence of the SV40-derived sequences upstream of the E'l ORF
in this plasmid might have placed the. E7 initiation codon in
a relatively unfavourable configuration for translat ion,
resul ting in the synthesis of less E7 protein.
These studies indicate a role for the nt aao and 2?G
splice sites in the stabilization of E6-E7 RNA. However, they
do not exclude the possible role of the nt 1301 splice site.
This splice site present in the nt aao splice site mutated
HPV-16 plasmids n'oight have contributed to the transformation
potential of these plasmids (Fig. 2.5). Contribution ot the.
nt 1301 splicp. site to the stabilization of E6-E7 RNA may not
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be significant_ 'fhis interpretation is based on two important
observations; (i) nt 1301 splice site has beer. reported to be
rarely utilized, and (ii) no stabilizing effect of this splice
site was detectable on E7 RNA, when it was tested in isolation
in the plasmid pD7KB. ThUS, it is more likely that the
integrity of nt 226 and/or 8ao splice sites determines, to a
larger extent, the stability of early region polycistronic
RNAs.
'fhese studies demonstrate a r01e(5) for E6 splice sites,
in posttranscriptional stabilization of HPV-16 early region
transcripts. This is in addition to the previously assigned
role for E6 splice sites in facilitating translation of E7
(Sedman at a1., 1991).
Another observation of considerable interest was the
presence of an additional protected band, of approximately 195
nt, in RNase protection assays for the plasmids pY72t4 and pD7
series (Fig. 2.7, 2.l2A, 2.12C). Although the identity of
this band could not be est<lblished with certainty, it is
possible that it represents an RNA species initiated around nt
552, within the E6 or E7 ORFs. Several X'ecent stUdies have
suggested the presence of an internal initiation site wit:~in
this early region (Doorbar et al., 1990; Rohlfs et aI., 1991;
Higgins et al., 1992).
Taken together, these results are in conformity with the
observations that the presence of an intron in the
transcription unit facilitates higher expression of genes by
promoting accumulation of RNA (Buchman and Berg, 1988; Huang
and Gorman, 1990; choi et al., 1991; Palmiter et al., 1991).
However, for the pY71 and pY75 plasmids, functional splice
sites, but not the process of splicing was required for
accumulation of RNA. Although functional splice site and
polyadenylation signal sequences were present for the RNA for
the pY7l and pY75 plasmids, the majority of the RNA for these
plasmids was not spliced and polyadenylated (Fig. J. 2, J. 7 ,
3.10, 3 .HA). Further, the lack of spl icing and
polyadenylation did not destabilize these unprocessed RNAs or
prevent their transportation to the cytoplasm, suggesting that
the presence of functional splice sites and polyadenylation
signal sequences were sufficient for the stabi lization and
possibly transportation of HPV-l6 RNA. Similar observations
have been made for the late mRNAs of polyoma virus. 'J'he
stabilization of late mRNA for thb virus wa~ strictly
dependent on the integrity of splice sites, but not on the
actual process of splicing (Barrett et 211., 1990; Lanoix et
al., 1991). The likely explanation(s) for the requirement for
the integral splice sites, but not splicing mu: ~e:, is
discussed further in chapter 4.
Although unlikely, a possible mechanism by which the nt
880 splice site mutations affected transformation could be
through the activation of a cryptic splice site located withi n
'"
the E7 coding region, resulting in the production or a
truncated, nonfunctional £7 protein. Results of RNase
protection assays with probes spanning the complete £7 ORF or
different regions ot the £7 ORF failed to detect products of
such aberrant splicing (data not shown). Further, no
potential cryptic splice donor site was present ~1ithin the E7
OR~' and the E7 upstream sequences of p'i7 series of plasmids.
It is also possible that the £7 RNA for the pY7 plasmid series
with the mutated nt 880 splice donor site and the £6-£7 RNA
for the pCMVE6ME7 plasmid with the mutated nt 226 splice donor
sit~ are retained within the nucleus and, consequently,
rapidly degraded. The splicing apparatus assembles on nascent
RNA transcripts. to form the splicesome. in which the actual
process of splicing occurs (Green, 1991; Guthrie. 1991).
splicing has been shown to increase the efficiency of
polyadenylation (Huang and Gorman. 1990; Niwa et al.. 1990).
The presence of poly("') tails at the ]. end of rnRNAs is known
to stabilize the mRNAs. The illlpaired splicing of E7 RNA for
the nt 880 splice site mutated p'i7 plasmid series and the E6-
E7 RNA for the pCMVE6ME7 plasmid may interfere with efficient
J' end processing of the
destabilization of this RNA.
RNA contributing to
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}!ATURALLY OCCURRING AS HPV-16 RNA
:3.1 INTRODUCTION
The genomes of viruses grouped under the family
papovavlridae are small compared with the qunomcs oE athel."
double stranded DNA viruses such as adenovirus, herpes vinH~
and pox virus. Members of the subf<lmily papovavlrin<lc 5uch as
polyomavlrus, SV40 and JC virus have a genome si;w 01
approximately 5 kb. The coding potentitll of tile sm,l) J Cjcnomc:;
of these viruses is maximized by the presence or onFt.: on both
strands of the DN1\. and utili<:ation of morc than one promoter
to produce a variety of mRNl\. species. In contrast to tile
papovaviruses, the members o[ the SUbfamily papillom<1virinac
have a genome size of apIJroxlmatelY 8 kb and only one cod in'1
strand in their genome. Al though more th"n one promoter lli):';
been mapped in the genomes of papillomaviruscs such <'IS llJ>V-],
CRPV and IIPV-B, the majority of IlPVs contain a sjnfJle miljor
promoter (Smotkin et al., 1989; Palermo-Dilts at ill., ]990;
Howley, 1990). Recently, an internal promoter hCls been mappcu
within the early region £6 of the low risk gcnit<.lJ III'V~; (Chow
at al., 1987a; 1987b; Nasseri ot al., 1967; smot"'in ct al..,
1989) . Several studies have suggested the prcscm;:c of iJ
similar promoter within the genome of il tli<Jh rif'y. IlI'V, Hi'V-16
(Doorbar et al., 1990; Rohlfs et al., 1991; Iliggi.ns at al.,
1992). The major promoter, termed p97, has been the only one
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mapped to date in the genome of HPV-16 (Srnotkin and wettstein,
1986; Baker at al., 1987: Srnotkin et al., 1989). Transcripts
initiated at this promoter are differentially spliced to
produce a variety of mRNAs with different coding potentials
(Smotkin and Wettstein, 1986; Smotkin et al.. 1989;
Cornelissen at al., 1990; Doorbar at al., 1990: Johnson et
al., 1990; Schneider-Maunoury et aI., 1990; Nasseri at al.,
1991: Rohlfs et al., 1991; Shirasawa et al., 1991: Sherman and
Alloul, 1992; Sherman at al., 1992).
Recently a number of reports have indicated the presence
of AS IIPV-16 RNA in several cervical carcinomi":.s and carcinoma-
derived cell lines (Higgins at al., 1991; Vormwald-Dogan at
al.. 1992). The 1\1> RNA corresponded to the NCR, E6-E7, L2 and
Ll sequences or to the entire viral genome (Higgins et a1.,
1991; Vormwald-Dogan at al., 1992). The AS RNA may be a
product ot read-through transcription of the integrated HPV
genome from flanking cellular promoter-enhancer sequences.
Attempts to map the 5' ends of these AS transcripts by cDNA
cloning were of limited success, because the 5' ends of these
transcripts \o,'ere heterogeneous and appeared to be non-
authentic (Vormwald-Oogan et a1., 1992).
'fhe other possibility was that the AS RNA was transcribed
from a novel viral promoter present on the negative strand of
the viral genome. I have detected AS RNA corresponding to the
E7 and E1 ORFs of HPV-16 in a transient expression assay
system which simulates the episomal state of the virnl genome.
The AS RNA was transcribed from an AS promoter located within
the genome of HPV-16. The significance of the production o(
AS RNA for the life-cycle of the virus is discussed.
3. 2 MATERIALS AND METHODS
3.2.1 Construction of recombinant plasmids
Standard molecular biological techniques were used in
constructing plasrnids (Sambrook et 0'11., 1989). Plasmlds p'OI
and p'i75 and P'i7l3'A plasmid series have been descrjbed
earlie= in chapter 2. The pY7lJ'1I2 series of deletion mutants
were constructed by Ba131 digestion of EcoRI-linearizcd
pY71SE1l76, that was derived from p'i71 by inserting iln EcolU
linker at the SspI site (nt 1179). Tho products of deletion
were cleaved at the unique PvuI site within the pBRJ22 vector
DNA. The smaller fragment containing the HPV-16 early region
sequences for polyadcnylation/clcavagc was gel-purified and
ligated to the flush-ended E7-containing lar-ger EcolU-rvur
fragment. All deletions were confirmed by sequencing. The
plasmid pSV2HPA2 was constructed by ligating the blunt-ended
small SspI-PvuI (nt 3978 of HPV-16-nt J7JJ of pBR322) fragmont
of pY71, to the blunt-ended large HpaI-PvuI fr-agmcnt 01
pSV2Cat. Plasmid p'i7SA was constructed by ligating the blunt-
ended HpaII-NcoI (nt 502--867) fragment of HPV-16 to the blunt-
ended larger HindIII to BglII fragment of pSV2DIlFIl.
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3.2.2 Cell culture and transfection
The techniques were as described in chapter 2.
J. 2. J RNA prilparation and analysis
For total RNA preparation, Cos-l cells transfected with
10 J.lg each of the indicated plasmids and pRSVCat, pRSV,GGai
internal control plasmids or pUC19 were used. The internal
control Cat and ,8Gal probes corresponded to nt 5018-'1768 and
nt 3063-3286 Df pSV2Cat and peHIlO (Pharmacia), respectively.
Cytoplasmic RNA was prepared according to Sambrook et
a1., (1989).
Double RNase protection was performed according to
l<rystal at al., (1990), to analyze dsRNA. For this
experiment, two samples of 10 IJg each of total RNA
digested with 1000 U of RNase Tl. After inactivating the
RNill,e '1'1, RNase-resistant dsHNA was precipitated and
hybridized to uniformly labelled strand-specific E7 or E7/El
RNA probes. The nt 502-720 E7 probe has been described
earlier in chapter 2. The E7/El probes used in this study
corresponded to nt 720-955 and 792-1179 of HPV-16.
RNase protection experiments were performed with the
indicated probes as described in chapter 2.
Primer extension analysis was performed as described by
Ausubel at al., (1990). Ten p.g of total RNA from Cos-l cells
transiently transfected with the plasmid, pY7l, was used for
analysis. The 5'-end-labelled primer sequences were nt 1292-
1312 continuing with nt 376J-3766, 25-mer oligonucleotide
complementary to the negative strand of HPV-16 sequences
present in the pY71 plasmid.
3.2.4 In situ hybridization
Forty eight hours after transfection. Cos-l cells
transfected with the indicated plasmids were trypsinb:cd ilnd
plated in chamber slides. Cells were fixed w.lth H
paraformaldchyde (PFA) and 5 roM MgCl2 at room temp(.Jraturc for
10 minutes. PFA-fixed cells were stored at "oc, in '/o's
ethanol. In situ hybridizdtion experiments were performed ..ni
described by Lawrence and singer, (1986), with biotinyliltml
sense and antisense E7 RNA probes. 'l'he hybridized probes were
detected with the DNA detection system (Bethesda Hcscan.:h
Labs), according to the manufacturer's recommendation~;.
3.2.5 Immunofluorescence
Cos-l cells transfected with the indicated plasmids were
fixed with a 4% solution of PFA for 10 minutes followed by
permeabilization with methanol for 2 minutes at room
temperature. After fixation and permeabilization, cells were
covered with an E7 specific monoclonal antibody, IlBD" (1: 1000
dilution in PBS) and incubated at ,,0 C for 1 hour. Calls were
washed thrice in PBS before applying the 1: 5 diluted
fluorescein isothiocyanate (FITC) -conj ugated anti mouse
antibody. Cells were washed thrice in PBS and analyzed by
fluorescent microscopy.
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J.3 RESULTS
3.3.1 Detection ot HPV-U; AS promoter
several IIPV-16 positive cervical squamous cell carcinomas
and carcinOllla derived cell linas have been shown to express AS
HPV RNA (Higgins et al., 1991; Vorllwald-Doqan et al., 1992).
In all these tUllors and cell lines, the viral genome was found
to be integrated with the cellular genome. Expression of the
AS HPV RNA in these cells may be a cor;sequence of integration
of the viral gcnomE.\. Read-through transcription of the
negative strand of the viral genome from the flanking cellular
promoter-enhancer sequence could result in the appearance of
AS HPV RNA. The AS HPV RNA may llisa result from the
transcription CJf the viral negative strand from a hitherto
unmapped viral promoter. However, no evidence for the
presence at a promoter other than the previously mapped p97
promoter exists. The presence of AS RNA in only a few cell
lines could be related to the pattern of viral integration.
It has been shown that regions of )' ORFs of the viral early
region, especially the El and/or £2 ORFs, are generally
deleted or disrupted as a consequence of integration of the
viral genome (Hatsukura et al., 1986; Durst et al., 19861
Daker et al .• 1987; Wagatsuma et al., 1990). If the proposed
AS promoter is located within the )' early region ORFs, it is
likely that this promoter is deleted in many cell lines and
these cell lines fail to express AS HPV RNA. Cells in which
the AS promoter is not deleted lIay continue to express AS HPV
RNA.
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Based on the hypothesis that there is an AS promoter, the
IIPV-16 sequences th""t may contain this promoter were tested in
the .apisomal form to avoid the effects of integra ticn, bee,tllSO
it has been shown that the cellular sequences n<lnking the
viral sequences at the site of int.egration often influence tho
activity of the viral transcriptional rcguintory elements (von
knebel-Ooeberitz et al., 1991). II plasmid, pY71, was
constructed in which the )' early region sequences downstr,;:>am
of El and/or E2 ORF were intact. This:)' early region
contains the E5 ORF, a cryptic splice acceptor site <lnd the
viral early region polyadenylation signal (Seedorf at ill.,
1985). In addition to E5, sequences corresponding to the E7
ORF and a part of E1 ORF were also present in this plUF>mid
(Fig. 3.1). To determine if this plasmid can result in the
expression of AS HPV RNA, the plasmid was transfected into
Cos-1 cells and the total RNA harvested from these cells was
analyzed for the presence of S and AS llPV ~NA by IWase
protection assays, using S and AS E7 probes. 'l'he S and /IS In
RNAs are detected by the AS and S E7 probes, respectively. As
shown in the fig. 3.1, both S and AS E7 RNAs were readi.ly
detected in cells transfected with the plasmid, pY71. 'I'he
relative levels of AS RNA with respect to the S nNA was
variable among different experiments. It was possible that
this AS RNA was transcribed from a cryptic promoter lOCllted
within the pBR322 vector sequences of pY71. To evaluate this
Fiqure 3.1 Diagrammatic representation of and RNase
protection experiments for E7 expression plasmids.
The cliafJram is on top. Both plasmids are expressed [rom
tho SV<\O early promoter-enhancer. The open boxes and the
filled box represent, the HPV-16 E7 ORF and the early)'
region inClUding the early polyadenylation signal sequences,
and the SV<\O small t intron and polyadcnylation signal
sequences, respecti ....ely. The deletion is indicated by the thin
line. The nu~.berti correspond to the HPV-16 nt sequence.
'rhe results are shown on the bottom for 5 p.g of total RNA
from CaSki calls, untransfected Cos-l cells and Cos-l cells
transf'ected with the indicated plasmids, analyzed by RNase
protection assays with S and AS E7 probes. The E7 probes
correspond to both strands of the Stu! (nt 5190 of SV40) to
Ssp! (nt 720 of HPV-16) fragment of pY71. The AS and S labels
on the tlJP of the lanes indicate thc Gcnse and antisense
probes used ill the assay. Control lanes and lanes for RNA
(rom transfected cells are indicated on top as: probe,
undigested £7 probes; CaSki, RNA [rom CaSki cells, Cos-I, RNA
from untransfected Cos-l cells; M, Hparr-digested pBRJ22
molecular size markers. The protected E7 Sand E7 AS
fragments are indicated by arrowheads. The protected E7
fragment for CflSki cells is small, because it lacks sequences
present in the probe and E7 expression plasmids.
pY71
pY7SA [;~o;::,=::::;;;:;------------
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possibility, the pY7SA plasmid was constructed by rej?lacing
the HP'J AS promoter region of pY71 with SV40 sequences (Fig.
3.1). Because the Af; promoter rr.' ion overlaps the splice and
polyadenylation signal sequence~ a functionally analogous
['eglon consisting of the small intron and the
polyadenylation signal sequ~nces was chosen from SV40. Only
S, but not AS, E7 RNA was detected for this plasmid (Fig.
3.1). Similarly, no AS E7 RNA was detected for caSki, a
cervical squamous carcinoma cell line that constitutively
expresses HPV-16 early region (F:i.g. 3.1). In this cell line,
the J I ~arly region ORFs of HPV 3' to nt 3728 are deleted as
a result of integration (Smits et a1., 1991). Taken together,
these results are suggestive of the presence of an AS promoter
within the HPV-16 region of the plasmid pY71.
3.3.2 Localization of the AS promoter
The S probe used to detect the AS E7 RNA contained the nt
502-720 of HPV-16 and 25 nt of the SV40 early promoter region
and additional nt derived from the pBSKS(+) vector. If the AS
RNA was transcribed from a promoter located within the TIt 502-
720 sequences of HPV'-16, not all of th~ HPV-16 sequences
prescnt in the probe would be protected from RNase digests ,;1,
resulting in a small size for the protected probe. In RNase
protection assays, all of the HPV-16 and SV40-derived
sequences present in \:his probe were protected indicating that
the AS aNA was transcribed from the AS promoter located
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further downstream of the probe sequences. Total RNA from
Cos-l cells transfected with the plasmids, pY71 and pY75, Wil$
analyzed by RNase protE~ction assays with the probe spanning nt
720-955 at the 3' end of the E7 and 5' end of the F.l ORF
sequences to address the possible location of the liS pr.o1\1otcr
within this region of the HPV-16 genome. The AS IUM was
detected for both of t~e plasmids, p'i71 and pY75 (Pig. 3.2).
Higher levels of AS RNA relative to the 5 RNA was detected [or
the plasmid pY71 compared with the plasmid pY75. As ObSel"Ved
earlier with the E7 probe, no AS RNA \-Jas detected for Casb
cervical carcinoma cells with this P.7/El prohe. All or the
sequences between nt 720 and 955 were protected [or the
plasmids, pY71 and pY75, indicating that the AS promoter Wil:::
located downstream of the nt 955. That the deletion between
the nt 1176 and 1312 in the plasmid, pY75, did not elililiniltc
AS RNA suggested that the AS promoter was not present wi thi n
this region of HPV-16. However, this deletion lowQred the
level of AS RNA for the plasmid pY75. Further, the AS WljEJ
probe which detected S RNA indicated that the gr.oatQr
proportion of 5 RNA was spliced at the nt 880 splice site for.
CaSki cells. In contrast, less of 5 RNA was spliced for the
plasmids, pY71 and pY75, at this splice site (Fig. 3.2). 'J'ho
effect of A5 RHA on splicing of S RNA is discussed later iI'
more detail.
Figure 3.2 RNase protection assays for plasmids pY71 and pY75
wi th the E7 lEI probes.
The results are shown for 5 IJg of total RNA from CaSki
cells and Cos-I cells transfected with the indicated plasmids,
analyzed by RNase proter::tion assays with S and AS E7/EI
probes. The E7/El probes correspond to nt 720-955 of HPV-16.
'rho AS and S labels on the top of the lanes indicate the sense
and antisense probes used in the assay. Control lanes and
lanes for RNA from transfected cells are indicated on top as:
probe, undigested E7jEI probes; caSki, RNA from CaSki cells,
HpaII-digested pBR322 molecular size markers are shown on the
right. Labels are: US, unspliced E7 sense RNA; 5, E7 sense
RNA spliced at nt 880. The protected spliced and unspliced
E7jEl fragments are indicated by arrowheads.
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To map the location of the AS promoter, additional
plasmids with deletions extending into the 5' end of the El
ORF sequences were used (Fig. l.3). Because the results of
Rtlase protection assays for the pYll plasmid had elbinated
the presence of the AS promoter between the nt 1312 and 37;SJ,
deletions were made starting from the nt 1312 and extending
towards the £7 ORP. Total RNA froll Cos-l cells transfected
with these deletion plasmids and the internal control pRsvcat
plasmid was analyzed by RNase protection assays with the
previously described E7 probes and the AS Cat probe. As
observed earlier, the plasmid, p'i71, produced higher levels of
AS RNA relative to S RNA compared with the plasmid pY75 (Fig.
3.3). progressive deletions between the nt 1176 and 876
resul ted in a gradual increase in the levels of AS RNA. For
the plasmids, pY7S, pY713'A15, pY713'A17 and !='Y713'Al, thero!
was less of AS RNA relative to S RNA, whereas for the
plasmids, pY713'O,29, pY713'A16, pY713'A1.2 and pY713'A2, more
of AS RNA relative to S RNA was observed (Fig. 3.3). As has
been reported earlier (Belaguli et aI., 1992), deletion of
sequences between the nt 876 and 3763 greatly reduced the
level of S E7 RNA (Fig. 3.3). Because the deletions between
the nt 867-3763 did not eliminate AS RNA, results of these
experiments indicated that the AS promoter is located
downstream of the nt 3763.
Figure 3.3 Diagrammatic representation of and RNase
protection experiments for pY71J' A series
of E7 expression plasmids.
The diagram is on top. All plasmids arc expressed frolll
the SV40 early prolloter-enhancer. The boxes and thin 1 ines
represent the HPV-16 sequences and deletions, respectively.
The numbers below the boxes correspond to IIPV-16 nt. The
abbreviations ATe, TAA and EP indicate the initiation .J.nd stop
codons of E7 (E7) ORF and the HPV-IG early po}yadenylilt lOll
signal sequence, respectively.
The results are shown on the bOttOl1 fC'Jr 5 Il!J of totill Imll
from CaSki cells and C05-1 cells transfect.cd w.lth the
indicated plasmids, analyzed by RNase protection as~ays wHh
S and AS E7 probes. The E7 probes correspond to both strio ntis
of the stu! (nt 5190 of SV40) to SSp! Cnt 720 of HPV-l6~
fragment of pY71. The cotransfected pRsvcat plasmid was u!;cd
as an internal control and the CAT probe corr(!SpOnd5 to nt
5018-4768 of pSV2Cat. A mixture of undirJe5ted eNl' probe
(upper band) ar.d AS and S E7 probes (lower bands) were run in
the lanes marked Probe. Abbreviations used arc: HSVCiJt, HilA
from C05-1 cells transfected with the pHSVC.J.t pJiJsmid; tmJII,
E. coli tRNA. The protected E7 S and AS and CAT rrugments Qre
indicated by, "::'owheads. Conditions and other labels uS in
figure J.1.
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It was likely that the AS promoter was present between
the nt 3763 and 4)]8 of HPV-16, because all of the 1\5 Iml\
expressing plasmids had these sequences in common and the
results of RNase protection assays for the plasmids wi til
progressive unilateral deletions in the El OIU~ sequences
suggested that the AS promoter was located downstn."lm or the
nt 3763. Several plasmids with unilateral deletions extend i 119
from the nt ]763 towards the early polyadenylation signal
sequences were constructed and tested by HNasc protct:tion
assays for their ability to produce S and AS E7 rlNA in Cos-l
cells, using E7 probes. All of the plams ids, pY" 1]' 111..? ,
pY713'42.5 and pY71J'l12.14 proc'.uced low levels of AS Imfl
relative to S RNA (Fig. 3.4). The deletion of 2611 bp in the
plasmid pY71J'42.l4 extending to nt 4031 did not eliminate AS
RNA. This deletion plasmid localized the AS promoter ilctivity
to sequences between the nt 4031 and 4338 of HPV-16.
3.3.3 The activity of the 11.8 promoter clonod dOllnstream of
Cat gene
Cloning the AS promoter in the sense orientation upstrc;~m
of a reporter gene would provide a convenient method of assily
for the activity of this promoter. A 362 bp of IIPV-J(. nt
3976-4338 fragment containing the AS promoter WilS cloned
upstream of the reporter Cat gene in the plasmid pAS{+)C<.Lt ilnd
tested in the monkey kidney cell line, Cos-I, and the mouse
fibroblast cell !ine, L cells. In both cell lines, the
Figure 3.4 Diagrammatic representation of and RNase
protection experiments for pY713'!J2 series
of E7 expression plasmids.
The diagram is on top. All plasmids are expressed from
the SV40 early promoter-enhancer. The boxes and thin lines
represent the llPV-16 sequences and deletions, respectively.
'rhe numbers below the boxes correspond to HPV-16 nt. The
abbreviations A'l'G, TAA and EP indicate the initiation and stop
codons of £7 (E7) ORf and the HPV-16 early polyadenylation
signal sequence , respectively.
The results are shown on the bottom for 5 /.19 of total RNA
from CaSki cells and Cos-l cells transfected with the
indicated plasmids, analyzed by RNase protection assays with
S and AS E7 probes. The E7 probes correspond to bath strands
of the StuI (nt !)190 of SV40) to Ssp! (nt 720 of HPV-16)
fragment of pY71. The cotransfected pRsVCat plasmid was used
as an internal control and the CAT probe corresponds to nt
5018-4768 of pSV2Cat. A mixture of u;ldigested CAT probe
(upper band) and AS and S E7 probes (lower bands) were run in
the lanes marked probe. Abbreviations used are: RSVCat, RNA
from Cos-l cells cells transfected with the pRSVCat plasmid:
tRNA, E. cal i tRNA. The protected E7 Sand E7 AS and CAT
fragments are indicated by arrowheads. Conditions and oth".!r
labels as in figure J. 1.
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activity of this plasmid was several-fold lower than the
promot€:rless parental plasmid, pBLCatJ (data not shown). The
low level of cat activity for the plasmid pAS (+) Cat compared
with the plasmid, pBLCatJ could be related to the out-of-frame
translation of the Cat mRNA, that would result in a
nonfunctional Cat protein. Consistent with this possibility,
several ATG triplets were present in the 5'region of AS RNA.
Another possible explanation for the poor activity of this
promoter could be related to the absence of enhancer sequences
in the plasmid pAS(+)Cat.
To test the AS expression of heterologous sequences and
because the activity for the AS promoter containing sequences
clonad upstream of the reporter Cat gene in the enhancerles$
plasmid was low, the nt 3976-4336 AS promoter containing
fragmen'L was cloned downstream of the Cat gene in the SV40
early promoter-enhancer-containing plasmid, pSV2HPA2. The
small t intran and the polyadenylation signal sequences of
SV40 present in the plasmid, pSV2cat, were replaced with HPV-
16 nt 3976-4338 AS promoter containing sequences to construct
the plasml.d, pSV2HPA2 (Fig. 3.5). This plasmid was
cotransfected with the internal control pRSV}3gal plasmid into
Cos-I cells and the total RNA e:-Ltracted from these cells was
analyzed by the S and AS Cat probes and AS .egal probe. The
IIPV-16 AS promoter was functional for the AS transcription of
the Cat gene. Compared with the control plasmid, pSV2Cat,
Figure 3.5 Diagrammatic representation ot and RNase
protection experiments for Cat plasllids.
The open boxes indicate the sequences of the pSV2Cat
plasmid. The black box represent the HPV-16 sequences
containing the AS promoter. The nt coordinates for the Celt
and AS promoter region are frolll pSV2Cat and IIPV-)(,.
respectively.
Five Ilg of total RNA from Cos-l cells trilnsfected with
the indicated plasmids were analyzed with S and AS CNr probes.
Cotransfected pRSV,8Cal plasmid was used as the internal
control. The CAT and pCal probes correspond to nt 5013-4763
and 3063-3286 of the pSV2Cat and pRSV!JGal plusmit..Is,
respectively. Symbols CAT and GAL indicate the protect0d Cat
<lnd ,eGal fragments. Conditions and other abbreviations <l~; in
the figure 3.3.
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significantly higher levels of AS Cat RNA were detected (0]'
the pSV2HPA2 plasmid (Fig. 3.5). 'fhcsc results coafi.rm ttll'
presence of an AS promoter between nt 3976 and 4JJU of IlI'V-]fi
and show that this promoter can be l1sed to tr.1n:;'~T i be
heterologous sequences.
3.3.4 Happing the 5' on45 of AS RNA
Primer extension analysis was used to map the 'i' cnrl~ of
the AS RNA. Total RNA from Cos-I cells tr<lns(cctetl with tilt'
plasmid, p¥71, was t..sed for this analysis. For CaSki cells,
which were consistently negative for AS RNA expression, no
primer extension product was detected (datil not shown). 'l'lw
results of the experiments done in duplicate for the pl;lsmid,
pY71, indicated that the AS P:NA has hctcroCJcncous ',' (~nd"
initiated in an AT-rich region around nt HOD (Fig. 3.6).
To confirm the results of primer extension ilnilly;~i:;
regarding the 5' ends of AS RNA, RNase protection e)(p~l-imc"lt:;
were performed on total RNA from pY7l- Clnd p'l75-trilnsfeeted
Cos-l cells with S and AS RNA probes corre5ponding to nt '1llrl-
4311. If the AS transcripts are initiated around the nt 41GO,
no signal corresponding to the AS RNA wOl1ld be p.xpcclcd for
this probe. Consistent with the previous obscrvatiolia wi-til
the E7 and E7/El probes, no 1\$ RNA Wi:lS detected f{)~ r;n:;)t; i
cells (Fig. 3.7). Because the 3' early region OIH" ~.' ~ucnce~;
of HPV-16 3' to the nt J728 are deleted as a consequence 01
integration of t.he viral genome, no S HNA was detected (or.
Figure 3.6 Primer extension analysis.
The left panel shows the resul ts. The nlaj or 1->r. imcr
extension product is indicated by the arrowhead. Lanes 1 <U10
2, are for total RNA from Cos-l cells transfected with the
pY71 plasmid. The tRNf. lane is for E. Coli tRNA. Lanes G, A,
T and C indicates the dideoxy sequencing reaction5 performed
wi th the primer that was used for primer extension.
Figure 3.7 RNase protection experiments with the nt 4107-431.1
probe.
The probes correspond to nt 4107-431] of flPV-16.
Abbreviations used are: UP, unprocessed RNA; P, RNA that has
undergone )' end cleavage downstre<lm of the early
polyadenylation signal. All other conditions and
abbreviations are as in figure 3.3.
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CaSki cells with the nt 4107-4311 probe. For the plasmids,
pY71 and pY7S, very law levels of AS RN.\ relative to the S RNA
were detected (Pig. 3.7). The representative figure shown W<lS
made from an overexposed autoradiogram to reveal the J' end
processing for S RN.... In lighter exposun".s, the AS RNA Wi\S
not detected for the plasmids, pY71 and p'l75, with the nt
4107-4311 probe. These results confirm that the AS RNA
transcripts are initiated within a narrow region around the nt
4100.
3.3.5 Detection of AS RNA in the cytoplasm
Analysis of the HPV-16 AS RNA in cervical cancers ilntl
cervical cancer-derived cell lines has indic~ted that the III'V-
16 AS RNA is predominantly found in the nucleus (111991ns ct
aI" 1991; VOrDlofald-Doqan et al., 1992). The 1\5 RNA detected
in cervical cancers and cancer-derived cell lines Illay be the
product of read-through transcription of the integrated IlPV-16
genome from flanking cellular promoter-enhancer sequences. In
contrast, the AS RNA detected for the HPV-16 expression
plasmids used in my study were initiated from the viral AS
promoter. It is possible that the intracellular location of
the AS RNA produced from t.he HPV-16 expression plaslllids such
as, pY7l and pY75, might be different frOB the 1\5 HNA detected
in cervical cancers and cervical cancer-derived cell lines.
To determine whether the AS RNA for the IfPV-16 expression
plasmids is present in the cytoplasm, the cytoplasmic RNA was
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isolated from Cos-! cells transfectt2d with the p'i71 and p'i75
plasmids and analyzed by RNase protection assays, with E7
probes. For CaSki cells, only the 5, but not the AS RNA was
detected. For the plasmids, pY71 and p'i75, both the S and AS
RNAs wera detected (Fig. 3.81'.). The levels of the AS RNA
relative to S RNA for the plasrnids, pY71 and pY75, were
comp<lrable for the experiment shown. However, ':"le relative
levels of AS RNA were variable among different experiments for
these plasmids.
Contamination of the cytoplasmic RNA with the nuclear RNA
during the process of isolation of the cytoplasmic RNA might
have resulted in AS cytoplasmic RNA for the pY71 and pY75
plasmids. To eliminate this possibility, in situ
hybridization experiments were performed on Cos-l cells
transfected with the p¥71 plasmid, using strand-specific
biotinylated E7 RNA probes. The pY7SA plasmid which does not
express AS RNA was used as the negative control. Under low
magnification, the 5 and AS RNAs were detected for the p'l71
plasmid transfected-Cos-l cells (data not shown). Because
only a small population of transfected cells take up the
transfected plasmid DNA, heterogeneity for the expression of
5 and AS E7 RNA was observed. Under higher magnification, the
AS HNA for the plasmid pY71-transfected Cos-l cells was
predominantly cytoplasmic (Fig. 3.88). Low levels of both 5
and 1'15 E7 RNAs were also present in the nucleus (Fig. 3.88).
Figure 3.8 RNase protection anel in situ hybridization
experiments for cytoplasmic RNA.
A. RNase protection experiments.
The results are shown on the top for 5 P9 of total
from CaSki cells and Cos-l cells transfee ted with the
indicated plasmids, analyzed by RNase protection assays with
S and AS E7 probes. The E7 probes correspond to both strands
of the stu! (nt 5190 of SV40) to Ssp! (nt 720 of HPV-l6)
fragment of pY7l. The AS and 5 labels on the top of the li:lncs
indicate the sense and antisense probes used in the assay.
Control lanes and lanes for RNA from transfected cells a("c
indicated on top as: Probe, undigested E7 probes; CaSkj, RNA
from CaSki cells, tRNA, E. coli tRNA; M, HpaII-digested pBRJ2?
molecular size markers. The protected 5 and AS E7 fragments
are in(,1.icated by arrowheads.
B. In situ hybridization experiments.
CaSk! cells and Cos-I cells trans£ected with the pY7l and
pY7SA plasmids were hybridized with 5 and AS biotinylated In
RNA probes. Labels are: S RNA, a::;says for E7 sense RNA "With
AS probe; AS RNA, assays for E7 AS RNA with S probe; CaSki,
CaSki cervical carcinoma cells; pY71, Cos-I cells transfectcd
with the plasmid pY71; pY7SA, Cos-I cells transfected with the
plasmid pY7SA. Magnification: 25x for CaSki cells and 40x for
Cos-l cells.
S RNA AS RNA
In agreemQnt with the results of RNase protection, only S, but
not AS E7 RNA ....as detected in the cytoplaslIl for CaSki celJ 5
and Cos-l cells transfected with the p'i7SA plasmid (Fig.
3.88). That the AS RNA detected for the p'i71 plasmid was not
because of hybridization of the S RNA probe to denatured
template DNA was suggested by the absence of AS RNA for the
pY7SA plasmid. Compared to CaSki cells, cos-! cells
transfected with the plasmids, p'i71 and p'i7SA, expressed very
high levels of S RNA and this could be related to the
amplification of these SV40 origin of replication-containing
plasmids, in Cos-l cells. The results of in ~itu
hybridization experiments confirmed the cytoplasmic location
of the AS RNA for the pY71 plasmid.
Only a few of the reported naturally occurring AS RNAs
have the coding potential and these AS RNAs have been detected
in the cytoplaslIl (Williams and Fried, 1986; Adelman et al.,
1987; Killelman and Kirschner, 1989; Lazar et al., 1989;
Miyajima et al., 1989; van Duin et al., 1989; Delnick, 1993).
The nt sequence of the naturally occurring AS RNA to the bfei"
mRNA of Xenopus is highly conserved among different species of
animals and encodes a protein of 25 kDa (Kime1man and
Kirschner, 1989). The AS RNA to the rat c-~!lQ'-2 mllNA
encoded a S6 kDa protein (Lazar et a1., 1989). Because the
HPV-16 AS RNA was also detected in the cytoplasm, it
possible that the AS RNA could code tor a protein. The
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possible coding potential of the HPV-16 AS RNA vas examined by
prediction of ORf's in these AS RNAs by Ficket·s method. No
significant ORF's were detected in HPV-16 AS RNAs.
3.3.6 Presence or AS RNA in tbe RNA-RNA duplex
The concurrent presence of the S and AS RN.4.s in the same
cell could allow hybridization of these two species of RNAS
resulting in daRNA. To examine this possibility, the double
RNase protection assays were used. The double RNase
protection assay depends on the sensitivity of single stranded
RNA, but not the dsRNA, to degradation by single strand-
specific RNase, RNase Tl. The double RNase protection assay
includes two steps. In the first step, the RNA samples are
treated with the single strand specific-RNase, RNase Tl. Only
dsRNA, but not the single stranded RNA remains after the RNase
treatment. At the end of the first step, the RNase is
inactivated. In the second step, hybridization is set up with
uniformly labelled strand-specific RNA probes and the standard
RNase protection assay is performed. The probes used for the
double RNase protection assays were from the E7 ORF 5' region
sequences. The p071 plasmid which expressed low level of AS
RNA was used as the negative controL For CaSki cells, which
does not express AS RNA, total RNA treated with RNase Tl prior
to hybridization to the probe resulted in total degradation of
E7 RNA (data not shown). In contrast, a significant
proportion of both the 5 and AS RNAs for the pY71 and pY75
1.7
plasmids remained RNase resistant when treated with
prior to hybridization (Fig. 3.9). Approximately comp.'rablc
levels of RNase resistant S and AS E7 RIIlAs were observed rOt"
the pY71 and pY75 plasmids. The RNase treatment prior to
hybridization of total RNA from cells transfcctcd with the
plasmid, p07l, resulted in the drastic reduction of the ~ RNA
signal (Fig. 3.9). These results clearly indicate th•.,t
significant proportions of the AS E7 RNA for the pY71 pl<\smid
exist in the form of RNA-RNA duplex with the S E:7 RNA.
3.3.7 Interference with splicing of £7 B RNA by Jl.8 RNA
Modulation of expression of specific genes by AS rmJ\ is
dependent upon hybridization of the AS RNA to its tar.qet
sequences present in specific pre-IllRNA. and mRNA. 'I'he
formation of such hybrids with pre-.RNA and mRNA has been
shown to interfere with the processes required for gene
expression (Helene and Toulme, 1990; Ta)r;ayama and Inouye,
1990) . This interference may cccur at any or all of the
levels of RNA processing and mRNA transportation on(j
translation and mRNA metabolism. The AS strategy has illso
been used to modulate the expression of high risk HPV E6 Qnd
E7 genes (von Knebel-Ooeberitz et al., 1988) 1992) Helene and
Tou1rne, 1990, Takayama and Inoue, 1990; Storey et 01., 1991).
Because the results presented in chapter 2 have indicated an
important role for the nt 880 splice donor site for the
expression of E7 RNA, the possible interference with splicing
Figure 3. 9 Double RNase protection experiments vi th the
E7 probe.
'l'he experiments were performed as described in materials
and methods. The £7 probes correspond to both strands of the
stu! (nt 5190 of SV40) to Ssp! (nt 720 of HPV-l6) fragment of
p'{7l. The lane labels are: +, RNA treated with RNase Tt
before hybridization. -, RNA not pretreated with RNase Tl.
Protected S and AS E7 fragments are indicated by arrowheads.
conditions and other abbreviations are as in figur~ 3.3.
Figure 3.10 RNase protection experiments with the E7/El
probe.
'l'hc results are sh,'wn for 5 1J,9 of total RNA from CaSki
cells and Cos-l cells transfectod with the indicated plasmids
ilnd analyzed by AS £7/El probe. The T antigen which is
constitutively expressed in Cos-l cells was used as an
internal control. The E7/El and the T antigen probes
correspond to nt 720-955 of HPV-16 and 3072-3225 of SV40,
respectively. Control lanes and lanes for RNA from CaSki
cells and transfected CO$-1 cells are shown on top for: Probe,
il mixture of undigested E7/El (upper band) and T antigen
probes (lower band). caSki, RNA from CaSki cells. Cos-I, RNA
[rom Cos-I celL;. Molecular size markers are shown on the
right side. Protected E7 and T antigen fragments. are
indicated by arrowheads.. Labels are: US, unspliced E7 RNA; S,
spl iced £7 RNA; T, internal control T antigen protected
fragment.
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of S RNA by AS RNA was evaluated by RNase protection assays,
with the E7/El nc 720-955 region probe. For CaSki cells,
which does not produce AS RNA, a significant proportion of S
RNA was spliced. For the plasmids, p'i7l and p'i75, that
produce high levels of AS RNA, all of the S RNA and the major
proportion of S RNA remained unspliced, respectively (Fig.
3.2; 3.10). Further, an inverse correlation between the
levels of spliced RNA and the AS RNA was observed for the
plasmids pY7l and p'i75. Less of the RNA was spliced at the nt
8ao splice site for the plasmid, p'i7l, which expressed high
level of AS RNA relative to the S RNA. For the p'i75 plaslnid,
which expressed lower leval of AS RNA compared with the S RNA,
a slightly higher pl:oportion of RNA was spliced (Fig. 3.2).
The possibility that the nt 8ao splice site and the
flanking sequences present in the S RNA hybridized with the AS
RNA and formed dsRNA was addressed by double RNase protection
assays, with the nt 792-1179 E7/E1 region probe. For this
probe, the relative intensities of signals for the protected
unspl iced and spliced RNA fragments do not clearly reflect the
proportions of spliced and unspliced RNAs, because fewer
labelled U residues are present in the protected spliced RNA
compared with the llnspliced RNA. for CaSki cell and the pD7I
plasmid transfected Cos-1 cell RN1I.s not treated with RNase TI,
splicing at the nt 880 splice site was observed. consistent
with the results of the double RNase protection experiments
Figure 3.11A Double RNase protection experiments with the
E7JE1 probe.
The experiments were performed as desc:-ibcd in
materials and methods. The probe corresponds to nt 79].-.l17Q
of HPV-16. The lane labels are: +, RNA treilted with RNase '1'1
before hybridization; -, Rt.'A not pretreated with RNase 1'1. S
and US are abbreviations for the protected spliced and
unspliced RNAs. Conditions and other abbreviatir>ns ilre as in
figure 3.3.
Figure 3.11B Immunofluorescence experiments.
CaSki cells and Cos-I cells transfected with the
indicated plasmids were analyzed for the E7 protein specific
immunofl'lOrescence with an anti E7 mon;;c1onal antibody.
Labels are: 071, Ccs-l cells transfC!cted with the plasmid
p07I; '{7I, Cos-I cells transfected with the plasmid pY71;
Y7SA, Cos-I cells transfected with the plasmid pY7SA; cNr,
Cos-l cells transfected wit:h the plasmid pSV2Cat. What might
appear to be the fluorescence for the pSV2Cat plasmid (CA'f) is
a photographic artefact. No signal was detected in the
original prints.
RNa ••
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with E7 probes, trec\l:ment of RNA from CaSki cells with RNase
Tl prior to hybridization to the probe resulted in total
degradation of E7/El RNA (Fig. 3.111'.). For the pO?l plasmid-
transfected Cos-l cell RNA, similar treatment with RNase '1'1
prior to hybridization to the probe resulted in degradation of
most of the 5 E7/El RNA. For the pY71 plasmid, which produced
high level of AS RNA, no spliced RNA was detected. Further,
approximately comparable levels of unspl iced E7 lEI 5 and AS
RNAs remained RNase resistant. The S RNA detected in the
RNase resistant dsRNA was not spliced (Fig. 3 ..111\).
Considered together. these results suggest that the 1\5 RNA
interferes with splicing of the S RNA at the nt 880 splice
s1te by forming an RNA duplex with the S RNA.
3.3.8 :Interference with synthesis of E7 protein by lI.8 RNA
Saveral experimental studies have indicated that the AS
RNA targeted to the cap site and the 5' unt':"anslated region o(
mRNA ef ficientlY interferes with translational in itiat ion
(Helene and Toulme, 1990; Takayama and Inouye, 1990). The
HPV-16 AS RNA detected for the HPV-16 expression plasmids was
complementary to the 5' and 3' regions and the coding region
sequences of the E7 RNA and formed RNA duplex with the E7 S
RNA (Fig. 3.9). To examine the possible interference with the
synthesis of E7 protein by AS RNA, immunofluorescence
experiments were performed on Cos-l cells transfected with the
plasmid, pY71, which produces high levels of the S and AS RNA
1••
and the plasmids, pO?1 and pY7SA, whlch produces high levels
of 5 RNA, but low levels of AS RNA and the control plasmid,
pSV2Cat. The Cos-l cells transfected with the plasmids, pO?1
and pY7SA, showed distinct nuclear staining lor the E7
protein. The nucleoli were clearly excluded (Pig. 3.11B).
Si.ilar nuclear staining for the E7 protein has been reported
earlier (Sate et al., 1989a). That the nuclear staining for
the plasmids, pO?1 and pY7SA, was specific was demonstr.ated by
the absence of staining for the negative control plasmid,
pSV2cat. Under similar experimental conditions, no E7 protein
WilS detected for the pY71 plasmid (Fig. 3.118). The inverse
correlation between the AS RNA expression and the E7 protein
synthesized for the plasaids, pY71, p071 and pY7SA, suggests
that the AS RNA Ilay interfere with the synthesis of E7
protein.
3. 4 DISCUSSION
In genital HPVs, the Illajority or transcripts are
initiated tram a promoter located in the LCR, immediately
upstream of the E6 ORF. Recently an internal promoter was
detected in the E6 carly region of the low risk HPVs (Chow ct
al., 1987a; 1987b; Nasseri et al., 1987; Smotkin et al.,
1989) . Presence of an internal promoter within the E6-E7
region of HPV-16 has been suggested by several recent studies
(Rohlfs et al., 1991; Higgins et al., 1992). My studies
,.0
provide evidence for the presence of a novel promoter within
the genome of HPV-16. Because of its orientation with respect
to the major promoter p97, I have termed this novel promotcl:"
the AS promoter.
The evidence for the presence of the AS promoter with i n
the genome of HPV-16 comes from the plasmids, p'i71, pV7Sl\ and
pSV2HPA2. The AS RNA was detected for the plasmid pY71. No
AS E7 transcripts were detected for the plasmid pY7SA, in
which the AS promoter was not present, confirming the presence
of the AS promoter within the HPV-16 sequences (fig. 3.1).
The AS promoter containing sequences cloned downstream of the
Cat gene in the plasmid, pSV2HFA2, was transcription.:Jtly
active and gave rise to AS Cat transcripts (Fig. 3.5). In
contrast to the AS E7 RNA. the levels of AS Cat RNA was always
lower compared with the S cat RNA (Fig. 3.5). This could be
related to the differences in the stability of AS Cat and AS
E7 RNAs.
By using various deletion Ilutants, the AS promoter WitS
localized to a region between nt 4031 and 4338 (fig. J.3;
3.4). progressive deletions extending towar.ds the E7 ORF [rom
the nt 1176 resulted in a gradual increase in the levels of AS
E7 RNA (Fig. 3.3). This could be related to the distance of
the probe from the AS promoter. The AS RNAs may have
heterogeneous ends resulting from random termination of AS
transcripts a short distance from the AS promoter and lack of
191
J' end processing tor these AS transcripts. The deletions in
the pY7lJ'A series ot plaslDids which brings the E7 probe
sequences close to the AS promoter lIight have facil i tated
inclusion of £7 ORr sequences in the AS RNA by preventing
random te[llination of AS RNA. In support of this, increased
distan-::e between the E7 probe sequences and the AS promoter
for the pD71 plasmid resulted in very low levels or AS RNA.
According to this model the deletions extending towards the AS
promoter region for the pY71J' 62 plasmid series were expected
to increase the levels of AS RNA. However, no increase in the
levels of AS RNA attributable to the progcassive deletions in
these pIa Sill ids were observed (Fig. 3.4). Al though the
deletions in these plaslIlids bring the AS promoter close to the
probe sequences, the deletions might have resulted in the loss
of transcription initiation sites, resulting in no net effect
on the levels of AS RNA. In support of this nypothesis,
several _inor initiation sites were detected for the deleted
regions of the pY11J '62 series of plasmids by primer extension
analysis (Fig 3.6).
It was reported that the 5' ends of AS RNA detected in
cervical squamous carcinoma cells were heterogeneous and
mapped to the NCR and the 5' region of Ll ORF sequences
(Vormwald-Dogan et a1., 1992). These authors suggested that
the production of AS RNA was a consequence of integration of
the viral genome, since no AS RNA corresponding to the NCR,
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E6-E7 and the Ll ORFs was detected in premalignant lesions
harboring the HPV-16 genome in the CpiSOl'lldl form. Inilbil ity
to detect the AS RNA in premalignant lesions could be related
to the lower levels of AS RNA a.nd the low sensitivity of the
in situ hybridization technique and the long distances between
the AS promoter and the E6-E7, LCR and Ll region probes used
in that study. Contrary to their findings and suggestion, AS
E7 and E7/El RNAs were detected in the transient expr.-ession
assay system in which the transfected plasm ids rama i.n
predominantly episomal, indicating that the integration of the
viral genome ;i.s not essential for the production of AS RNA.
The 5' ends of the AS RNAs were heterogeneous and found to be
initiated over an AT-rich region around nt 4100. Several
minor transcription initiation sites were detected (Fig. 3.G).
This observation was further confirmed by RNase protection
experiments with the nt 4107-4311 probe corresponding to the
upstream sequences of this putative initiation sites. Very
low levels of AS RNA, as compared with the S RNA, wct"c
detected for this probe (Fig. 3.7). The low levels of AS HNA
I
seen with longer autoradiography may correspond to transcripts
originating from the pBR322 vector sequences of the plasmid.
Approximately 30 nt upstream of the initiation site for
the major AS RNA species was a TATA element which might
represent the potential TATA box element for these AS
transcripts (Seedorf et al., 1985). The TATA element binding
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plCotein, TBP, has been shown to be required for the activity
of RNA polymerase I, II and III promoters (Greenblatt, 1991;
Rigby, 1993). Thus, the HPV-16 AS RNA could be transcribed by
RNA polymerase I or II or polymerase III. RNA polymerase II
generally requires the TATA box element. Presence of the TATA
box element at an appropriate distance upstream of the major
liS RNA transcription initiation site suggests that this
polymerase is involved in the transcription of AS RNA.
'rhe pD71 plasmid consistently expressed lower levels of
AS E7 and E7/El RNA (Fig. 3.9, J.llA). There are several
possible explanations for this observation: (i) The AS RNA
produced from this plasmid has termination sequences
downstream of E7 and is not detectable by the E7 probe. (ii)
'i'he pl<lsmid, p071, possesses splice signals for the AS RNA,
that are deleted from the plasmids of the pY7 series, and the
liS RNA undergoes splicing. I f the probe used to detect the AS
RNA corresponded to the intronic region, it would only detect
unspliced 1I.S RNA. (iii) The downregulation of the AS promoter
by the viral gene products El and/or E2 Which are encoded in
the pD7l plasmid could result in lower levels of AS RNA. (iv)
Certain destabilizing sequences are present in the AS RNA
produced from the plasmid p071, but not for the plasmids of
pY7-series. (v) As suggested earlier, the lo"'er liS RNA levels
for the pD7l plasmid could be related to the distance of the
probe from the AS promoter.
Previous reports have indicated th.:\t the AS RNA is
predominllntly nuclear in cervical carcino:n<'l cells (Higgins et
I'll., 2991; Vormwald-Dogan et al., 1992). In contrast, the AS
E7 RNA was detected in both the nucleus and cytoplasm of Cos-l
cells (Fig. 3.8, 3.9). Several possible re<lsons could
underlie this discrepancy regarding the local ization of the AS
RNA. In cervical carcinoma cells, in which the vil:al genome
is integrated with the host cell genome, the AS RNA may arise
as a result of read-thr.ough transcdption from flanking
cellular promoter-enhancer sequences find arc of hirJh molecular
weight. Such high molecular ....eight AS RNAs may not be
transported efficiently to the cytoplasm. Some of the
naturally occurring AS RNAs transcribed [r.om the cellular
promoters are high molecular weight RNAs of heterogeneous size
distribution and localized to the nucleus {Khochbin and
Lawrence, 1989; Khochbin et I'll .• 1992; ()olnick, 1993).
Because the HPV-l6 AS RNA detected in Cos-l cells <Ire
transcribed from the viral AS promoter, it is less likely that
this AS RNA accumulates in the nucleus <IS high molecular
weight RNA. The cytoplasmic location of the IlPV-l6 1\5 RNA
detected in Cos-1 cells could be rel<lted to the high copy
number of the templ<lte DNA from which the AS RNA is
transcribed in Cos-l cells. The SV40 b<.n::ed E7 expression
plasmids undergo amplification in Cos-l cells.
1.S
My studies indicate that the AS RNA interferes with the
expression of S RNA by fOIlling an RNA. duplex with the S RNA
(Pig. 3.9, 3.11A, 3.11B). This interferencGI dUG to AS RNA can
occur at different levels such as, splicing, mRNA 3' end
fOnlation, IIRNA transportation, translation and RNA
metabolism. splicing and polyadenylation of pre-mRNA
important posttranscriptional steps essential for the
production of mature mRNA. The efficiency of splicing of the
nt 880 splice site was lower for the plasm:.i..ds, pY71 and p'i75,
compared with the plasmid, pD71 (Fig. 3.2, 3.10, 3.118). The
formation of duplex RNA for the plasmids, pY71 and pY75, might
excludoe the assembly of spliceosomes over the splice site
sequences. The duplex foraation could prevent the base-pair
interactions between the components of splicing machinery such
as, Ul snRNP, U2 snRNP and US snRNP. and the ill-acting splice
site sequences and other elements essential for the function
of splice sites. It has been established that the binding ot
Ul snRNP to the 5' splice site is essential tor the assembly
of spliceosofle (Green, 1991). Binding of the Ul snRNP
involves base-pair interactions between the first 9 nt of Ul
snRNA and the 5' splice site sequence. The duplex formation
between the nt B80 5' splice site and the flanking region
sequences of S RNA and the AS RNA might prevent the binding of
U1 snRNP to the nt 880 splice site. This interference with
tho binding of Ul snRNP and other essential splicing factors
lIlight have resulted in reduced splicing tor the plasmids, Py"l
and pY75. Further support for this hypothesis comes fr:-olll
studies which have shown that the AS RNA intct"fet"es with
etticient splicing of 5 RNA by forming an RNA-RNA duplex with
the S RNA (Munroe, ~988; Munroe and Lazat", J.9!H). Very low
levels ot' spliced product detected for the pY7l and pV75
plasmlds could have reSUlted from splicing of unhybridizod
E7/El S RNA (Fig. 3.2). The other possibility for t"oducod
splicing for the pY71 and pY75 plasmids is the suboptimal
cryptic splice acceptor site sequences for these plasmlds
compared with the authentic spl.i.ce acceptor sites (or tho
p1aslllid, p07!. This is an unlikely possibility because, the
de1etlon of the authentic siJlice acceptor sites did not affect
transformation and RNA levels for the pY71 and pY75 plaf'mid&
compared with the p07! plasmid.
The possible interference with the 3' end format ion fOI;"
S RNA by AS RNA is considered now. In addition t.o I;"cduced
splicing, the efficiency of J' end fOrtflllltion was l.ower tal;" the
pY71 and pY75 plasllids (Fig. 3.7). This could be related to
the formation at duplex RNA tor the polyadenylati.on si.gnal
containing region ot the S RNA. It is loss likely that the AS
RNA directly interfered with the process of J' end fOl;"mntion
because, no AS RNA was detected for the nt 4107-4311 probe,
Which spans the early polyadenylation signal soquence
containing re9ion of the HPV-16 (Fig. 3.7).
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possibility for the low efficiency of 3' end formation for the
pY71 and pY75 plasmids could be related to the reduced
splicing for these plasmicls. In support of this argument, it
has been reported that for terminal exons containing the
polyadenylation signal sequences, the splicing of the upstream
splice sites increases the efficiency of )' end formation
(Niwil et al., 1990). It is more likely that the reduced )'
cnd [ormation for the pY71 and pY75 plasmids is a consequence
of reduced splicing of the upstream splice sites for these
plasmids. Thus, the AS RNA for the pY71 and pY75 plasmlds
might indirectly interfere with the process of :1' end
formation by interfering directly with splicing of the nt 8BO
splice site.
'l'he transportation of mRNA from the nucleus to cytoplasm
is an essential prerequisite for translation of mRNA. Some of
the naturally occurring and experimentally produced AS RNAs
have been shown to interfere with this step, resulting in
accumulation of S RNA in the nucleus (Helene and Toulme, 1990;
Takayama and Inouye, 1990). Irrespective of their ability to
produce AS RNA, the S RNA for the pY71 and pY75 plasmids was
detected in the cytopl~sm (Fig. J. 86) . only the single
stranded AS RNA which did not hybridize with the S RNA was
detected in in situ hybridization experiments, because the
cells were not denatured prior to the addition of the probe.
In in situ hybridization experiments for the plasmid pY71,
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high level of S RNA was detected in the cytoplasm and there
was no evidence for the accumulation of S RNA in the nucleus.
Thus, it is unlikely that the HPV-16 AS RNA interfered wi th
the transportation of S RNA.
For the pY71 plasmid-transfected Cos-! cells, no 87
protein was detected by immunofluorescence experiments.
Distinct nuclear staining was detected for the plasmid pH?]
and pY7SA-transfected Cos-l cells. A similar pattcm of
nuclear staining has been reported for Cos-l cells transfccted
with SV40 early promoter-enhancer-based E7 expression plasmids
(Sate et a1., 1989a). For CaSki cells, a similar nuclear
staining pattern was observed. However, the staining was not
reproducible in all the experiments. 'rhe difficulty In
demonstrating the E7 protein for CaSki cells by
immunofluorescence has been shown to be due to the low level
of E7 expression compared with the SV40 promoter containing E-'
expression plasmid-transfected Cos-I cells and the masking of
the E7 epitopes in the nucleus of CaSki cells (Kanda at al .•
1991). The cytoplasmic location of the AS RNA, the
hybridization of the AS RNA with the E7 S RNA to form RNA
duplex and the inverse correlation between the level of AS nNA
and the E7 protein synthesis suggested that the AS nNA
inte:.:fered with synthesis of E7 protein.
The AS RNA has been shown to destabilize S nNA
(Hildebrandt and Nellen, 1992; Nellen et a1.. 1992). 'rhe
effect of AS RNA on the stability of S RNA may be due to
".
degradation of dsRNA by dsRNA-Specific RNases. The dsRNA-
specific activity called unwindase, has been shown to induce
A to I conversion in dsRNA (Bass and weintraub, 1987;
Rebagliati and Melton, 1987). Such modifications alter the
stability of dsRNA (Bass and weint.caub, 1988; Kimelman and
Kirschner, 1989). The unwindase activity is present in a
vadety of cell types including epithelial cells, which are
the natural target cells for HPV-16 (wagner at a1., 1990).
Although the HPV-16 AS RNA formed the RNA-RNA duplex with the
S RNA, the AS RNA-induced destabilization of S RNA was not
apparent. This could be due to the lower stability of AS
RNl\s. Ueteroqeneous 5' and 3' ends for AS RNAs might be an
indication of their lower stability.
Evaluating the different mechanisms by which the AS RNA
could interfere with gene expression, it is more likely that
the HPV-16 A5 RNA interfered with the expression of the E7
gene by interfering with splicing and/or polyadenylation
and/or translation of E7 5 RNA. polyadenylation has been
shown to enhance the stability and translatability of tnRNA
(Huang and Gorlllan, 1990; Jackson and Standardt, 1990). My
results indicated that the AS RNA interfered with
polyadenylation of 5 RNA (Fig. 3.7) . Further, the
complementarity between the 5' and 3' flanking regions and the
coding region sequences of the E7 5 RNA and the AS RNA
suggested the possible interference with translation of E7 S
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RNA by A.S RNA. Thus, the AS RNA could lo,;/er the expression oC
E7 directly by interfering with the trallslation of S RNA <lnd
indirectly b~ interfering with the process of poly'H.lcnyliltion.
Only the pO?1 plasmid, but not tile p'i71 pl'll:.mid,
expressed detectable levels of E7 protein in tr,l11siclltly
transfected Cos-l cells. Because the expression of 1::7 is
essential for transformation of BRK cells, the pY71 pl',H;IQid
which c..i.d not express detectable levels or E7 protein m<,y be
expected to be nontransforming. !lowcver, there werC' no
significant differences in the trtlnsform<ttion frequency [or
the pO?1 and p,{71 plasmids, although t".herc were clcilr
differences in the levels of E7 protein expressed for thcrlc
plasmids (Fig. 2.1, 3.11B). The discrepancy between the level
of £7 protein expressed and the transformation competency [or
the pY71 plasmid could be due to the pref.:encc of a low level
of E7 protein expression for this plasmid th;lt could not be
detected by immunofluorescence. Because the apitopes 01' ~;'I
protldin are masked, it may not be possible to detect the Po7
protein unless it is expressed at high levels (Gr.eenfield et
al., 1991; Kanda et al., 1991). A more sensitive technique
such as immunoprecipitation might have detected the g', protein
for the pY71 plasmid. The other possibility for thQ observed
discrepancy could be the differences in ce.ll type:.: and the
assays used. Transient transfections were u:,;cd for Cos-l
cells, whereas st.able expression was used for transformation
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of I3RK cells. The transient transfections in COS-J. cells did
not depend on the integration of the transfected plasmid DNA
into the cellular DNA and the pY71 plasmid expressed high
levels of AS RNA, which interfered with the processing of E7
S RNA, reSUlting in low levels of E7 protein (Fig. ).10,
J.llA, 3.116). The stable expression in BRK cells, which
resulted in transformation was dependent on integration of the
trllnsfected plasmid DNA with the cellular DNA. It is possible
that during the process of integration, deletion of the AS
promoter region sequences from the plasmid pY71 might have
prevented the interference with the processing and translation
of the E7 S RNA by AS RNA. This was shown to occur in Caski
cells in Which the AS promoter had been deleted (Smits et al.,
1991).
There is considerable evidence that HPV gene expression
is closely coupled to the differentiation status of the host
epithelial cells (erum et al., 1988; Sterling et al., 1990;
Dollard at al., 1992; Durst et al., 1992; Higgins et al.,
1992; Meyers et al.. 1992; Stoler et al., 1992). The activity
of the AS promoter may also be coupled to the differentiation
status of cells. Differential regUlation of the AS promoter
could have an influence on the growth properties of cells
expressing high levels of AS E7 RNA. Consistent with this
hypothesis, AS nucleic acids targeted to the E6-E7 genes
suppressed the growth rate of HPV-16 and HPV-18 positive
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transformed cells (von Knebel-Doeberitz ct .. l • 1988; Crook at
a1., 1989; Storey at al .• 1991; von Knebel-Doeberitz at ,,1.,
1992). Further, the AS promoter llIay be regulated by the viral
early proteins. Thus, the AS RNA may either directly or
indi rectly regulate HPV-16 gene expression
posttranscriptionally.
The significllInce of expression of the AS RNA. to the lifc-
cycle of the virus is not clear. Interfering with the
expression of E7 does not appear to be the primary effect of
AS RNA, because for the p07! plasmid, which expresses the
majority of the early region, very low lcvc.l of AS E7 RN.-. was
uetected and this AS RN~ did not inhibit the expression of E7
(Fig. 3.9, 3.11A, ).118). If all the early region ORFs such
as El, E2 and E4 are intact, the AS RNA may terllinate randolllly
a short distance from the AS promoter within these sequences.
Deletion of these sequences from the pY1 series plasaids could
have resulted in the inclusion of E1 ORF sequences in the I\S
RtIA. If this is the case, under the conditionz of natural
infection in which the complete viral genome is maintained in
an episomal form, S transcripts corresponding to OIU·s
immediately downstream of the AS promoter are likely to be
found in an RNA duplex. In support of this, AS RNA
corresponding to the E4, E2 and El ORF were detected 1n
several naturally occurring tumors (Higgins at aL, 1991).
The dsRNA is a potent inducer of interferons (lFNs),
which interfere with the virus life-cycle. The effect of IFNs
is mediated by IFN inducible genes. The DNA tumor viruses
have evolved a mechanism to prevent the activation of IFN
inducible genes. The adenoviral oncogene, ElA, has been shown
to impair the formation of IFN inducible transcription
initiation complex (Lengyel, 1993). It is possible that
similar to E1A, the HPV-16 E7 may provide anti-IFN activity to
the virus.
Accumulation of dsRNA might be important for the life-
cycle of the virus. One of the mechanisms by which viruses
such as, Epstein-Barr virus, adenoviruses and HIV, overcome
the cellular defence mechanism, the global inhibition of
protein synthesis, is by producing high levels of dsRNA or
single stranded RNA with a potential to form double stranded
secondary structure (Mathews and Shenk, 1991). High
concentrations of dsRNA inhibit the activity of dsRNA
dependent protein kinase (PKR), an important enzyme inVolved
in the shut-off of the host's translational machinery (Hunter
at al., 1975; Farrell et al., 1977; Hovanessian, 1989; Kostura
and Mathews, 1989). Production of AS RNA by HPV-16 might be
a mechanism to inhibit the activity of PKR. Recent studies
have implicated PKR as a tumor suppressor gene (Clemens, 1992;
Koromilas et aI., 1992; Meurs et al., 1993). The outcome of
inhibition of PKR provides distinct advantages to the virus:
(i) the virus can overcome the translational inhibitory
affects of PKR and (ii) inhibition of this candidate tumor
suppressor gene can enhance the ability of the virus to induce
deregulated prol i feration of host cells.
20.
CHJr.P'l'ER ,
FUTURE DIRECTIONS
Posttranscriptional events play an important role for the
expression of HPV-16 genes. This is reflected by the ability
of the viral genome to produce a number of alternately splicC!d
mRNAs from a limited number of primary transcript(s)_ It is
possible that certain genes are selectively expressed or
repressed by peeferential utilization of specific splice
sites. This can be best exemplified by the complex splicing
pattern of transcripts corresponding to the early region ORFs,
EG, E7, E1 and E2 (Fig. 1.1).
It has been reported that the splicing of the E6 intrao,
nt 226 splice donor site spliced to either nt 409 or 526
splice acceptor s1tes. upregulates the expression of E7 by
stabilizing the £6-E7 mRNA and facilitating the translation of
E7 (Smotk:in et aI., 1989; sedman et al., 1991; results
presented in chapter 2). The same splice donor site can also
be used to downregulate the expression or E7. This can be
achieved by skipping the E7 exon from the primary transcript
by splicing the nt 226 splice donor site to nt 2708 or ))57
splice acceptor sites located downstream of E7 (Doarbar et
aI., 1990; Sherman et aI., 1992).
The production af the £2 protein can be regulated by
al ternate splicing. The mRNA. encoding the full length E2
protein is produced by splicing the nt 226 or 880 splice donor
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sites to the nt 2581 or 2708, but not the )357 splice acc~"ptDr
sites (Nasseri et al., 1991; Rohlfs at al., 1991; Sherman and
"lioul, 1992; Sherman at a1., 1992). Another mechanism by
which alternate splicing downregulates the activity of £2 is
by producing transcripts encoding the £2 repressor. splicing
out the 5' region of £2 from the primary transcript of BPV-l
resulted in the production of lllRNA encoding the E2 repressor.
This truncated form of E2 protein interferes with the activity
of full length E2 by competing for the E2 binding sites (Ham
et a1., 1991; McBride et aI" 1991). Similar HPV-16
transcripts capable of encoding the 1::2 repressor can be
generated by splicing the nt 1301 splice donor site to the nt
3357 splice acceptor site (Doorbar at al., 1990; Sherman et
al., 1992). The full length E2 protein mcxtulates the activity
of the viral proDloter, p97, and is required for the
replication of the viral genome. Thus the regulated
prOduction of the full length E2 transactivator protein or the
truncated E2 repressor protein by alternate splicing
facilitates indirectly, regulation of the viral gene
expression and replication. DNA replication is generally
closely tied to transcription, but more so for the PV system,
because the E2 transactivator protein has an important and
direct role in replication of BPV and HPV genomes.
Another early region splice site, t.he activity of which
lIay be important for the HPV-16 life-cycle is the nt 1301
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splice donor site. Splicing of this site to the nt 56J7
generates mRN1I. encoding the major capsid protein Ll. The Ll
protein can also be expressed from a double-spliced mRNlI., the
p:.:-oduction of which depends on the utilization of the nt 1301
splice donor site (Doorbar at a1., 19901 Sherman at ill.,
1992) • The restricted expression of late genes to
differentiating and differentiated keratinocytes could be
related to the preferential utilization of the nt 1301 splice
site in these cells.
The results presented in Chapter 2 clearly demonstrated
the role of the early region splice donor sites located at nt
226 and 880, for the expression of E6-E7 RNA. Both of tho nt
226 and 880 splice sites have been shown to be utilized
predominantly (Srnotkin et al., 1989; Dilts et a1., 1990;
Doorbar et al., 1990; Sherman et al., 1992). For the whole
HPV-16 plasmids mutated for the nt 880 splice donor site, the
transforming activity was dependent on the presence of
functional nt 1301 splice donor site. Deletion of both the nt
880 and 1301 splice donor sites resulted in loss of
transformation, whereas deletion of only the nt 880 splice
donor site severely reduced, but did not abolish
transformation (Pater et al., 1992b). Alt-hough the role for
the nt 1301 splice donor site for the e>.:pret>sion of the early
region of HPV-16 genes was evident, my studies did not
investigate the role of this splice donor site in sufficient
2.7
detail. A mutational analysis of this splice site in the
context of the wild type and mutant nt 226 and aso splice
sites would contribute to a greater understanding of the
function of this splice site for posttranscriptional
regUlation of HPV-16 gene s;.cpression.
The complex pattern of the alternate splicing of HPV-16
transcripts may be regulated by the interaction of tissue
enriched and tissue restricted illn§-acting splicing factors
with certain ili-acting elements present in the flanking exon-
intran sequences of these alternately spliced splice sites.
Presence of a specific splicing factor or differences in the
abundance of ubiquitous splicing factors such as ASF/SF2, DSF
and SR proteins could affect the choice of a splice site
(Harper and Manley, 1991: Lamond, 1991: Zahler at al., 1993).
The possible relation between the mechanism (5) and the process
of splicing for the product'. ion of specific alternately spliced
RNAs and the differentiation program of the target epithelial
cells deserves further investigation. The possible
correlation between the restricted expression of late genes to
differentiating and differentiated keratinocytes and the
utilization of the nt 1301 splice donor site for the
production of spliced late region RNAs would be interesting to
pursue further. The use of an in Y...i...t.xQ splicing system should
facilitate a better understanding of the mechanisms of complex
splicing pattern of HPV-16 transcripts.
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Several studies have indicated that the presence of a
spliceable intran in the transcription unit promotes
stabilization and accumulation of mature RNA (Buchman and
Berg, 1988; Huang and Gorman, 19901 Chef at 1'11., 1991;
Palmiter et 1'11., 1991). The reSll1ts for the plasmids of pD"!)
and pCMV series confirmed this observation. For the pY7
plasmids series, the integrity of the nt BBO splice site, but
not the actual process of splicing, was essential for the
accumulation of E7 RNA. SimilarlY, for the accumulation of
polyomavirus late region mRNAs, the splice sites, but not
splicing, was essential (Barrett et 1'11., 1990; Lanoix et 1'11.,
1990). The requirement for the functional splice sites but
not the splicing process can be explained if the splice donor
site sequences are also essential for function/s other than
splicing. Recently, the compartmentalization of splicing
machinery to discrete subni.1clear foci was elegantly
demonstrated (Fu and Maniatis, 1990; Spector, 1990; Carmo-
Fonseca et al., 1.991.a; 1.991b; Huang and Spector, 1991b;
Spector at al., 1991). It was also suggested that the
splicing of pre-mRNA occurs in thes:::! foci (Lawrence et al.,
1989; Huang and Spector, 1991a; Wang at al., 1991; Carter at
al., 1993; Xing et al., 1993). It is possible that the splice
signals target the nascent transcripts to these spl icing
compartments. Transcripts with mutated splice sites may
undergo degradation due to failure to reach these splicing
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compartments. Appropriate experiments can be designed "to test
such hypotheses.
In chapter J, I have provided evidence for the presence
of an AS promoter within the genome of HPV-16. Similar to the
major promoter, p91, the activity of the AS promoter may also
be closely coupled to the differentiation program of the host
api thelial cells. Further studies can be done to test whether
the activity of the AS promoter is dependent on the cell type
or the differentiation status of cells.
The promoter may be regulated by viral transcriptional
transactivator proteins, such as E7 and E2. For the p07l
plasmid, the level ..:;,f AS RNA was low. The low level of AS RNA
expression for this plasmid could be related to the
downregulation of the AS promoter activity by the viral E2
protein, which ""as encoded in the same plasmid.
The AS RNA appeared to interfere with the expression of
E7 gene, possibly by blocking the splicing of E7 RNA at the nt
880 splice donor site and by interfering with the synthesis of
E7 protein. The AS RNA may affect the production of other
viral proteins such as, ES and E2, by interfering with the
production of mRNlI.s encoding these proteins. The E2 protein
encoding mRNAs are produced by splicing of the nt 226 or 880
splice donor sites to the nt 2581 or 2708 splice acceptor
sites. By forming an RNA duplex with these splice acceptor
containing regions of the S RNA, the AS RNA may block the
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splicing to these splice acceptor sites. Thus, the AS RNA Ilay
interfere with the production of the £2 protein. In addition,
by forming an RNA duplex with the mRNA containing the ES ORF
sequences, the AS RNA may directly interfere with the
translation of the E5 RNA. By regulating the production of
E2, the AS RNA Illay indirectly affect the activity of the viral
promoter p97. More studies are needed to determine whether
the AS RNA undergoes posttranscriptional processing such as
splicing and polyadenylation. It is also important to map the
termination sites for these AS RNAs. Depending on the extent
of overlap, the AS RNA may affect the splicing pattern of the
early region transcripts.
The possible role of the AS RNA in overcoming the global
translational inhibition, a protective cellular mechanism
against the viral infection, can also be investigated. The
cellular dsRNA dependent protein kinase, PKR, when activated
by dsRNA, inhibits the initiation of translation by
phosphorylating the a-subunit of the eukaryotic initiation
factor, eIF-2. However, the activation of PKR is prevented by
high concentrations of dsRNA (Hovanessian, 1989). Because it
is likely that high levels of dsRNA accumulate during the
life-cycle of HPV-16, the .:!sRNA may inhibit the activity of
PKR and facilitate the complete life-cycle of the virus
(Mathews and Shenk, 1991). In addition, inhibition of the
activity of this tumor suppressor protein may enhance the
"neogenic potential of HPVs (Clemens, 1992).
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